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Functional Topology and Regulation of Endothelial Nitric Oxide Synthase and 
Associated Caveolar Components 
Brenda R. Flam 
 
ABSTRACT 
The discovery of nitric oxide (NO) as the endothelial-derived relaxing factor has 
led to significant research on NO and the proteins involved in its function, generation, 
location and regulation. Synthesis of NO by blood vessel endothelial cells results from 
the enzymatic oxidation of arginine by endothelial nitric oxide synthase (eNOS) resulting 
in the formation of equimolar amounts of NO and citrulline. Citrulline is sequentially 
recycled to arginine by successive reactions involving the enzymes argininosuccinate 
synthase (AS) and argininosuccinate lyase (AL), respectively. eNOS activity has been 
shown to be regulated by post-translational modifications including dynamic 
phosphorylation on multiple serine/threonine and tyrosine residues and dynamic O-linked 
ß-N-acetylglucosamine (O-GlcNAc) modifications on serine/threonine residues. 
Previous studies showed that even though intracellular endothelial arginine levels 
range from 0.1 to 0.8 mM and the Km of eNOS for arginine is 3 µM, the addition of 
exogenous arginine caused an increase in NO production. To explain this “arginine 
paradox”, we hypothesize that there is a separate and distinct cellular source of arginine 
substrate directed to NO production and that this source is maintained through the 
regeneration of arginine via a citrulline-NO cycle. The presented research has provided 
the following evidence in support of this hypothesis: 
· Citrulline stimulates NO production in an arginine-rich medium, without an 
increase in intracellular arginine. 
· The enzymes of the citrulline-NO cycle, eNOS, AS and AL, co-fractionate with 
caveolin-1 in an endothelial cell caveolar membrane fraction. 
 xv 
· In vitro interaction assays demonstrate protein-protein interactions between fusion 
tagged AS or AL with eNOS or caveolin-1. 
· Simultaneous monitoring of apparent citrulline and NO production demonstrates 
an efficient and essential coupling of the reactions of the citrulline-NO cycle. 
· Glucosamine treatment of endothelial cells results in increased NO production in 
the basal state and decreased NO production in the stimulated state. 
Our findings demonstrate the enzymes of the citrulline-NO cycle, eNOS, AS and 
AL, are functionally associated, the reactions are efficiently coupled and enzyme 
activities are changed by post-translational modifications based on nutrient levels. These 
alterations ensure a constant and distinct source of arginine which is available for NO 
production to ensure vascular health. 
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Introduction 
Nitric oxide (NO) is a simple free radical once thought of only as an 
environmental toxin. However, in 1987, NO produced by endothelial cells was 
determined to be the endothelial-derived relaxing factor. Endothelial NO is necessary to 
regulate vascular tone, homeostasis, blood pressure and vascular remodeling (Naseem 
2005). 
NO is formed in vascular endothelial cells, platelets, macrophages and neuronal 
cells. Nitric oxide synthases (NOS) catalyze the reaction converting arginine to citrulline 
and NO in stoichiometric amounts (Fig. 1). In the endothelium, citrulline is recycled to 
arginine successively by the enzymes argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL) with the conversion of citrulline to argininosuccinate as the 
rate-limiting step in the citrulline-NO cycle. There are three NOS isoforms encoded by 
separate genes, neuronal NOS (nNOS; NOS1), inducible NOS (iNOS, NOS2) and 
endothelial NOS (eNOS, NOS3), which share approximately 50% sequence homology 
(Feelisch et al. 1996). The NOS isoforms were named for the cells where they were 
originally discovered, but it was later found that many of the isoforms are expressed in 
other cell types, e.g. eNOS is also found in astrocytes. NOS requires the cosubstrates 
nicotinamide adenine dinucleotide phosphate (NADPH) and molecular oxygen and the 
cofactors flavin adenine dinucleotide, flavin mononucleotide, heme and 
tetrahydrobiopterin (BH4) for activity and functionality. The constitutively active forms, 
nNOS and eNOS are membrane associated, require increased calcium concentrations for 
activation and bind the calcium-calmodulin complex in a reversible manner (Marletta 
1994). iNOS, found in macrophages, neutrophils and vascular smooth muscle cells is 
induced by cytokines and is active at the lowest levels of calcium found in the cell. Both 
nNOS and eNOS produce intracellular NO at nanomolar concentrations while iNOS 
forms NO at micromolar concentrations (Blatter et al. 1995). 
 arginine
eNOS
citrulline
argininosuccinate
eNOS — endothelial nitric oxide synthase
AS — argininosuccinate synthase (rls: rate limiting step)
AL — argininosuccinate lyase
NO
AL
AS
(rls)
aspartate
adenosine
triphosphate
fumarate
Figure 1. Citrulline-NO Cycle  
The half-life of NO in aqueous solution is approximately 10 seconds. NO is 
lipophilic and acts on the heme iron center of soluble guanylyl cyclase (sGC) found in 
vascular smooth muscle cells and blood platelets (Ignarro 1990). NO activates sGC to 
convert guanosine triphosphate (GTP) to 3,5-cyclic guanosine monophosphate (cGMP), a 
second messenger. cGMP levels are increased up to several hundred-fold (Munzel et al. 
2005). cGMP then causes a signaling cascade, and cytosolic calcium levels decrease in 
the smooth muscle cells because voltage-gated calcium channels are inhibited (Bolotina 
et al. 1994). Calcium is sequestered in the sarcoplasmic reticulum when protein kinases 
that phosphorylate sarcoplasmic reticulum proteins are activated (Cohen et al. 1999). 
When the cytosolic calcium levels drop, the phosphorylation of regulatory myosin light 
chains is affected, promoting smooth muscle relaxation (Horowitz et al. 1996). NO levels 
are adjusted in response to physiologic stimuli (e.g. bradykinin, shear stress and oxygen 
tension), intracellular and extracellular nutrient concentrations, genetic mutations in NOS 
gene sequences or changes in citrulline-NO cycle proteins. 
Inadequate endothelial NO concentrations lead to endothelial dysfunction, which 
is observed in hypertension, diabetes, hypercholesterolemia, atherosclerosis and 
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cardiovascular disease (CVD) (Naseem 2005; Sase et al. 1997; Scherrer et al. 1994; 
Yoshizumi et al. 1993). CVD is an endemic disease in the Western world and is the 
fundamental cause of many deaths (Ignarro et al. 1987a; Ignarro et al. 1987b; Palmer et 
al. 1987). Increasingly, CVD is appearing in Japan, India and Eastern Europe due to 
increased Westernization (Naseem 2005). CVD incidence is increased by factors such as 
hypercholesterolemia, hyperglycemia, obesity, high blood pressure and smoking. 
However, the underlying pathology is atherosclerosis, the deposition of plaques 
containing cholesterol and lipids on the damaged endothelial cell layer in the arteries and 
other large vessels (Naseem 2005; Widlansky et al. 2003). Inadequate synthesis and 
increased NO inactivation (NO insufficiency) leading to endothelial dysfunction is the 
earliest stage of atherosclerosis (Voetsch et al. 2004). The first phase of atherosclerosis is 
alteration in endothelial cell phenotype causing dysfunction of the endothelial cells lining 
the vasculature. These changes occur because of high blood pressure, high glucose levels 
(caused by diabetes) and high lipid concentrations. Once there is an impaired endothelial 
section, endothelial cells express adhesion molecules on their cell surface and monocytes 
attach to the damaged cells (Quyyumi 1998). These monocytes differentiate into 
macrophages which destroy the damaged endothelial cells. In this scenario, macrophages 
fail to return to the circulation and accumulate lipids. As a consequence, smooth muscle 
cells at these sites change their phenotypic characteristics, becoming less contractile. This 
new phenotype secretes collagen, and participates in the formation of a fibrous mass, or 
plaque. Plaque formation eventually may reduce or block blood flow in localized regions. 
Loss of oxygen and nutritional transport occurs and the affected cells become necrotic. 
Local angiogenesis replaces the dead endothelial cells in the blood vessels, further 
enhancing plaque formation. If the fibrous mass is thin, an actual rupture of the vessel 
may occur. At this point, blood platelets would be activated to form a clot to prevent 
bleeding and loss of vessel integrity. If these events occur in the coronary artery, death 
can ensue since the heart is no longer supplied with oxygenated blood (Naseem 2005). In 
individuals with uncompromised cardiovascular systems, NO inhibits smooth muscle 
proliferation to prevent overproduction of the extracellular matrix proteins leading to 
atherosclerosis (Lusis 2000; Napoli et al. 2006). 
 4 
Lifestyle and diet influence the risk for CVD. Obesity, often associated with a 
sedentary lifestyle and/or overeating, leads to endothelial dysfunction and oxidative 
stress. In obesity, there are high circulating levels of tumor necrosis factor alpha (TNFα), 
which can cause circulating monocytes to adhere to vascular endothelial cells eventually 
leading to atherosclerotic lesions. In response to increased circulating levels of TNFα, 
adiponectin circulating levels are decreased in obese animals and humans (Chen et al. 
2003). Full length adiponectin prevents the expression of certain adhesion molecules like 
VCAM (due to increased TNFα levels) on the endothelial cell surface, preventing 
circulating monocyte adhesion, an early hallmark of atherosclerosis (Goldstein et al. 
2004). Adiponectin also regulates endothelial NO production (Hattori et al. 2003). Both 
the full length and proteolytic cleavage product, globular adiponectin, were shown to 
prevent atherosclerosis in apolipoprotein E knockout mice (Goldstein & Scalia 2004). 
Hattori et al. determined that human umbilical vein endothelial cells treated with globular 
adiponectin had increased eNOS mRNA and protein expression and that globular 
adiponectin treatment caused an increase in phosphorylation of eNOS increasing NO 
levels (Hattori et al. 2003). However, administration of globular adiponectin along with 
TNFα, which is known to decrease eNOS mRNA stability (Anderson et al. 2004), failed 
to prevent the accelerated eNOS mRNA degradation caused by TNFα (Hattori et al. 
2003). Using human aortic endothelial cells, Tan et al. determined that adiponectin 
increases NO production in these cells (Tan et al. 2004). More recently, Xi et al. 
determined that eNOS phosphorylation caused by globular adiponectin produced an 
association between eNOS, heat shock protein 90 (hsp90) and protein kinase B (Akt) 
resulting in increased NO production (Xi et al. 2005). When hsp90 association with 
eNOS was inhibited in bovine aortic endothelial cells (BAEC) treated with globular 
adiponectin, there was a decrease in endothelial NO production (Xi et al. 2005). When 
aortic rings were incubated with L-NAME, an eNOS inhibitor, globular adiponectin had 
no effect on vasodilation (Xi et al. 2005). 
Hyperglycemia contributes to endothelial dysfunction and at least three 
mechanisms have been proposed to account for the inhibition of endothelial NO 
production by elevated serum glucose (Buse 2006; Ding et al. 2004; Ho et al. 1999; Wu 
 et al. 2001b). It has been postulated that elevated serum glucose as well as glutamine and 
glucosamine, may inhibit NO production by promoting hexosamine synthesis in 
endothelial cells. 
glucose
(glut1 transporter)
glucose 6-phosphate
GFAT
(rls)
fructose 6-phosphate glucosamine 6-phosphate
GFAT — glucosamine:fructose-6-phosphate amidotransferase (rls: rate limiting step)
DON — 6-diazo-5-oxo-L-norleucine (GFAT inhibitor)
UDP-GlcNAc — UDP N-acetylglucosamine (substrate for O-GlcNAc transferase)
UDP-GlcNAc
glucosamine
(glut1 transporter)
glutamine
Figure 2. Hexosamine Biosynthetic Pathway
DON
 
In the hexosamine biosynthetic pathway (Fig. 2), UDP-N-acetylglucosamine 
(UDP-GlcNAc) is produced and used as the donor sugar for O-linked ß-N-
acetylglucosamine (O-GlcNAc, Appendix D) protein modifications (Wells et al. 2003). 
The enzyme O-GlcNAc transferase transfers O-GlcNAc from UDP-GlcNAc to serine or 
threonine residues on proteins (Haltiwanger et al. 1992) while O-GlcNAcase removes O-
GlcNAc from serine or threonine residues (Dong et al. 1994). O-GlcNAcase activity is 
inhibited by O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate 
(PUGNAc, Appendix D). Glutamine and fructose 6-phosphate are combined to form 
glucosamine 6-phosphate which is eventually converted to UDP-GlcNAc. Glucosamine 
(Appendix D), synthesized from fructose-6-phosphate and glutamine, enters the 
hexosamine biosynthetic pathway past the glucosamine:fructose-6-phosphate 
amidotransferase (GFAT) rate limiting step and was shown to increase O-GlcNAc 
modifications on eNOS protein near the protein kinase B phosphorylation site (Du et al. 
2001). Wu et al. demonstrated that endothelial cells cultured in glucosamine had 
decreased levels of NO production which was attributed to decreased cellular cofactor 
(NADPH) availability (Wu et al. 2001a; Wu et al. 2002). They also demonstrated that 
high glucose and glutamine concentrations decrease endothelial NO production and this 
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inhibition was reversed by incubation with the GFAT inhibitor, 6-diazo-5-oxo-L-
norleucine (DON, Appendix D). Elevated concentrations of glucose and glucosamine 
were both shown to inhibit NO production in cultured endothelial cells (Buse 2006). 
Glucose transporters on the cell surface transport glucose or glucosamine into the cell, 
which can increase O-GlcNAc modifications found on proteins under conditions of high 
glucose, such as in diabetes (Akimoto et al. 2005). O-GlcNAc modifications of certain 
proteins may cause a desensitization of glucose transport by causing a change in the 
movement of glucose transporters to the cell surface for glucose uptake, possibly leading 
to insulin resistance (McClain 2002; McClain et al. 2002; Walgren et al. 2003). Dynamic 
O-GlcNAc modifications also regulate the activities of eNOS, Sp1 and calmodulin and 
typically occur in response to changes in the cellular environment in a manner similar to 
phosphorylation/dephosphorylation and may involve substitution of the same residues 
(serine/threonine) (Hart 1997; Jackson et al. 1988b; Majumdar et al. 2006; Slawson et al. 
2003; Whelan et al. 2003; Zachara et al. 2006). Leptin gene transcription, important in 
insulin-resistance and obesity, is modulated by O-GlcNAcase and levels of UDP-GlcNAc 
(Wang et al. 1998). 
There are many transcription factors that also contain O-GlcNAc modifications, 
with Sp1 being the most well characterized (Jackson & Tjian 1988b). Sp1 is modified by 
phosphorylation and O-GlcNAc modification (Jackson et al. 1993; Jackson & Tjian 
1988b). These modifications change Sp1’s association with transcription binding sites in 
gene promoter regions causing changes in mRNA and protein expression. AS, another 
essential protein for NO production and endothelial survival contains three Sp1 
transcription binding sites within the human AS promoter (Anderson et al. 1991). In 
Caco-2 cells, a human intestinal cell line, glutamine and glucosamine were shown to 
increase O-GlcNAc modification of Sp1 causing greater nuclear translocation. There was 
greater Sp1 binding to the AS promoter initiating increased transcription (Brasse-Lagnel 
et al. 2003). Nandi et al. (Nandi et al. 2006) demonstrated a technique to locate O-
GlcNAc modified proteins on a global scale for proteomic analysis. The authors 
confirmed O-GlcNAc modifications on many proteins while increasing the known 
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number of O-GlcNAc modified proteins to over 200 including the determination that AS 
can be O-GlcNAc modified (Nandi et al. 2006). 
A third essential protein for endothelial NO production, AL, contains one Sp1 and 
one nuclear factor-Y (NF-Y) transcription factor binding site in the rat AL promoter 
(Matsubasa et al. 1994; Takiguchi et al. 1995). Examination of the NF-Y sequence with 
the YinOYang prediction server shows many potential O-GlcNAc modification sites 
(Blom et al. 1999). This prediction server contains O-GlcNAc modified protein amino 
acid sequences in its database and attempts to predict O-GlcNAc attachment sites in 
proteins using these data (Love et al. 2005). It is possible, but has not been demonstrated, 
that O-GlcNAc modification of NF-Y causes a change in the binding of this transcription 
factor to the AL promoter and changes AL gene transcription. 
Genetic polymorphisms in the eNOS gene which spans 26 exons may result in 
decreased NO production. One polymorphism is linked to a reduction in promoter 
activity. Another polymorphism which causes a change in the primary structure of the 
protein causes a reduction in NO production in healthy individuals. Other polymorphisms 
can cause changes in protein stability, post-translational modifications, intracellular 
distribution or cofactor association (Naseem 2005). 
Endothelial NOS activity may be regulated by a number of mechanisms including 
lipidation, calcium-calmodulin interaction, protein-protein interactions, phosphorylation, 
O-linked glycosylation and substrate/cofactor availability (Schulz et al. 2005). eNOS 
regulation involves reversible phosphorylation on serine, threonine and tyrosine that 
affects the activity and subcellular localization of eNOS (Fulton et al. 2005; Michel et al. 
1993). This phosphorylation/dephosphorylation causes changes in shear stress and 
contributes to vascular complications from CVD and type 2 diabetes. Depending on the 
type of stimulus, different residues in eNOS can be phosphorylated resulting in either an 
up- or down-regulation of eNOS activity. Phosphorylation by PKB, protein kinase G and 
AMP-activated protein kinase, at serine 1179 (bovine) in eNOS results in an increase in 
enzymatic activity by increasing electron flux through the eNOS reductase domain (Butt 
et al. 2000; Chen et al. 1999; Dimmeler et al. 1999; Fulton et al. 1999; Gallis et al. 1999; 
McCabe et al. 2000). Phosphorylation of serine 635 activates eNOS and phosphorylation 
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of serine 617 increases eNOS calcium-calmodulin sensitivity leading to increased activity 
(Michell et al. 2002). However, phosphorylation of threonine 497 by PKC inhibits eNOS 
activity by decreasing eNOS calcium-calmodulin sensitivity (Fleming et al. 2001; Schulz 
et al. 2005). However, Lin et al. demonstrated that threonine 497 dephosphorylation in 
eNOS caused an increase in both NO and superoxide production and that the production 
of these products was balanced by eNOS accessory proteins and protein phosphorylation 
(Lin et al. 2003). Serine 116 phosphorylation decreases eNOS activity (Corson et al. 
1996; Kou et al. 2002). Tyrosine 83 phosphorylation by Src kinase was associated with a 
three-fold increase in basal NO release from transfected COS-7 cells (Fulton et al. 2005). 
NOS is regulated by and targeted to different subcellular fractions by post-
translational modifications. For example, eNOS is acylated — either myristoylated, 
palmitoylated or both — targeting it to the cell membrane (Busconi et al. 1993; Liu et al. 
1994; Pollock et al. 1992). Palmitoylation is a reversible modification which can serve as 
a mechanism for changing the way a protein is regulated under different physiologic 
states (Chen et al. 2001). For instance, COS-7 cells were transfected with palmitoylation-
deficient eNOS or myristoylation- and palmitoylation-deficient eNOS (Shaul et al. 1996). 
There was a threefold increase in myristoylated eNOS in caveolae in cells transfected 
with the palmitoylation-deficient eNOS, and a tenfold increase in palmitoylated and 
myristoylated eNOS in caveolae in cells transfected with wild-type eNOS, when 
compared to cells transfected with the myristoylation and palmitoylation-deficient eNOS. 
In cells treated with bradykinin, Robinson et al. showed that this agonist promoted the 
loss of eNOS palmitoylation causing the enzyme to change its subcellular localization 
and translocate from the membrane to the cytosol (Robinson et al. 1995). Also, in 
response to certain agonists, eNOS can be recovered in the soluble supernatant fraction 
from cell lysates (Michel et al. 1993). Targeting of eNOS to membranes was further 
investigated by Shaul et al. who found that palmitoylated eNOS is targeted to a specific 
invaginated region of the plasma membrane (Shaul et al. 1996). This region is called the 
caveola, meaning “small cave” (Yamada 1955). Caveolae are characterized by high 
cholesterol concentration resulting in a low buoyant density and enrichment in 
glycosphingolipids (Pike et al. 2002; Shaul et al. 1998; Smart et al. 1995). More than 50 
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signaling molecules are localized to caveolae which are found in abundance in such cells 
as adipocytes, fibroblasts and endothelial cells (Schulz et al. 2005). Endothelial cell 
caveolae contain the structural protein caveolin-1, an integral membrane protein. 
Caveolin-1 forms oligomeric complexes of up to 15 molecules with a molecular mass of 
~350 kDa (Spisni et al. 2005) and binds cholesterol in a 1:1 ratio (Murata et al. 1995). 
Approximately 15% of the endothelial cell volume is comprised of caveolae and ~95% of 
the plasma membrane vesicles are caveolae (Wang et al. 2005). The N- and C-terminal 
domains of caveolin-1 interact with eNOS and inhibit its catalytic activity by interfering 
with electron transport from the reductase to the oxygenase domain of eNOS (Garcia-
Cardena et al. 1997; Ghosh et al. 1998; Ju et al. 1997; Michel et al. 1997a; Michel et al. 
1997b). Gonzalez et al. (Gonzalez et al. 2004) described experiments using small 
interfering RNAs to knockdown caveolin-1 protein expression in endothelial cells. They 
reported that although caveolin-1 protein levels were decreased by approximately 90%, 
many signaling molecules, including eNOS, were still targeted to the endothelial cell 
membrane. 
Protein-protein interactions also modulate eNOS activity. Some of the proteins 
shown to interact with eNOS are caveolin-1, eNOS interacting protein (NOSIP), eNOS 
traffic inducer (NOSTRIN), hsp90 a cytosolic chaperone protein, AS and AL (Dedio et 
al. 2001; Flam et al. 2001; Garcia-Cardena et al. 1997; Ju et al. 1997; Pritchard et al. 
2001). When endothelial cells are stimulated with calcium agonists or by shear stress, 
there is a displacement of eNOS from caveolin-1 in the caveolae facilitated by a calcium-
calmodulin complex. Following the release of eNOS from caveolin-1, eNOS binds to 
hsp90. Hsp90 also recruits PKB and prevents dephosphorylation of PKB by protein 
phosphatase 2A (Schulz et al. 2005). This action can help increase the phosphorylation of 
eNOS at serine 1177 (human). In COS-7 cells transfected with eNOS and carboxyl 
terminus of Hsp70-interacting protein (CHIP), a co-chaperone protein of hsp90, Jiang et 
al. showed that soluble eNOS was segregated to an insoluble and inactive cellular 
compartment (Jiang et al. 2003). The authors concluded that CHIP was incorporated into 
the eNOS-hsp90 complex. To complement these observations, basal eNOS activity 
measured in lung endothelial cell lysates from CHIP -/- mice was significantly greater 
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than from CHIP +/+ cell lysates (Jiang et al. 2003). To inhibit NO synthesis, NOSIP, 
binds to the oxygenase domain of eNOS and causes translocation of eNOS from the 
plasma membrane to intracellular sites (Dedio et al. 2001). Similarly, overexpression of 
NOSTRIN causes a decrease in eNOS activity due to its translocation away from the 
plasma membrane (Oess et al. 2006; Zimmermann et al. 2002). 
Cofactor availability can change NO production. A reduction in the levels of the 
pterin, BH4, an essential eNOS cofactor, causes a decrease in NO production. Werner et 
al. reported that suboptimal concentrations of BH4 cause eNOS to function as a monomer 
in the uncoupled state, converting arginine to superoxide rather than NO (Werner et al. 
1996). These superoxide radicals can react with NO forming peroxynitrites, which further 
reduce NO levels causing inactivation (Stroes et al. 1998). These peroxynitrites are strong 
oxidants that can be protonated and, in high concentration, can undergo either heterolytic 
or hemolytic cleavage forming damaging free radicals (Brovkovych et al. 1999). This 
leads to oxidative stress and damage to eNOS (Zou et al. 2002). Supplementation with 
sepiapterin, a BH4 precursor, or BH4 alone can prevent superoxide generation (Werner-
Felmayer et al. 1993). It is presumed that in vascular endothelial dysfunction, most 
bioavailable NO is inactivated by its reaction with superoxide (Naseem 2005). As a 
result, NO levels are reduced, leading to vasoconstriction, blood pressure increases and 
eventually CVD if left unresolved (Malinski 2005). 
Endothelial NOS substrate availability also regulates endothelial NO production. 
Arginine, first isolated from lupin seedlings, is classified as a semi-essential amino acid 
because at times the body is unable to synthesize enough for cellular processes depending 
on subject age, disease or injury (Morris 2004). In 1988, arginine was determined to be 
the physiologic precursor of NO (Palmer et al. 1988). Average dietary intake of arginine 
in the United States is 5.4 g/day (Visek 1986). However, due to high arginase activity in 
the small intestine, approximately 40% of the ingested arginine is degraded during 
absorption (Flynn et al. 2002). Intravenous arginine administration is an effective method 
of introducing arginine to extrahepatic tissues, like the endothelium (Flynn et al. 2002). 
Mammalian plasma arginine levels are 80 ± 20 µM (Cynober 2002). Arginine can be 
converted to other metabolites by enzymes in mammalian cells such as nitric oxide 
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synthases, arginases, arginine:glycine amidino-transferase and arginine decarboxylase 
(Morris 2004). Most arginine is synthesized in the intestinal-renal axis pathway by 
epithelial cells in the small intestine and proximal tubular cells of the kidney which 
produce arginine from glutamine and glutamate (Morris 2002; Morris 1992). Therefore 
renal function impairment can affect the body’s ability to synthesize arginine leading to a 
need for increased arginine intake. Arginase 2 which converts arginine to ornithine and 
urea is expressed in endothelial cells (Wu et al. 1998). The Km of arginase for arginine is 
2-20 mM while the Km of NOS for arginine is 2-20 µM (Davis et al. 1998). 
Extracellular arginine is transported into endothelial cells mainly by the system 
y+ transporter, a high affinity, sodium-independent transporter that transports basic 
amino acids like arginine, lysine, histidine and ornithine (Closs et al. 2000). This 
transporter is responsible for ~70-90% of arginine uptake in endothelial cells (Zharikov et 
al. 2001). The CAT1 transporter, a system y+ transporter, mediates arginine uptake in 
porcine aortic endothelial cells and is responsible for 60-80% of arginine uptake 
(McDonald et al. 1997). However, there are other arginine transport systems including L, 
B0,+ (sodium dependent) and b0,+ (Bae et al. 2005). 
Citrulline, found in high concentrations in watermelon, obtains its name from the 
Latin for watermelon, Citrullus vulgaris. Even though citrulline is a non-essential amino 
acid and is not used in protein synthesis, it is an important amino acid, especially in the 
citrulline-NO cycle (Curis et al. 2005). Mammalian plasma citrulline levels are 38 ± 8 
µM (Cynober 2002). 
For those individuals with cardiovascular risk factors like hypercholesterolemia, 
hypertension, diabetes, obesity and coronary artery disease, arginine administration has 
sometimes proved effective in improving endothelial function (Bode-Boger 2006; Bode-
Boger et al. 2003; Loscalzo 2004; Maxwell et al. 2001; Preli et al. 2002; Wu et al. 2000; 
Wu & Meininger 2002). Although arginine is not toxic, high oral doses may result in 
nausea and gastrointestinal distress due to rapid NO production in the gut or poor 
absorption of other basic amino acids (Cooke et al. 2000). More recently citrulline has 
also been used to treat endothelial dysfunction in an effort to increase endothelial NO 
production (Curis et al. 2005; Hayashi et al. 2005). It may be a better alternative than 
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arginine since it is used in less cellular processes, the main function in endothelial cells is 
to be recycled to arginine for endothelial NO production. 
Glutamine also plays a role in regulating endothelial NO synthesis. Hecker et al. 
and others demonstrated a decrease in NO production in cultured endothelial cells in the 
presence of increasing concentration of glutamine although each group suggested 
different mechanisms (Arnal et al. 1995; Hecker et al. 1990a; Meininger et al. 1997; Su et 
al. 1995; Wu et al. 2001a; Wu et al. 1993). It is thought that glutamine may inhibit AS 
leading to a decrease in recycling of citrulline to arginine and consequently a decrease in 
endothelial NO production. Glutamine does not change eNOS expression or essential 
cofactor concentrations (Wu et al. 2001b). Rats that were fed a diet rich in glutamine 
showed a decrease in NO production in vivo (Houdijk et al. 1998). Glutamine can be 
metabolized to glucosamine and may decrease intracellular NADPH levels, leading to a 
decrease in NOS activity and NO production (Wu et al. 2001a). As mentioned previously, 
glutamine enters the hexosamine biosynthetic pathway ultimately leading to increased 
intracellular UDP-GlcNAc levels. These increased UDP-GlcNAc concentrations lead to 
O-GlcNAc protein modification and for eNOS, decreased enzyme activity (Du et al. 
2001). 
Vane and others determined that arginine was essential for NO synthesis and that 
the enzymes of the citrulline-NO cycle, eNOS, AS and AL were essential to ensure 
regeneration of the arginine substrate for endothelial NO production (Flam et al. 2001; 
Hecker et al. 1990b; Wu & Meininger 1993). They showed that even though intracellular 
endothelial arginine levels are on the order of 0.1-0.8 mM and the Km of eNOS for 
arginine is ~3 µM, endothelial NO production is enhanced by the addition of exogenous 
arginine (Hardy et al. 2002; Hecker et al. 1990b; Mitchell et al. 1990). Endothelial NO is 
an important component in maintaining the health of the cardiovascular system. As 
outlined in this introduction, the ability to control and optimize the production of NO is 
critical to the reduction of morbidity and mortality due to cardiac failure. Research to 
determine the location, function and regulation of eNOS and other associated caveolar 
components which support endothelial NO production is vital to this goal. The following 
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research has been focused in this area and the results are in the four manuscripts which 
form the body of my dissertation. The major results of this body of work are: 
· Citrulline stimulates NO production in an arginine-rich medium, without affecting 
intracellular arginine levels. 
· The enzymes of the citrulline-NO cycle, eNOS, AS and AL, co-fractionate with 
caveolin-1 in an endothelial cell caveolar membrane fraction. 
· In vitro interaction assays demonstrate protein-protein interactions between fusion 
tagged AS and AL with eNOS and caveolin-1. 
· Simultaneous monitoring of apparent citrulline and NO production demonstrates 
an efficient and essential coupling of the reactions of the citrulline-NO cycle. 
· Glucosamine treatment of endothelial cells results in increased NO production in 
the basal state and decreased NO production in the stimulated state. 
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Abstract 
 Although normal intracellular levels of arginine are well above the Km, and should 
be sufficient to saturate nitric oxide synthase in vascular endothelial cells, nitric oxide 
production can, nonetheless, be stimulated by exogenous arginine. This phenomenon, 
termed the “arginine paradox”, has suggested the existence of a separate pool of arginine 
directed to nitric oxide synthesis. In this study, we demonstrate that exogenous citrulline 
was as effective as exogenous arginine in stimulating nitric oxide production, and that 
citrulline in the presence of excess intracellular and extracellular arginine further 
enhanced bradykinin stimulated endothelial nitric oxide production. The enhancement of 
nitric oxide production by exogenous citrulline could therefore be attributed to the 
capacity of vascular endothelial cells to efficiently regenerate arginine from citrulline. 
However, the regeneration of arginine did not affect the bulk intracellular arginine levels. 
This finding not only supports the proposal for a unique pool of arginine, but also 
suggested channeling of substrates that would require a functional association between 
nitric oxide production and arginine regeneration. To support this proposal, we showed 
that nitric oxide synthase, and the enzymes involved in arginine regeneration, 
argininosuccinate synthase and argininosuccinate lyase, co-fractionated with 
plasmalemmal caveolae, a subcompartment of the plasma membrane. Overall, the results 
from this study strongly support the proposal for a separate pool of arginine for nitric 
oxide production that is defined by the cellular co-localization of enzymes involved in 
nitric oxide production and the regeneration of arginine. 
 
Key Words: endothelial nitric oxide synthase, citrulline, argininosuccinate synthase, 
argininosuccinate lyase 
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Introduction 
 The body’s vascular endothelial cells constitute a large potential reservoir for 
regulation of blood vessel tone through the vasodilatory effects of endothelial nitric oxide 
(NO). Impaired production of endothelial nitric oxide has been associated with 
hypertension, heart failure, hypercholesterolemia, atherosclerosis and diabetes. 
Circulating effectors, such as bradykinin, bind to receptors on the luminal surface of 
endothelial cells signaling the transient release of nitric oxide to the adjacent smooth 
muscle layer, resulting in “relaxation” of the vessel wall. To affect endothelial nitric 
oxide production, the enzyme that catalyzes the formation of nitric oxide in endothelial 
cells, endothelial nitric oxide synthase (eNOS), is subject to multiple modes of 
regulation, including Ca+2-calmodulin binding, reversible phosphorylation and 
palmitoylation, substrate and cofactor availability, dimerization of enzyme subunits, and 
intracellular translocation (Sase & Michel 1997). 
 In cultured endothelial cells, intracellular arginine concentrations have been 
reported to range from 0.1 to 0.8 mM (Baydoun et al. 1990; Block et al. 1995; Gold et al. 
1989; Harrison 1997; Hecker et al. 1990b; Mitchell et al. 1990). At these concentrations 
of substrate, eNOS would be operating at or close to maximal velocity since reported Km 
values for arginine are less than 10 µM (Harrison 1997). However, a number of studies 
have shown that nitric oxide production by vascular endothelial cells under physiological 
conditions can be increased by extracellular arginine, despite intracellular arginine 
concentrations that should be “saturating” (Aisaka et al. 1989; Cooke et al. 1991; 
Eddahibi et al. 1992; Rossitch et al. 1991). These results suggest that the source of 
arginine utilized by eNOS is distinct from bulk cellular arginine pools. To explain these 
findings and to identify the source of arginine utilized by eNOS, McDonald et al. showed 
that the CAT1 transporter, responsible for 60-80% of total carrier-mediated arginine 
transport into endothelial cells, co-localizes in the plasma membrane in caveolae with 
endothelial nitric oxide synthase (Greene et al. 1993; McDonald et al. 1997a; McDonald 
et al. 1997b). Thus, they proposed that the arginine utilized by eNOS, at least in part, may 
be maintained by the CAT1 transporter accessing serum arginine (~90 µM). 
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 An alternative source of arginine has also been suggested to result from the 
recycling of citrulline. Hecker et al. (Hecker et al. 1990b) initially demonstrated that 
citrulline, produced in the conversion of arginine to NO, can be recycled to arginine in 
cultured endothelial cells. Other cell types have subsequently been found to have the 
capacity to regenerate arginine from citrulline utilizing two of the urea cycle enzymes, 
argininosuccinate synthase and argininosuccinate lyase (Shuttleworth et al. 1995; Xie et 
al. 2000). In neural tissue, histochemical staining for the localization of nitric oxide 
synthase demonstrated that argininosuccinate synthase, one of the enzymes involved in 
arginine regeneration is co-localized with nitric oxide synthase (Arnt-Ramos et al. 1992; 
Shuttleworth et al. 1995). 
 A linkage between arginine regeneration (citrulline-arginine cycle) and NO 
production has also been established for cells that contain the inducible form of nitric 
oxide synthase (iNOS). Such cells have a high and sustained demand for arginine owing 
to the large and Ca2+-independent increase in activity following induction of iNOS 
synthesis by inducers such as bacterial lipopolysaccharide (LPS) and certain cytokines. 
Major lines of evidence for a linkage between the arginine regeneration and 
immunostimulant-induced nitric oxide production include a demonstration of a co-
induction of iNOS and argininosuccinate synthase in a murine macrophage cell line 
(Nussler et al. 1994) and enhancement of immunostimulant-induced NO production in 
vascular smooth muscle cells following transfection with argininosuccinate synthase (Xie 
et al. 1997). 
 Several reports have further indicated a possible role for arginine regeneration in 
the transient, Ca2+-dependent, production of nitric oxide in vascular endothelial cells, but 
the evidence has been less direct. For example, Su and Block showed that during 
hypoxia, both nitric oxide production and arginine regeneration in endothelial cells were 
inhibited (Su & Block 1995); however, in this case the effect of hypoxia on nitric oxide 
production could also be explained on the basis of the Km for oxygen use by eNOS 
(Rengasamy et al. 1996). Most significant, however, was a report where two infants with 
a deficiency in argininosuccinate lyase, who could therefore not regenerate arginine, were 
shown to be hypertensive. Upon infusion of L-arginine, these patient’s blood pressure 
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decreased, supporting the critical role for arginine regeneration (citrulline-arginine cycle) 
in the regulation of systemic blood pressure (Fakler et al. 1995). 
 Although previous reports support the role of the citrulline-arginine cycle in the 
regeneration of arginine for endothelial nitric oxide production, there has heretofore been 
no strong evidence that the arginine generation system is directly coupled to the receptor-
mediated stimulation of nitric oxide production in vascular endothelial cells. In this 
report, we present evidence that arginine regeneration from citrulline is rate-limiting for 
bradykinin-mediated nitric oxide production, and that the enzymes involved in recycling 
citrulline to arginine are co-localized in discrete cellular domains (caveolae) with nitric 
oxide synthase. The localization of the arginine regeneration enzymes with caveolae and 
the synergistic response to citrulline and arginine supports the hypothesis that the 
citrulline-arginine cycle plays an important, and possibly essential, role in the production 
of nitric oxide by vascular endothelial cells. 
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Experimental Procedures 
 Materials – Dulbecco’s modified Eagle’s medium (DMEM), 
antibiotic/antimycotic, and gentamycin were obtained from Cellgro by Mediatech. Fetal 
bovine serum was purchased from Hyclone Labs. Bovine aortic endothelial cells (BAEC) 
were isolated from bovine aorta and were also obtained from a commercially available 
source (Clonetics). Percoll, Tricine, L-citrulline, and L-aspartate were acquired from 
Sigma. Sucrose was from BRL, Life Technologies Inc. OptiPrep™ was purchased from 
Gibco BRL. Broad range prestained protein markers were from New England BioLabs. 
Antibodies used for immunoblotting were: anti-caveolin-1 IgG (Transduction 
Laboratories), anti-NOS3 (c-20) IgG (Santa Cruz Biotechnology), anti-ecNOS IgG 
(Transduction Laboratories), anti-argininosuccinate synthase IgG (AnaSpec Inc.), anti-
argininosuccinate lyase IgG (AnaSpec Inc.), anti-GM130 (Golgi Matrix Protein of 130 
kDa, Transduction Laboratories), goat anti-rabbit IgG horseradish peroxidase (HRP) 
conjugated (Santa Cruz Biotechnology, Jackson ImmunoResearch Laboratories) and goat 
anti-mouse IgG horseradish peroxidase (HRP) conjugated (Jackson ImmunoResearch 
Laboratories). 
Preparation of Antibodies against Argininosuccinate Synthase (AS) and 
Argininosuccinate Lyase (AL) Peptide Sequences – A peptide region corresponding to 
amino acid residues 41-55 of the bovine sequence for AS and a peptide region 
corresponding to residues 89-103 of the human sequence for AL were used to prepare the 
AS and AL antibodies, respectively. Both antibodies and peptides were prepared by 
AnaSpec, Inc. of San Jose, CA. Antibody specificity was determined by performing a 
peptide neutralization procedure where the antibody was neutralized by preincubation 
with excess antigen (peptide). Antibody and 5x excess of corresponding peptide (by 
weight) were incubated overnight at 4°C on a rotator. This mixture was then added to 
blocking buffer and a standard Western blot procedure was performed. 
 Growth and Stimulation of Endothelial Cells – BAEC were grown to confluence 
(6-well cluster dishes; 9.6 cm2/well) in high-glucose DMEM containing 10% fetal bovine 
serum, penicillin, streptomycin, gentamycin and amphotericin B. Cells were used 3 days 
after confluence. 
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 Nitric Oxide Production Assay – Production of nitric oxide by endothelial cells 
was monitored by measuring the stable nitric oxide degradation product, nitrite, in the 
culture media. Nitrite content in the media was assayed using a fluorometric method 
(Misko et al. 1993). 
 HPLC Analysis of PITC-Derivatized Amino Acids from Endothelial Cell 
Lysates – Cells were lysed in 90% methanol, and the soluble fraction derivatized by 
PITC (phenylisothiocyanate). HPLC analysis was carried out on a Beckman HPLC 
System equipped with two model 160 pumps and controller, and a Supelcosil LC-18-DB 
column (5 µm, 4.6 mm x 250 mm) (Supelco) maintained at 45°C with a circulating water 
bath. Separation was achieved by controlling the solvent composition. Solvent A was 50 
mM ammonium acetate, with the pH adjusted to 6.8 with ammonium hydroxide. Solvent 
B was 100 mM ammonium acetate: methanol (30:70), with the pH adjusted to 6.8 using 
acetic acid. The elution program consisted of the following: (a) initial conditions, flow 
rate equal to 1.0 ml/min, 5% B, gradient curve value 6 (concave gradient); (b) starting at 
time zero, concave gradient to 10% B over 12 min; (c) at 12 min, concave gradient to 
30% B over 48 min; (d) at 60 min, concave gradient to 60% B over 7 min; (e) at 67 min, 
concave gradient to 5% B over 3 min; (f) at 70 min, return to initial conditions for 20 
min. The eluate was monitored at 254 nm with a Beckman model 160 absorbance 
detector, and the PITC-amino acids were quantified by the integral values of their peaks. 
 Caveolar Fractionation – Caveolar preparations were carried out using 
approximately 5 x 108 BAEC. Two different caveolar fractionation protocols were 
followed. The first was a detergent-free, non-alkaline protocol reported by Smart et al. 
(Smart et al. 1995) involving multiple gradient fractionations under neutral pH 
conditions. Media was removed and the cell culture flasks were washed with Buffer A 
(250 mM sucrose, 1 mM EDTA, 20 mM Tricine, pH 7.8, 1 mM L-citrulline, and 1 mM 
L-aspartate) and the cells were collected by scraping into 10 ml of Buffer A and by 
centrifugation at 1400g for 5 min. The cell pellet was resuspended in 1.0 ml of Buffer A 
and homogenized using a glass-Teflon homogenizer, and the suspension was centrifuged 
at 1000g for 10 min. The pellet was resuspended in 1.0 ml of Buffer A and re-
homogenized as described previously. The membrane fraction was collected again by 
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centrifugation and the supernatant pooled with the first and designated as the post-nuclear 
supernatant (PNS). The PNS fraction was layered on top of 30% Percoll (in Buffer A), 
and centrifuged at 84,000g for 30 min. A visible band representing the plasma membrane 
was removed and sonicated, then mixed with Buffer C (125 mM sucrose, 3 mM EDTA, 
60 mM Tricine, pH 7.8, 1 mM L-citrulline, and 1 mM L-aspartate in 50% OptiPrep). A 
10-20% gradient of OptiPrep in Buffer C diluted with Buffer A was layered on top of the 
sample and centrifuged at 53,000g for 90 min. The top 5 ml of the gradient were 
collected and 2 ml of 5% OptiPrep in Buffer C diluted with Buffer A were overlayed and 
the samples were again centrifuged. Fractions were collected and analyzed. 
 The second procedure described was carried out according to Song et al. (Song et 
al. 1996) using only a single discontinuous gradient of sucrose in Mes-buffered saline 
(MBS; 25 mM Mes, pH 6.5, 150 mM sodium chloride, 1 mM L-citrulline, 1 mM L-
aspartate) containing 250 mM sodium carbonate. BAEC were washed twice with cold 
phosphate-buffered saline (PBS), scraped into approximately 15 ml of PBS and pelleted 
at 1400g for 5 min. The supernatant was aspirated and the cell pellet was resuspended in 
1 ml of freshly prepared 500 mM sodium carbonate buffer, pH 11, containing 1 mM L-
citrulline and 1 mM L-aspartate. The cell suspension was homogenized (10 strokes) using 
a Dounce homogenizer, then further disrupted by a Polytron tissue grinder (three bursts) 
followed by sonication (Heat Systems sonicator on power output 4 at 40% duty cycle 
using a microprobe tip). The disrupted lysate was mixed with 1 ml of a 90% sucrose 
solution in MBS and transferred to a polyallomer centrifuge tube. A discontinuous 
gradient of 35%, 25%, 15%, and 5% sucrose in MBS containing 250 mM sodium 
carbonate was layered on top of the sample. Centrifugation was carried out at 164,000g 
for 16-20 h. After centrifugation, fractions (~ 0.4 ml) were removed from the top of the 
tube and neutralized with 1 N hydrochloric acid. Protein was determined using the BCA 
protein assay (Pierce) for each fraction, and the samples were stored at -80°C for further 
analysis. 
 Immunoblotting – Samples from the detergent-free, non-alkaline and alkaline 
methods of caveolae isolation were analyzed by dot blot. Samples were diluted in 50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20 (TBST) containing 0.5 mM 
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dithiothreitol and spotted on nitrocellulose. The membrane was washed and blocked in 
5% non-fat dry milk in TBST (blocking buffer), rinsed in TBST, and then incubated (60 
min) with the primary antibody (i.e. anti-caveolin, anti-eNOS, anti-argininosuccinate 
synthase, anti-argininosuccinate lyase or anti-GM130) prepared in blocking buffer. 
Following extensive washing with TBST, membranes were incubated (60 min) with the 
secondary antibody (anti-rabbit IgG HRP conjugated antibody) in blocking buffer. After 
washing with TBST, the membrane was incubated in ECL reagent (Amersham Pharmacia 
Biotech Inc.) according to the manufacturer’s instructions and then exposed to film. 
 Polyacrylamide Gel Electrophoresis and Western Blotting – Samples from the 
detergent-free alkaline method of caveolae isolation were precipitated with 
trichloroacetic acid and resuspended in a sample buffer containing sodium dodecyl 
sulfate (SDS), ß-mercaptoethanol and tracking dye. Equal amounts of protein (except 
where noted) were loaded in each lane of a precast 12% Tris-HCl mini-gel (Bio-Rad 
Laboratories). The gel was run according to the manufacturer’s instructions and then the 
proteins were transferred to Immobilon-P membranes (Millipore Corporation) using a 
wet transfer method (Bio-Rad Laboratories). The membranes were incubated with 
antibodies against caveolin-1, endothelial nitric oxide synthase, argininosuccinate 
synthase, and GM130 following the protocol outlined in the immunoblotting section 
above. Also, a peptide neutralization procedure was performed with the anti-AS antibody 
and 5x AS peptide (by weight) to show specificity of the antibody. 
 Statistical Analyses – Experimental values are expressed as mean ± SE. At least 
three independent experiments were performed for quantitative analyses of nitric oxide 
production and amino acid determinations. 
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Results 
 The Effect of Exogenous Arginine or Citrulline on Nitric Oxide Production in 
Bradykinin- Stimulated Endothelial Cells Grown in an Arginine Deficient Medium – 
Cultured endothelial cells are typically maintained in media containing 0.5-1.1 mM L-
arginine. In comparison, normal plasma arginine concentrations are approximately 0.1-
0.2 mM (Castillo et al. 1993; Wu & Morris 1998a). Such high concentrations of 
extracellular L-arginine could affect L-arginine utilization by endothelial cells, 
particularly in relation to nitric oxide production. Therefore, we examined the 
relationship between intracellular and extracellular L-arginine concentrations on nitric 
oxide production in cultured endothelial cells (BAEC). Thirty minutes prior to 
stimulation with bradykinin (10 µM), the media was changed to a synthetic DMEM 
media containing no serum and the indicated levels of either L-arginine or L-citrulline, 
respectively. As shown in Fig. 1, incubation of BAEC with various concentrations of L-
arginine resulted in a significant increase (~5- to 10-fold) in nitric oxide production for 
values from 125 to 500 µM. When the same experiment was carried out with citrulline, in 
place of arginine, a similar increase in nitric oxide production was observed. The 
measured nitric oxide activity was inhibited by the addition of the eNOS inhibitor, L-
NAME (data not shown, Appendix D). 
 The Effect of Exogenous Citrulline or Arginine on Intracellular Arginine and 
Citrulline Levels in Bradykinin-Stimulated Endothelial Cells – To determine whether 
changes in intracellular L-arginine content contributed to the changes in nitric oxide 
production, intracellular arginine and citrulline levels were determined using HPLC 
analysis. As shown in Fig. 2A, incubation of BAEC in a synthetic media with 0 to 1000 
µM L-arginine resulted in a dose-dependent increase in intracellular arginine. However, 
the intracellular concentrations of citrulline were not influenced by changes in the level 
of extracellular or intracellular arginine. Similarly, when extracellular citrulline was 
varied, intracellular arginine levels were not significantly affected in spite of the fact that 
enhanced nitric oxide release was nearly identical to that caused by varying extracellular 
arginine (Fig. 2B). This result suggested that citrulline was efficiently converted to 
arginine maintaining the arginine required to support nitric oxide production. The fact 
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that exogenous arginine or citrulline effectively sustained nitric oxide production in 
BAEC also suggested that the arginine necessary to support nitric oxide production could 
be efficiently maintained by extracellular arginine or citrulline even though “bulk” 
intracellular arginine levels appeared to be sufficient to “saturate” eNOS. Most 
importantly, though, citrulline efficiently mimicked the arginine effect on enhanced nitric 
oxide production. 
 The Effect of Exogenous Citrulline or Arginine on Nitric Oxide Production in 
Bradykinin- Stimulated Endothelial Cells Grown in Complete Medium – The 
proficiency of exogenous arginine or citrulline to support nitric oxide production in 
medium lacking arginine was compared with their capacity to support nitric oxide 
production in medium where arginine was not limiting. In medium lacking arginine (Fig. 
3A), both exogenous arginine (500 µM) and citrulline (500 µM) enhanced nitric oxide 
production. However, under conditions where the same medium now contained 443 µM 
L-arginine (comparable to the levels normally found in DMEM medium, Fig. 3B), 
citrulline enhanced nitric oxide production in spite of the fact that both endogenous and 
exogenous arginine levels were saturating and therefore sufficient to support nitric oxide 
production. Moreover, the demonstration that additional arginine (500 µM) did not 
further enhance nitric oxide production (compare Figs. 3A and 3B) in the arginine 
supplemented medium supported the conclusion that the uptake of exogenous arginine 
was saturating under these conditions. Note that the control sample of Fig. 3B is 
equivalent to the ‘Arg’ sample of Fig. 3A. All measurable nitric oxide production was 
inhibited by the eNOS inhibitor, L-NAME. 
 Interestingly, the intracellular arginine and citrulline levels for any given 
concentration of exogenous addition (data not shown) were found to be identical to those 
corresponding levels shown in Fig. 2. Again, intracellular citrulline levels remained 
unaffected by the increased intracellular arginine that resulted from the addition of 
exogenous arginine, and most significantly, the addition of citrulline (500 µM) did not 
affect intracellular arginine levels despite the observed enhanced production of nitric 
oxide. The fact that there was a proportionate increase in nitric oxide production with the 
addition of citrulline by stimulated endothelial cells saturated in arginine also suggested 
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that citrulline was limiting and that the generation of arginine from citrulline provided the 
substrate, arginine, for nitric oxide production. 
 The Co-Fractionation of Nitric Oxide Synthase, Argininosuccinate Synthase 
and Argininosuccinate Lyase with Plasmalemmal Caveolae – Definition of a unique 
pool of arginine may occur through the functional association of enzymes involved in the 
generation of arginine from citrulline. To address this possibility, a caveolar fraction was 
generated by successive gradient fractionations using a detergent-free, non-alkaline 
procedure for purifying caveolae membranes (Smart et al. 1995). As shown in Fig. 4, 
where membrane and caveolae fractions were followed by immunoblotting, both eNOS 
as well as argininosuccinate synthase and lyase were identified in the caveolar fraction. 
Although all immuno-crossreacting material for argininosuccinate synthase and lyase co-
fractionated with the membrane fraction in the initial gradient, the association of 
argininosuccinate synthase and lyase in the final caveolar fraction was not quantitative. 
This result was not unanticipated considering argininosuccinate synthase and 
argininosuccinate lyase are not integral membrane proteins, nor do they possess 
myristoylation or palmitoylation that would secure their association with eNOS in the 
caveolar plasmalemmal fraction. Probable protein-protein interactions that are likely 
involved in their plasmalemmal localization with nitric oxide production may not 
quantitatively withstand the rigors of all the gradient fractionation steps. There was no 
Golgi matrix protein crossreacting material found in the second gradient step indicating 
that this fraction was not contaminated by Golgi membrane (data not shown). 
 To ensure that the co-localization observed was not simply intrinsic to the 
caveolar purification protocol, a different caveolar protocol with very different 
fractionation conditions was used. In this procedure, after cell lysis and homogenization, 
a single alkaline sucrose step-gradient separates caveolae from the other membranes and 
cellular material (Song et al. 1996). As shown in Fig. 5, both argininosuccinate synthase 
and argininosuccinate lyase were again shown to co- fractionate with caveolae, even 
under relatively extreme alkaline conditions. Golgi membrane, based on an anti-Golgi 
matrix protein antibody, was detected only in fractions 5 through 7 of the alkaline 
gradient (data not shown) corresponding to approximately 22-26% sucrose where the 
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Golgi membrane was expected to fractionate (Vleurick et al. 1999). Results, showing that 
cellular argininosuccinate synthase and argininosuccinate lyase remain associated with a 
highly purified caveolar plasmalemmal fraction, are consistent with the proposal that the 
regeneration of arginine from citrulline defines a unique caveolar pool of arginine utilized 
by vascular endothelial cells for nitric oxide signaling. 
 The identity of argininosuccinate synthase, eNOS and caveolin-1 was confirmed 
by Western blotting of fractions separated by the alkaline caveolae membrane isolation 
procedure. As shown in Fig. 6, the Western blot data shows co-fractionation of caveolin-
1, eNOS and argininosuccinate synthase proteins. The amount of argininosuccinate lyase 
present in the caveolae membrane fraction after SDS-PAGE and transfer was below the 
primary antibody limit of detection by Western blotting. A marker protein for the Golgi, 
the GM130 protein, was detected in fractions 5 through 10 of the alkaline gradient (data 
not shown) (Vleurick et al. 1999). The protein profile shows that the bulk of the protein 
remains in the more dense gradient fractions (fractions 6-10). 
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Discussion 
 We have shown that exogenous citrulline effectively stimulated nitric oxide 
production, and that it was sufficient to affect maximal endothelial nitric oxide 
production in spite of apparent saturating levels of both endogenous and exogenous 
arginine. Exogenous citrulline did not affect intracellular arginine levels, indicating that 
there was no direct correlation between bulk intracellular arginine levels and nitric oxide 
production. These findings were taken to support the proposal that the regeneration of 
arginine from citrulline is necessary and sufficient in providing the substrate, arginine, for 
nitric oxide production. By defining a unique source of arginine for nitric oxide 
production (Fig. 7), the endothelial cell spares the bulk of cellular arginine for other 
metabolic pathways. In support of this proposal are reports demonstrating that the 
inhibition of argininosuccinate synthase in cultured endothelial cells blocked production 
of arginine, and consequently blocked nitric oxide production in spite of intracellular 
arginine levels sufficient to support nitric oxide production (Hecker et al. 1990a; Hecker 
et al. 1990b; Sessa et al. 1990b). 
 If regeneration of arginine from citrulline defines the source of arginine for nitric 
oxide production, this would suggest that these two processes are functionally associated. 
Since endothelial nitric oxide synthase is targeted by acylation to caveolae, where it 
interacts with caveolin-1, we asked the question as to whether the arginine regenerating 
enzymes, argininosuccinate synthase and argininosuccinate lyase, co-localize with this 
same subcellular fraction. Two different fractionation protocols for the purification of 
caveolae were used to demonstrate co-fractionation (Smart et al. 1995; Song et al. 1996). 
Each protocol generated a caveolar membrane fraction that was highly enriched in 
caveolin-1, nitric oxide synthase, argininosuccinate synthase and argininosuccinate lyase. 
These results, therefore, were taken to support the proposal that the endothelial cell can 
effectively distinguish the bulk of intracellular arginine from the arginine needed for 
nitric oxide production through the functional co-localization of arginine regeneration 
enzymes and nitric oxide synthase with plasmalemmal caveolae. Although not 
demonstrated in these results, a possible consequence of this functional association would 
be the channeling of intermediates through these regeneration enzymes, similar to that 
28 
observed for urea cycle intermediates, where essentially no metabolite between citrulline 
to arginine would be found in an intracellular pool of the endothelial cell. 
 The only known metabolic fate of citrulline is as a substrate for argininosuccinate 
synthase. Conjugation of citrulline with aspartate, catalyzed by argininosuccinate 
synthase, provides the amino nitrogen that ultimately is released as nitric oxide from 
arginine. Arginine formed by argininosuccinate lyase from argininosuccinate would be 
channeled to nitric oxide synthase; whereas, fumarate could be recycled to oxaloacetate. 
Oxaloacetate, in turn, can accept another amino group to reform aspartate (Fig. 7). Thus, 
in endothelial cells, the funneling of amino groups from other amino acids into either 
aspartate (or glutamate) provides the nitrogen for nitric oxide production. In this way, the 
backbone of citrulline/arginine is conserved and the expendable nitrogen for nitric oxide 
derives from the transamination of amino groups from other amino acids into aspartate. 
29 
Acknowledgments 
 This work was initiated by Dr. Paul J. Hartmann as a graduate student in the 
laboratory of Dr. Duane C. Eichler. His early work was supported by an American Heart 
Association, Florida Affiliate Fellowship #9504007. This work was also supported by 
AHA Florida Affiliate Grant #9701711, #9950864V and AHA National Grant 
#9750222N. 
Figure 1. Effect of L-arginine and L-citrulline on bradykinin stimulated nitric oxide 
production in DMEM minus arginine. Endothelial cells were grown to confluence (6-
well cluster dishes; 9.6 cm2/well) in complete DMEM as described in Experimental 
Procedures. As indicated, concentrations of L-arginine or L-citrulline were added to their 
respective wells (in duplicate) in a total of 2 ml of synthetic DMEM (minus arginine) 
containing 2.5 mM CaCl2. After 30 min, 100 µl of media was removed for nitrite 
determination, and, where indicated, the cells were stimulated by the addition of 
bradykinin (final concentration of 10 µM). Incubation was continued for an additional 60 
min at which time samples (100 µl) of media were taken and assayed for nitric oxide 
production (nitrite determination). Conditions are indicated in each panel. Error bars 
represent the standard error of the mean. 
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Figure 2. Effect of exogenous arginine or citrulline on intracellular concentrations of 
arginine and citrulline. Endothelial cells were grown in DMEM as described in 
Experimental Procedures. The indicated concentration of L-arginine or L-citrulline was 
added in a total of 2 ml of synthetic DMEM (minus arginine) containing 2.5 mM CaCl2. 
After 30 min, the cells, where indicated, were stimulated by the addition of bradykinin 
(final concentration of 10 µM). Incubation was continued for an additional 60 min. Cells 
were lysed in 90% methanol, and the soluble fraction derivatized by PITC. PITC 
derivatized samples were fractionated on a 5 µm C-18 reverse phase column (4.6 mm x 
250 mm) (Supelco) as described in Experimental Procedures. Integrated values for 
arginine and citrulline peaks were normalized against an internal standard (threonine) to 
assess changes. (A) Levels of intracellular arginine and citrulline affected by the addition 
of arginine. (B) Levels of intracellular arginine and citrulline affected by the addition of 
citrulline. Arginine levels: plus bradykinin (filled circles), minus bradykinin (open 
circles). Citrulline levels: plus bradykinin (filled triangles), minus bradykinin (open 
triangles). 
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Figure 3. Effect of arginine and citrulline on bradykinin stimulated nitric oxide 
production in the absence (Fig. 3A) and presence (Fig. 3B) of arginine in the 
medium. Endothelial cells were grown as described in Experimental Procedures. L-
arginine (‘Arg’, 500 µM) or L-citrulline (‘Cit’, 500 µM) was added in a total of 2 ml of 
synthetic DMEM (plus or minus 443 µM L-arginine) containing 2.5 mM CaCl2. After 30 
min, 100 µl of media was removed for nitrite determination, and the cells were 
stimulated, where indicated, by the addition of bradykinin (‘Bk’, 10 µM). Incubation was 
continued for another 60 min at which time samples (100 µl) of media were taken and 
assayed for nitric oxide production (nitrite determination). The amount of nitrite found in 
the sample at the 30 min equilibration time point was subtracted from the amount of 
nitrite found at the 90 min time point. This value was converted to pmol of nitrite formed 
in 60 min per number of cells in each plate well. ‘C’ represents control in synthetic 
DMEM. Error bars represent the standard error of the mean. 
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Figure 4. Detergent-free, non-alkaline, co-fractionation of plasmalemmal caveolae, 
nitric oxide synthase, argininosuccinate synthase and argininosuccinate lyase. 
Fractions from the last 5% OptiPrep centrifugation step (see Experimental Procedures) 
were collected from the top of the tube and analyzed by immunoblotting using the 
appropriate primary antibody, and visualized by enhanced chemiluminescence. Boxed 
areas represent the plasmalemmal caveolar fractions. Fraction numbers are in ascending 
order from the top to the bottom of the tube. 
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Figure 5. Alkaline sucrose co-fractionation of plasmalemmal caveolae, nitric oxide 
synthase, argininosuccinate synthase and argininosuccinate lyase. After 
centrifugation, fractions (~ 0.4 ml) were collected from the top of the gradient and 
analyzed by immunoblotting using the appropriate primary antibody, and visualized by 
enhanced chemiluminescence. Boxed areas represent the plasmalemmal caveolar 
fractions. Fraction numbers are in ascending order from the top to the bottom of the tube. 
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Figure 6. Western blotting with caveolin-1, endothelial nitric oxide synthase, and 
argininosuccinate synthase. Gradient fractions from an alkaline sucrose caveolae 
membrane preparation were electrophoresed and then analyzed by Western blotting using 
the appropriate primary antibody, and visualized by enhanced chemiluminescence. Boxed 
areas represent the plasmalemmal caveolar fractions. Fraction numbers are in ascending 
order from the top to the bottom of the tube. In the Western blots showing caveolin-1 and 
eNOS co-fractionation, 3 µg of total protein from Fractions 1-2 and 10 µg of total protein 
from Fractions 3-11 were loaded on the gel. In the Western blot illustrating 
argininosuccinate synthase co-fractionation, the following total protein amounts were 
loaded on the gel: Fraction 1: 2 µg, Fraction 2: 8 µg and Fractions 3-11: 21 µg. 
Prestained protein marker apparent molecular weights (kDa) are labeled at the left of 
each blot. Also shown at the bottom of the figure is a graph of the gradient fraction 
protein profile. 
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Figure 7. Arginine regeneration for nitric oxide production in vascular endothelial 
cells. The integration of pathways for the synthesis of nitric oxide, regeneration of 
arginine from citrulline, and the recycling of fumarate to aspartate are illustrated in the 
diagram. 
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Abstract 
Nitric oxide (NO), a key vasorelaxant, is formed by sequential reactions where 
arginine is converted to NO and citrulline by endothelial nitric oxide synthase (eNOS). 
Citrulline is regenerated to arginine by argininosuccinate synthase (AS) followed by 
argininosuccinate lyase (AL). This series of reactions constitutes the citrulline-NO cycle, 
which plays an essential role in endothelial NO production. The enzymes of the 
citrulline-NO cycle are associated with caveolae but there is no evidence for direct 
protein interactions between these components. AS and AL were cloned and expressed in 
E. coli with two different N-terminal fusion tags, a glutathione S-transferase (GST) or a 
hexahistidine, T7 (6xHis-T7) tag. Bovine aortic endothelial cells (BAEC) were either 
untreated or stimulated with a calcium agonist to increase NO production. Endothelial 
cell lysates were prepared and used to test for protein-protein interactions using in vitro 
interaction assays with bacterially expressed fusion proteins. AS and AL with 6xHis-T7 
tags pulled down eNOS and caveolin-1 from a BAEC lysate. These results provide, for 
the first time, evidence for a physical association between AS, AL, eNOS and caveolin-1, 
consistent with the important functional role of the citrulline-NO cycle in endothelial NO 
production. 
 
Keywords: nitric oxide, argininosuccinate synthase, argininosuccinate lyase, citrulline, 
arginine 
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Introduction 
 Nitric oxide (NO), is an essential signaling component for a broad array of 
physiological processes important for immune, neurological and cardiovascular 
functions. It is produced by the conversion of arginine to NO and citrulline in a reaction 
catalyzed by nitric oxide synthase (NOS). The endothelial (eNOS) and neuronal (nNOS) 
forms of NOS are largely constitutive and are activated by association with Ca-
calmodulin in response to transient increases in intracellular Ca2+ levels, while the 
inducible form is regulated primarily at the transcriptional level. NO produced by the 
endothelium plays a key role in vasorelaxation. Because of the important role of 
endothelial-derived NO, eNOS is regulated at several different levels including 
translational, post-translational, protein-protein interactions, cofactor availability and 
substrate (arginine) availability. The product, citrulline, is regenerated to arginine by the 
sequential action of argininosuccinate synthase (AS) and argininosuccinate lyase (AL), 
two enzymes which have received a great amount of study for their role in the urea cycle. 
In 1990, Vane and colleagues, and subsequently others, observed that in cultured 
endothelial cells in the presence of saturating amounts of arginine, the addition of 
exogenous arginine caused endothelial cells to produce more NO (Hecker et al. 1990; Wu 
et al. 1998; Wu et al. 1993). This is surprising given that the Km of eNOS for arginine is 
~3 µM and intracellular endothelial arginine levels average between 100-800 µM. This 
phenomenon is termed the “arginine paradox”. 
 Van Geldre et al. showed that in muscle layer nerve fibers and neurons in the 
myenteric plexus of the rat gastric fundus, AS and AL co-localized with nNOS, another 
calcium-dependent NOS. They also showed in smooth muscle strips that administration 
of arginine completely, and citrulline partially, prevented L-NAME (NOS inhibitor) 
inhibition of muscle relaxation (Van Geldre et al. 2002). Mohacsi et al. demonstrated that 
arginine availability was not limiting for recombinant eNOS activity (Mohacsi et al. 
1999). Adenovirus mediated eNOS transfer into rabbit aorta was performed and the 
researchers noted improved vascular relaxation with or without arginine administration. 
Simon et al. demonstrated that there are different intracellular compartments of arginine 
depending on cell type and eventual fate (Simon et al. 2003). McDonald et al. 
 43 
demonstrated using confocal microscopy in porcine aortic endothelial cells that caveolin-
1, the structural protein of caveolae, colocalized with the cationic amino acid transporter 
1, system y+ (CAT1) and that eNOS and CAT1 colocalized to caveolae. They concluded 
that the intracellular arginine was inaccessible to eNOS and that eNOS was colocalized 
with the arginine transporter, CAT1, at the plasma membrane surface to allow for NO 
production from arginine transported into the cell (McDonald et al. 1997). More recently, 
Li et al. established that eNOS and CAT1 directly interact, but that this interaction 
increases NO production in an arginine transport independent manner (Li et al. 2005). 
Hellermann et al. examined the effects of sodium orthovanadate (vanadate), a protein 
tyrosine phosphatase. They demonstrated that stimulation of NO production by 
bradykinin and sodium orthovanadate, greatly increased NO production over the basal 
state which they attributed to changes in eNOS protein-protein interactions (Hellermann 
et al. 2000). Venema et al. also showed an interaction through heat shock protein 90 
(hsp90) between eNOS and soluble guanylate cyclase which is activated by NO binding 
to the heme within the enzyme (Venema et al. 2003). Jiang et al. showed that in COS-7 
cells transfected with eNOS and carboxyl terminus of Hsp70-interacting protein (CHIP), 
a co-chaperone protein of hsp90, CHIP was incorporated into the eNOS-hsp90 complex 
and then soluble eNOS was segregated to an insoluble and inactive cellular compartment 
(Jiang et al. 2003). The eNOS interacting protein, NOSIP, was also shown to associate 
with eNOS causing it to translocate from the caveolae to other subcellular fractions 
(Dedio et al. 2001). Zimmermann et al. demonstrated that overexpression of eNOS traffic 
inducer, NOSTRIN, also caused a translocation of eNOS away from the plasma 
membrane resulting in reduced NO production in Chinese hamster ovary cells stably 
expressing eNOS (Zimmermann et al. 2002). Our laboratory demonstrated a co-
fractionation of eNOS, AS and AL with caveolin-1 from endothelial cell caveolar 
membranes (Flam et al. 2001). 
 To complement our results and the results of others outlined above, we designed a 
series of in vitro interaction assays to assess direct protein-protein interactions and those 
associations that may occur as the result of post-translational modifications. We prepared 
AS and AL bait proteins with either 6xHis or GST N-terminal fusion tags. In vitro 
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translated AS and endothelial cell lysates were used as prey proteins. We demonstrated a 
direct interaction between AS and AL and associations between AS and eNOS; AL and 
eNOS; AS and caveolin-1; and AL and caveolin-1. These results further support our 
hypothesis of a functional association between enzymes of the citrulline-NO cycle. These 
functional associations provide strong evidence for a physical association between AS, 
AL, eNOS and caveolin-1, consistent with the important functional role of the citrulline-
NO cycle in endothelial NO production. 
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Materials 
Cloning of bovine argininosuccinate synthase (bAS) into plasmid pGEX-5X-1 and 
pET-28b(+) – bAS-pcDNA3.1-V5HisB, a plasmid encoding bAS with carboxy-terminal 
V5 and hexahistidine fusion tags, was previously prepared. The coding portion of bAS 
was amplified from bAS_pcDNA3.1_V5HisB using primers bASL_BamHI_pGEX (5´ – 
GTA CCG AGC TCG GAT CCG CCC CTG CTC CGC CGA CTG – 3´) and 
ASR1248EcoRI (5´ – TGC AGA ATT CTT TTT GGC GGT GAC CTT GTT CTG – 3´) 
synthesized by IDT. PCR was accomplished using Pfu Turbo DNA polymerase 
(Stratagene) and 30 cycles with a 2 minute extension time. The Qiaquick PCR cleanup kit 
(Qiagen) was used to remove excess nucleotides and the bAS PCR product, pGEX-5X-1 
(GE Healthcare) and pET-28b(+) (Novagen) were doubled digested with BamHI and 
EcoRI. The bAS PCR product (1419 bp) was ligated into the pGEX-5X-1 and pET-
28b(+) plasmids using the LigaFast Rapid DNA ligation system (Promega) and then 
transformed into E. coli DH5α (Invitrogen). Colonies were analyzed and a positive clone 
from each group, pGEX-5X-1-bAS or pET-28b(+)-bAS, was sequenced (Retrogen). 
Cloning of human argininosuccinate lyase (hAL) into plasmid pGEX-5X-1 and 
pET-28c(+) – The plasmids pAL3b_pUC8 (ATCC 57497, accession number M14218), 
pGEX-5X-1 and pET-28c(+) were digested with BamHI. The digested plasmids, pGEX-
5X-1 and pET-28c(+), were treated with calf alkaline phosphatase (Promega) to prevent 
plasmid religation. The hAL insert (1628 bp) was ligated into the pGEX-5X-1 and pET-
28c(+) plasmids using the LigaFast Rapid DNA ligation system and then transformed 
into DH5α. Colonies were analyzed and a positive clone, pGEX-5X-1-hAL or pET-
28c(+)-hAL, from each group was sequenced. 
Expression of fusion proteins – All the previously prepared plasmids in either 
pGEX-5X or pET-28 were transformed into E. coli Rosetta 2 or Rosetta 2(DE3), 
respectively, competent cells (Novagen). A 10 ml culture of Rosetta 2 was grown in P-
0.5G minimal medium according to the method of Studier (Studier 2005) in a 125 ml 
flask at 225 rpm and 37°C in an incubator shaker (New Brunswick Scientific). 5 ml of 
this culture was added to ZYP-5052 medium, an auto-induction medium containing 1% 
tryptone, 0.5% yeast, 0.5% glycerol, 0.05% glucose, 0.2% α-lactose and trace metals 
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(FeCl3, CaCl2, MnCl2, ZnSO4, CoCl2, CuCl2, NiCl2, Na2MoO4, Na2SeO3 and H3BO3). 
The ZYP-5052 medium also contained 34 µg/ml chloramphenicol and either 100 µg/ml 
carbenicillin for pGEX plasmids or 30 µg/ml kanamycin for pET-28 plasmids. 500 ml of 
each culture was grown in a 2 liter flask at 200 rpm and 22°C in an incubator shaker. The 
pGEX-5X-1, pGEX-5X-1-hAL, pGEX-5X-1-bAS, pET28c(+)-hAL and pET28b(+)-bAS 
cultures in ZYP-5052 medium were grown for 48 hours. The cells were collected by 
centrifugation at 6000xg for 20 minutes and stored frozen at -20°C until use. 
Purification of GST fusion proteins – Cell pellets were thawed on ice and 15 ml 
lysis buffer A (50 mM Tris-HCl, pH 7.8; 1 mM EDTA; 10% glycerol (v/v); 150 mM 
NaCl) containing 1.5 ml of mini EDTA-free protease inhibitor cocktail tablet (Roche) 
and 200 µg/ml of lysozyme was added to each 500 ml culture pellet. The bacterial 
suspension was lysed by stirring at 4°C for 20 minutes followed by pulsed sonication. 
The sonicated bacterial suspension was centrifuged at 25,000xg for 30 minutes at 4°C to 
pellet insoluble material. For GST, GST-bAS and GST-hAL protein purification, the 
following steps were performed. Six ml of glutathione-agarose slurry (50% slurry in lysis 
buffer A, Pierce Biotechnology) was added to the soluble fraction and placed on a 
Nutator rocker for 1 hour at 4°C. The soluble fraction and glutathione-agarose were 
centrifuged to pellet the glutathione-agarose beads. After five washes with glutathione 
wash buffer (50 mM Tris-HCl, pH 7.8; 400 mM NaCl), enough buffer was removed to 
create a 50% slurry. Fusion proteins bound to agarose beads were stored at 4°C. 
Purification of 6xHis-T7 tag fusion proteins – 6xHis bacterial pellets were thawed 
on ice and resuspended in 15 ml of lysis buffer B (50 mM Tris Base; 300 mM NaCl; 5 
mM imidazole, pH 8.0) containing 1.5 ml of mini EDTA-free protease inhibitor cocktail 
tablet and 200 µg/ml of lysozyme. The bacterial suspension was lysed by stirring at 4°C 
for 20 minutes followed by pulsed sonication. The sonicated bacterial suspension was 
centrifuged at 25,000xg for 30 minutes at 4°C to pellet insoluble material. For 6xHis-bAS 
and 6xHis-hAL protein purification, the following steps were performed. Six ml of 
nickel-nitriloacetic acid (Ni-NTA) agarose slurry (50% slurry in lysis buffer B, Qiagen) 
was added to the soluble fraction and placed on a Nutator rocker for 1 hour at 4°C. The 
soluble fraction and Ni-NTA agarose were centrifuged to pellet the Ni-NTA agarose 
 47 
beads. After five successive washes each with wash buffer 1 (50 mM Tris Base; 300 mM 
NaCl; 10 mM imidazole, pH 8.0), wash buffer 2 (50 mM Tris Base; 300 mM NaCl; 20 
mM imidazole, pH 8.0) and wash buffer 3 (50 mM Tris Base; 300 mM NaCl; 45 mM 
imidazole, pH 8.0) the buffer was removed and lysis buffer B was added back to create a 
50% slurry. Fusion proteins bound to agarose beads were stored at 4°C. 
In vitro transcription and translation – bAS-pcDNA3.1-V5HisB was in vitro 
translated using the TNT T7 Coupled Reticulocyte Lysate System (Promega) according 
to the manufacturer’s protocol. 
Cell culture and reagents – Bovine aortic endothelial cells (BAEC) in 100 mm 
dishes were cultured in Dulbecco’s modification of Eagle’s medium (DMEM) containing 
10% fetal bovine serum (fbs), 100 IU penicillin, 100 µg/mL streptomycin and 0.25 
µg/mL amphotericin B at 37°C in a 5% CO2 incubator. DMEM, HBSS, HEPES, and L-
glutamine were obtained from Mediatech, Inc. Fetal bovine serum was obtained from 
HyClone. DMEM without phenol red was obtained from Invitrogen. Bradykinin was 
obtained from Sigma-Aldrich. Sodium orthovanadate was obtained from Alexis 
Biochemicals. 
BAEC lysate preparation – On the day of the experiment, BAEC were rinsed in 
Hanks’ balanced salt solution without phenol red containing 20 mM HEPES. Phenol red-
free DMEM containing 10% fbs and 4 mM L-glutamine was added to each dish. Some 
cells were treated with 10 µM bradykinin plus 20 µM sodium orthovanadate for 90 
minutes. A portion of medium was removed for nitric oxide determinations at the 
beginning and end of the treatment. Following the treatment, the dishes were placed on 
ice, medium was removed and the cells were washed with cold 1x Dulbecco’s phosphate 
buffered saline (Mediatech). Modified RIPA buffer (20 mM Tris-HCl, pH 7.4; 1% Triton 
X-100; 1% sodium deoxycholate; 0.1% SDS; 1 mM sodium orthovanadate, 50 mM 
sodium fluoride; 10 mM sodium pyrophosphate; 1x Calbiochem protease inhibitor 
cocktail III) was added and the cells were scraped off the dish. The cell suspension was 
removed to a 2 ml microfuge tube and the suspension was disrupted by pulsed sonication 
for six seconds at 20% duty cycle. Protein content was determined using the BCA Protein 
Assay (Pierce Biotechnology) and the lysates were stored at -80°C until used. 
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In vitro interaction assays – In vitro translated proteins as bait – After the bAS 
and hAL fusion proteins were prepared, 40 µl of GST fusion protein bound to 
glutathione-agarose was added to 1.5 ml microfuge tubes. 20 µl of in vitro translated 
protein was added, the final volume was brought to 1 ml using binding buffer and the 
mixture was then placed on end-over-end rotator for two hours at 4°C. Following 
binding, the agarose beads were pelleted by centrifugation at 1000xg for 5 minutes at 
4°C. Pull-down assay tubes containing GST fusion proteins bound to glutathione-agarose 
were washed six times with wash buffer A (50 mM HEPES, pH 7.5; 400 mM NaCl; 0.5% 
CHAPS detergent; 1 mM AEBSF). The final wash was removed and 25 µl of 2x 
Laemmli sample buffer containing 320 mM dithiothreitol was added to each sample. 
In vitro interaction assays – BAEC lysates as bait – After the bAS and hAL 
fusion proteins were prepared, 20 µl of 6xHis fusion protein bound to Ni-NTA agarose 
was added to 1.5 ml microfuge tubes. 250 µg of BAEC lysate was added, the final 
volume was brought to 1 ml using binding buffer (50 mM Tris-HCl, pH 7.4; 20% 
glycerol; 100 mM NaCl; 20 mM 2-mercaptoethanol; Calbiochem 1x protease inhibitor 
cocktail III) and the mixture was then placed on end-over-end rotator for two hours at 
4°C. Following binding, the agarose beads were pelleted by centrifugation at 1000xg for 
5 minutes at 4°C. Pull-down assay tubes containing 6xHis fusion proteins bound to Ni-
NTA agarose were washed six times with wash buffer B (50 mM HEPES, pH 7.5; 10 
mM imidazole, pH 7.5; 400 mM NaCl; 0.5% CHAPS detergent; 1 mM AEBSF). The 
final wash was removed and 25 µl of 2x Laemmli sample buffer (Bio-Rad Laboratories) 
containing 320 mM dithiothreitol was added to each sample. 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting – Samples in reducing Laemmli sample buffer were heated for 5 minutes 
at 95°C, cooled to room temperature and loaded on a 4-15 % Tris-HCl gradient gel (Bio-
Rad Laboratories). The proteins were separated using a Mini-Protean II (Bio-Rad 
Laboratories) following the manufacturer’s instructions. Following SDS-PAGE, the 
proteins were transferred to Immobilon-P polyvinylidene fluoride (PVDF) membranes 
(Millipore) using a Mini-Protean transfer system (Bio-Rad Laboratories) and following 
the manufacturer’s instructions. After the transfer, the membrane was removed and 
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blocked in 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 
(TBST) for 1 hour at room temperature. The SDS-PAGE gel was soaked in water to 
remove SDS and to dissociate the filter paper from the gel. The gel was then stained with 
GelCode Blue to determine protein loading. Primary antibody prepared in 5% non-fat dry 
milk/TBST was added to the membrane and incubated overnight at 4°C. The primary 
antibodies that were used included anti-V5, mouse monoclonal (Invitrogen; 1:5000); anti-
GST, mouse monoclonal (Santa Cruz Biotechnology; 1:4000); anti-His-tag, mouse 
monoclonal (Novagen; 1:5000); anti-AS, mouse monoclonal, (BD Transduction 
Laboratories; 1:2500); anti-caveolin1 monoclonal, (BD Transduction Labs; 1:1000) and 
anti-eNOS, mouse monoclonal (BD Transduction Labs; 1:2500). The membrane was then 
rinsed with TBST several times. A secondary antibody prepared in 5% non-fat dry 
milk/TBST was added to the membrane and incubated for 1 hour at room temperature. 
The secondary antibody used was peroxidase-conjugated affinipure goat anti-mouse IgG, 
(Jackson ImmunoResearch Laboratories, Inc). The membrane was again washed with 
TBST and proteins were detected using ECL (GE Healthcare). 
SDS-PAGE and staining – 30 µl of 2x reducing Laemmli sample buffer was 
added to 15 µl of fusion protein bound to agarose beads. The samples were heated for 5 
minutes at 95°C, cooled to room temperature and loaded on a 4-15 % Tris-HCl gradient 
gel. The proteins were separated using a Mini-Protean II following the manufacturer’s 
instructions. Following SDS-PAGE, the gel was water washed and stained with GelCode 
Blue to visualize total protein loading. The gel was fixed in 2% glycerol, 10% methanol 
and dried on Whatman 3MM filter paper. The gel was scanned and band densitometry 
was performed using ImageQuant 5.2 (GE Healthcare). 
Statistics – The results shown are representative immunoblots from experiments 
repeated at least two times. 
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Results 
Expression of bAS and hAL fusion proteins – Fusion proteins encoded by the 
pET-28 vectors contained either an N-terminal 6xHis-thrombin-T7 tag plus an optional 
C-terminal 6xHis (6xHis). The plasmid conferred resistance to 30 µg/ml kanamycin and 
protein expression was controlled by a T7 promoter. Fusion proteins encoded by the 
pGEX-5X vectors contained an N-terminal glutathione-S-transferase-factor Xa cleavage 
tag (GST). The plasmid conferred resistance to 100 µg/ml ampicillin and protein 
expression was controlled by a tac promoter. Table 1 indicates plasmid designation, 
fusion protein name and theoretical size (Gasteiger et al. 2005). Using the Gap program 
the percent similarity between bAS and hAS was 97% and between bAL and hAL was 
96% (Seqweb 3.1, Accelrys, Inc.) 
 After the fusion protein plasmids were sequenced, the pET-28 plasmids were 
transformed into Rosetta 2(DE3) and the pGEX-5X plasmids were transformed into 
Rosetta 2 competent bacteria for protein expression. The Rosetta 2 strain is derived from 
BL21 and contains the pRARE plasmid conferring resistance to chloramphenicol. This 
pRARE plasmid contains tRNA genes that decode for seven rare codons, improving full 
length eukaryotic protein expression. Originally some of the plasmids were transformed 
into BL21(DE3)pLysS for protein expression, but greater protein yields were obtained 
with the Rosetta 2 strains. Also, the use of 2 liter flasks for the 500 ml cultures improved 
aeration, growth and protein yield (Studier 2005). 
 After extensive washes and batch purification, fusion proteins bound to agarose 
beads were mixed with reducing sample buffer and separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Proteins were transferred from the gel to PVDF 
membranes and fusion proteins were detected by immunoblotting (Figures 1B-C). The 
polyacrylamide gel was stained with GelCode Blue after transfer to visualize those 
proteins remaining in the gel (Figure 1A). 
In vitro interaction assay with in vitro translated protein as prey – An in vitro 
interaction assay was performed using GST fusion protein as bait and in vitro translated 
bAS-V5-6xHis protein as prey as described in the methods section. Proteins were 
transferred from the gel to PVDF membranes and the in vitro translated bAS-V5-6xHis 
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was detected by immunoblotting with antibodies against V5 (Figure 2A) and AS (Figure 
2B). After transfer, the polyacrylamide gel was stained with GelCode Blue to visualize 
proteins remaining in the gel (Figure 2C). These data show a direct interaction between in 
vitro translated AS and bacterially expressed AL. This is not surprising since both AS 
and AL are components of the citrulline-NO cycle and both exist as homotetrameric 
proteins (O'Brien 1979; O'Brien et al. 1981). 
In vitro interaction assay with endothelial cell lysate proteins as prey – An in 
vitro interaction assay was performed using 6xHis fusion protein as bait and endothelial 
cell lysate as prey as described in the methods section. Proteins were transferred from the 
gel to PVDF membranes and eNOS was detected by immunoblotting with an antibody 
against eNOS (Figure 3). Caveolin-1 was detected by immunoblotting with an antibody 
against caveolin-1 (Figure 4). There was no apparent difference in the amount of eNOS 
or caveolin-1 from either basal or stimulated endothelial cell lysates that associated with 
either 6xHis-hAL or 6xHis-bAS. There also was no apparent difference in the amount of 
eNOS that associated with 6xHis-hAL or 6xHis-bAS from endothelial cells transfected 
with a plasmid for overexpression of bAS-V5-6xHis (data not shown). However, there 
were some interactions noticed in the negative control lanes 5-6 (Figure 4A). It was 
reported by Chatenay-Rivauday et al. that caveolin-1 alpha interacts with the microsomal 
form of NADH cytochrome B5 reductase which was bound to the Ni-NTA resin and used 
as a negative control protein (Chatenay-Rivauday et al. 2004). Nevertheless, the signal 
generated in lanes 5-6 (Figure 4A) is much lower than that in lanes 1-4 (Figure 4A). 
These data show an association between eNOS and caveolin-1 from endothelial cell 
lysates with bacterially expressed AS and AL. 
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Discussion 
 The in vitro interaction assays described provide additional and compelling 
evidence for protein-protein interactions between enzymes involved in the citrulline-
nitric oxide (NO) cycle. The co-localization of argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL) with neuronal nitric oxide synthase (nNOS) in muscle layer 
nerve fibers and neurons of the myenteric plexus of the rat gastric fundus (Van Geldre et 
al. 2002), the immunoprecipitation of tyrosine-phosphorylated eNOS associated proteins 
upon stimulation (Hellermann et al. 2000) and the interaction between eNOS, heat shock 
protein 90 (hsp90) and guanylate cyclase (Venema et al. 2003) all support the hypothesis 
of a protein complex for efficient NO production. Ju et al. also showed a direct 
interaction between eNOS and caveolin-1 using GST-caveolin-1 as bait and insect cell 
expressed eNOS as prey protein (Ju et al. 1997). Using a yeast two-hybrid system they 
were able to map the domains involved in the interaction between the two proteins. Our 
lab showed a co-fractionation from endothelial cell caveolae, where many signaling 
molecules are found, of eNOS, AS and AL (Flam et al. 2001). 
 Proteins that are in close physical association with one another tend to act more 
efficiently in channeling substrates from one enzyme to another (Cheung et al. 1989). 
Also, our laboratory recently showed that endothelial NO production is tightly coupled to 
the citrulline-NO cycle (Paper III). The unique arginine source in endothelial cells, 
reserved for NO synthesis, does not rely on the bulk intracellular arginine substrate for 
NO generation. Instead, this unique arginine source is converted by eNOS to NO and 
citrulline. Citrulline is recycled to arginine by subsequent reactions catalyzed by AS and 
AL, respectively. When endothelial cells are stimulated with calcium agonists to produce 
additional NO, the citrulline-NO cycle ensures there is a sufficient arginine supply for 
endothelial NO production. The ability of the enzymes of the citrulline-NO cycle to 
efficiently move citrulline through AS and AL without loss of citrulline or 
argininosuccinate to diffusion becomes critical for arginine regeneration. Most probably 
the interactions between these enzymes occur dynamically, depending on the state of the 
endothelial cell and its ability to produce NO (Slon-Usakiewicz et al. 2004). 
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 Through the use of bacterially expressed fusion proteins, we demonstrated a direct 
interaction between AS and AL and associations between AS and eNOS, AL and eNOS, 
AS and caveolin-1 and AL and caveolin-1. Further investigations will explore 
interactions and associations between accessory proteins like hsp90, carboxyl terminus of 
Hsp70-interacting protein (CHIP), eNOS interacting protein (NOSIP), eNOS traffic 
inducer (NOSTRIN) or the bradykinin receptor (Dedio et al. 2001; Garcia-Cardena et al. 
1997; Jiang et al. 2003; Ju et al. 1998; Ju et al. 1997; Zimmermann et al. 2002). Also, 
interactions between exact protein domains will be examined using the in vitro 
interaction assays. The knowledge gained from these studies will improve our 
understanding of how protein-protein interactions in normal and disease states can affect 
substrate availability, ultimately leading to sufficient or insufficient endothelial NO 
production. 
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Table 1. Fusion protein plasmids and protein molecular weight 
 
Plasmid name Fusion protein name Size (aa) Theoretical MW (kDa) 
pET-28b(+)-bAS 6xHis-bAS 480 53.8 
pGEX-5X-1-bAS GST-bAS 668 76.1 
    
pET-28c(+)-hAL 6xHis-hAL 538 59.5 
pGEX-5X-1-hAL GST-hAL 732 82.3 
    
pGEX-5X-1 GST 240 28.0 
 
 Figure 1. Purification of 6xHis and GST fusion proteins. Bacterially expressed 6xHis-
hAL and 6xHis-bAS were purified using Ni-NTA agarose as described in the methods. 
Bacterially expressed rat cytochrome B5 reductase (rCyB5R)-4xHis used as a negative 
control for the in vitro interaction assays was a gift (G. Roma, University of South 
Florida). Bacterially expressed GST-hAL, GST-bAS and GST were purified using 
glutathione agarose as described in the methods. Precision Plus prestained standards 
(Bio-Rad Laboratories) were used to estimate molecular weight. (A) Proteins were 
separated by SDS-PAGE under reducing conditions on a 4-15% Tris-HCl gel and 
following transfer, the gel was stained with Gelcode Blue to visualize total protein 
loading. (B) An immunoblot of 6xHis fusion proteins following detection with anti-His-
Tag monoclonal antibody (Novagen; 1:5000), HRP-conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch Labs; 1:100,000) and ECL reagent is shown. (C) An 
immunoblot of GST fusion proteins following detection with anti-GST monoclonal 
antibody (Santa Cruz Biotechnology; 1:2000), HRP-conjugated goat anti-mouse IgG 
(1:100,000) and ECL reagent is shown. 
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 Figure 2. Interactions between in vitro translated AS-V5-6xHis and bacterially 
expressed GST-AL or GST-AS. Bacterially expressed GST-hAL, GST-bAS or GST 
bound to glutathione-agarose was used as the bait protein. In vitro translated bAS-V5-
6xHis was used as the prey protein. Precision Plus prestained standards (Bio-Rad 
Laboratories) were used as approximate molecular weight markers. Proteins were 
separated by SDS-PAGE under reducing conditions on 4-15% Tris-HCl gels. (A) An 
immunoblot of bAS-V5-6xHis detected with anti-V5 monoclonal antibody (Invitrogen; 
1:5000), HRP-conjugated goat anti-mouse IgG (1:100,000) and ECL reagent is shown. 
Lane 1 contains 0.1% AS-V5-6xHis input protein. Lane 4 contains the negative control. 
(B) An immunoblot of bAS-V5-6xHis detected with anti-AS monoclonal antibody (BD 
Transduction Labs; 1:2500 ), HRP-conjugated goat anti-mouse IgG (1:50,000) and ECL 
reagent is shown. Lane 6 contains the negative control. (C) Following the transfer, the gel 
was stained with Gelcode Blue to visualize total protein loading of bait protein. 
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 Figure 3. Interactions betweeen eNOS from an endothelial cell lysate and bacterially 
expressed 6xHis-AL or 6xHis-AS. Bacterially expressed 6xHis-hAL, 6xHis-bAS or 
rCyB5R-4xHis bound to Ni-NTA agarose was used as the bait protein. Endothelial cells 
were left in the basal state (basal) or stimulated with 10 µM bradykinin plus 20 µM 
sodium orthovanadate (BkV). After treatment for 90 minutes, endothelial cell lysates 
were prepared and used as the prey protein. Proteins were separated by SDS-PAGE under 
reducing conditions on 4-15% Tris-HCl gels. (A) An immunoblot result of eNOS 
detected with anti-eNOS monoclonal antibody (BD Transduction Labs; 1:2500), HRP-
conjugated goat anti-mouse IgG (1:50,000) and ECL reagent is shown. Lanes 1-2 
contains 3% endothelial cell lysate input proteins. Lanes 7-8 contain the negative 
controls. (B) Following the transfer, the gel was stained with Gelcode Blue to visualize 
total protein loading of bait protein. 
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 Figure 4. Interactions betweeen caveolin-1 from an endothelial cell lysate and 
bacterially expressed 6xHis-AL or 6xHis-AS. Bacterially expressed 6xHis-hAL, 6xHis-
bAS or rCyB5R-4xHis bound to Ni-NTA agarose was used as the bait protein. 
Endothelial cells were left in the basal state (basal) or stimulated with 10 µM bradykinin 
plus 20 µM sodium orthovanadate (BkV). After treatment for 90 minutes, endothelial cell 
lysates were prepared and used as the prey protein. Proteins were separated by SDS-
PAGE under reducing conditions on 4-15% Tris-HCl gels. (A) An immunoblot result of 
caveolin-1 detected with anti-caveolin-1 monoclonal antibody (BD Transduction Labs; 
1:1000), HRP-conjugated goat anti-mouse IgG (1:50,000) and ECL reagent is shown. 
Lanes 5-6 contain the negative controls. (B) Following the transfer, the gel was stained 
with Gelcode Blue to visualize total protein loading of bait protein. 
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Abstract 
Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline 
from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS). 
Previous studies suggested that the recycling of L-citrulline to L-arginine is essential for 
NO production in endothelial cells. However, there is no direct evidence demonstrating 
the degree to which the recycling of L-citrulline to L-arginine is coupled to NO 
production. We hypothesized that the amount of NO formed would be significantly 
higher than the amount of L-citrulline formed due to the efficiency of L-citrulline 
recycling via the citrulline-NO cycle. To test this hypothesis, endothelial cells were 
incubated with [14C]-L-arginine and stimulated by various agents to produce NO. The 
extent of NO and [14C]-L-citrulline formation were simultaneously determined. Under 
basal and stimulated conditions, NO exceeded L-citrulline on the order of 8 to 1, 
respectively. As further support, α-methyl-DL-aspartate, which specifically inhibits L-
citrulline recycling, also inhibited NO production in a dose-dependent manner. The 
results of this study provide evidence for the essential and efficient coupling of L-
citrulline recycling, via the citrulline-NO cycle, to endothelial NO production. 
 
Key words: nitric oxide; L-citrulline; L-arginine; endothelial nitric oxide synthase; 
argininosuccinate synthase 
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Introduction 
 Endothelial nitric oxide synthase (eNOS) plays a key role in vasoregulation 
through the conversion of L-arginine to L-citrulline and the vasorelaxant, nitric oxide 
(NO). Impaired production of NO associated with hypertension, heart failure, 
hypercholesterolemia, atherosclerosis, and diabetes may be due to disruption of 
appropriate regulation of endothelial nitric oxide synthase (eNOS) at several different 
levels, including substrate availability. The availability of extracellular L-arginine 
appears to be “rate-limiting” for NO production (Shen et al. 2005; Van Geldre et al. 
2002) even though normal intracellular concentrations are well in excess of the reported 
Km (~3 µM) for L-arginine (Hardy et al. 2002; Pollock et al. 1991). This phenomenon has 
been termed the “arginine paradox” (Flam et al. 2001; Hardy & May 2002; 
Vukosavljevic et al. 2006). Intracellular L-arginine levels have been reported to range 
from 0.1 to 0.8 mM (Hardy & May 2002; Shen et al. 2005; Van Geldre et al. 2002), 
indicating that the bulk of intracellular L-arginine may not be available for conversion to 
NO. We hypothesized that the other product of the eNOS-catalyzed reaction, L-citrulline, 
is efficiently recycled via the enzymes of the citrulline-NO cycle, in a tightly coupled 
process, to the substrate, L-arginine, effectively segregating the L-arginine directed to 
NO production from bulk intracellular L-arginine. Figure 1 shows the regeneration of L-
arginine from L-citrulline in the citrulline-NO cycle. Argininosuccinate synthase (AS) 
converts L-citrulline to argininosuccinate (Xie et al. 2000). Argininosuccinate is 
converted to L-arginine by argininosuccinate lyase (AL). The L-arginine so formed is 
then converted to NO by the action of eNOS to complete the cycle. AS catalyzes the rate-
limiting step in the conversion of L-citrulline to L-arginine. 
 Because eNOS and the cationic amino acid transporter 1 (CAT1), responsible for 
most of the transport of extracellular L-arginine into endothelial cells, are co-localized in 
caveolae, it has been widely accepted that this transporter provides the L-arginine 
directed to NO production (McDonald et al. 1997). However, Li et al. recently showed 
that endothelial NO production is enhanced through protein-protein interaction between 
eNOS and CAT1, but L-arginine transport by CAT1 was not required for the observed 
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enhancement, suggesting that CAT 1 is important for endothelial NO production, but not 
for providing the L-arginine directed to NO production (Li et al. 2005). 
In contrast, several reports have demonstrated that NO production is limited by the 
capacity to regenerate L-arginine from L-citrulline via the citrulline-NO cycle, 
particularly under stimulated conditions (Flam et al. 2001; Shen et al. 2005; Su et al. 
1995; Van Geldre et al. 2002; Xie et al. 1997; Xie et al. 2000). Amongst the early 
evidence in support of an important role for the citrulline-NO cycle in endothelial NO 
production was our observation that extracellular L-citrulline was as effective as L-
arginine in stimulating NO production. Even in medium containing saturating levels of L-
arginine, L-citrulline stimulated endothelial NO production (Flam et al. 2001). Because 
extracellular L-citrulline levels had no effect on bulk intracellular L-arginine levels, we 
concluded that L-arginine regeneration from L-citrulline plays a role in directly providing 
the L-arginine for NO production in stimulated endothelial cells rather than via 
conversion to intracellular L-arginine. Similarly, Wu et al. (Wu et al. 1993), showed that 
synthesis of L-arginine from L-citrulline was stimulated by addition of exogenous L-
citrulline. Other evidence supporting an important role for the citrulline-NO cycle in NO 
production includes the demonstration that overexpression of AS in vascular smooth 
muscle cells dramatically enhanced the capacity of transfected cells to produce NO even 
in the presence of excess extracellular L-arginine (Xie & Gross 1997; Xie et al. 2000), 
leading to the conclusion that the capacity to recycle L-citrulline to L-arginine is “rate-
limiting” to NO production. Su et al. (Su & Block 1995) arrived at a similar conclusion, 
showing that hypoxia inhibited both the induction of AS by endotoxin in pulmonary 
artery endothelial cells as well as the production of NO, independent of extracellular L-
arginine levels. 
 Recently, Shen et al. (Shen et al. 2005) demonstrated that the AS inhibitor, α-
methyl-DL-aspartic acid (MDLA), inhibited NO production in calcium ionophore 
stimulated endothelial cells, indicating that the recycling of L-citrulline to L-arginine is 
important for endothelial NO production. Also, gene expression studies demonstrated 
significant and coordinate upregulation of endothelial AS gene expression in response to 
fluid shear stress stimulation of NO production (McCormick et al. 2001). Since 
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extracellular L-arginine was not limiting in these studies, the authors concluded that a 
prerequisite for shear stress induced NO production, in the absence of synthesis of 
additional eNOS, was an increase in L-arginine regeneration via increased AS expression 
(McCormick et al. 2001). The essential role of AS and the citrulline-NO cycle in 
endothelial NO production was further reinforced by our recent demonstration of a direct 
connection between knockdown of AS expression by AS siRNA and reduced NO 
production (Goodwin et al. 2004). 
 The enzymes, AS and AL, have been most extensively studied in liver, where 
they function in the urea cycle to dispose of excess nitrogen as urea. Clearly the 
functional role of AS and AL is different in endothelial cells than in liver. Previous 
studies from our laboratory (Pendleton et al. 2002; Pendleton et al. 2005) and others 
(Cohen et al. 1996) suggested that regulation of AS and localization of AS and AL are 
also different in liver than in endothelial cells. In liver, AS and AL localize with 
mitochondria (Cohen & Kuda 1996) to complete the urea cycle. In endothelial cells, we 
demonstrated that AS and AL co-localize with eNOS in the caveolae fraction of the 
plasma membrane (Flam et al. 2001). AS has also been shown to respond to metabolite 
signaling differently in the two tissues. Glutamine induces AS activity in liver tissue 
(Quillard et al. 1996), but may interfere with AS activity in endothelial cells (Sessa et al. 
1990). We found no difference in the primary structure of hepatic and endothelial AS, but 
in endothelial cells there are additional forms of AS mRNA, with extended upstream 
open reading frames, that play a role in controlling expression of endothelial AS 
(Pendleton et al. 2002). 
 We propose that differences in function, co-localization and regulation of AS 
relate to the structure/function relationships of a caveolae-localized “nitric oxide 
synthase/L-arginine regeneration complex”, which in endothelial cells, comprises the 
citrulline-NO cycle. Herein we report the first direct evidence for the operation of the 
citrulline-NO cycle through the simutaneous measurement of NO production (as nitrite) 
and apparent L-citrulline production (as conversion of [14C]-L-arginine to [14C]-L-
citrulline) (Hardy & May 2002). The magnitude of the apparent ratio of endothelial NO 
to L-citrulline produced is an indicator of the degree of coupling of the citrulline-NO 
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cycle to endothelial NO production. 
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Experimental Procedures 
Cell culture and reagents – Bovine aortic endothelial cells (BAEC) were grown to 
confluence in 12-well plates in Dulbecco’s modification of Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (fbs), 100 IU penicillin, 100 µg/mL streptomycin and 
0.25 µg/mL amphotericin B at 37°C in a 5% CO2 incubator. On the day of the 
experiment, BAEC were rinsed in Hanks’ balanced salt solution, without phenol red, 
containing 20 mM HEPES (HBSS/HEPES). HBSS/HEPES containing 330 µM L-
arginine plus 100 µM (S)-(2-Boronoethyl)-L-cysteine hydrochloride (BEC-HCl) was 
added to each well. After 35 min, the medium was removed and HBSS/HEPES 
containing 3.0 µM [U-14C]-L-arginine monohydrochloride (specific activity 305 
mCi/mmol, GE Healthcare) was added to each well. Cells were treated with 10 µM 
bradykinin plus 20 µM sodium orthovanadate for 90 min, in the absence of fbs. For the 
inhibition studies, cells were treated with an AS inhibitor, α-methyl-DL-aspartic acid 
(MDLA). For the arginine-deprivation experiments, cells were incubated in a synthetic 
DMEM plus 10% fbs lacking L-arginine, except for the small contribution of L-arginine 
by the serum, for 48 h prior to the start of the experiment. All cells were treated with 
BEC-HCl, a competitive inhibitor of arginases I and II prior to and during the stimulation 
experiments to prevent conversion of L-arginine to L-ornithine. To inhibit eNOS activity, 
the NOS inhibitor, NG-nitro-L-arginine methylester (L-NAME; 2 mM), was added to 
cells 35 min prior to and during the stimulation experiments. DMEM, HBSS, HEPES and 
trypan blue were obtained from Mediatech, Inc. Fetal bovine serum was obtained from 
HyClone. Bradykinin, L-arginine and MDLA were obtained from Sigma-Aldrich. 
Sodium orthovanadate and A23187 were obtained from Alexis Biochemicals. BEC-HCl 
was obtained from EMD Biosciences. 
Measurement of cell viability – BAEC were washed with HBSS/HEPES and 
HBSS/HEPES containing 330 µM L-arginine was added to each well for 60 min. 
Following this, the medium was removed and HBSS/HEPES containing 330 µM L-
arginine, 10 µM bradykinin and 20 µM sodium orthovanadate was added to each well 
with increasing concentrations of MDLA up to 8 mM. Following a 135 min incubation, 
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the medium was removed, cells were trypsinized from the plates and cell viability was 
assessed using trypan blue exclusion counting. 
Measurement of endothelial NO production – After addition of HBSS/HEPES plus 
agonists and inhibitors, a portion of the medium was removed from each well for NO 
determination (as nitrite). At the end time point, another sample of medium was removed 
for NO determination (as nitrite). L-NAME-inhibitable nitrite production was measured 
and calculated according to the method of Misko et al. (Misko et al. 1993). 2,3-
Diaminonaphthalene used to quantitate nitrite production was obtained from Sigma-
Aldrich (Dejam et al. 2004; Kleinhenz et al. 2003; Lundberg et al. 2005; Misko et al. 
1993). Samples were read in a Jasco FP-770 spectrofluorometer (excitation = 365 nm; 
emission = 409 nm), and a standard curve was generated from sodium nitrite standards. 
As a test of the fluorometric assay, nitrite production in duplicate samples was 
determined by an alternate method using the Griess assay (Promega). Samples were read 
in a Beckman DU640B spectrophotometer at 540 nm. Essentially the same results were 
obtained with either method but the fluorometric method was routinely used because of 
its greater sensitivity. NOx production was also determined using a nitrate/nitrite 
colorimetric assay kit (Cayman Chemical Company). Nitrate was reduced to nitrite by 
nitrate reductase. Following this reduction, nitrite and NOx were measured in all samples 
using the Griess reagent and samples were quantitated at 540 nm in a µQuant 
spectrophotometric platereader (Biotek). Standard curves were generated from sodium 
nitrite and sodium nitrate standards. 
NO has a half-life of approximately five sec and, in the presence of water and 
molecular oxygen, quickly converts to nitrite, a stable end-product. Nitrite can be 
measured using the fluorescent 2,3-diaminonaphthalene assay (DAN assay) where 2,3-
diaminonaphthalene reacts with a nitrosonium cation forming the fluorescent product, 
1H-naphthotrazole (Kleinhenz et al. 2003; Misko et al. 1993). Nitrite can also be 
measured using the spectrophotometric Griess assay (Promega) where nitrite reacts with 
sulfanilic acid and N-(1-naphthyl)ethylenediamine to form a purple derivative 
measurable with a spectrophotometer. Nitrite produced from duplicate samples using 
either the DAN or Griess assays was comparable for both assays and the fold-activation 
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observed following exposure of cells to the calcium ionophore A23187 or to bradykinin 
and sodium orthovanadate was the same (data not shown). 
 Nitrate is also a possible degradation product of NO, in addition to nitrite. 
Therefore, nitrate was converted to nitrite by nitrate reductase in order to measure total 
NOx (nitrate plus nitrite) under basal and stimulated conditions. We found approximately 
equimolar quantities of nitrite and nitrate under both basal and stimulated conditions 
(~55% nitrate; ~45% nitrite) and the fold stimulation observed was the same whether 
measuring total NOx or nitrite alone. Samples were measured by both the fluorometric 
assay and the Griess method for nitrite. Thus, quantitation of nitrite alone accurately 
reflects the amount of endothelial NO produced, in agreement with previous reports 
(Dejam et al. 2004; Kleinbongard et al. 2006; Kleinbongard et al. 2003; Lauer et al. 
2001; Lundberg & Weitzberg 2005; Misko et al. 1993). It should be noted, however, that 
the apparent ratios of NO (as nitrite) to L-citrulline produced are minimal estimates and 
are probably as much as two fold higher if total NOx was used as a measure of NO 
produced. 
 Measurement of endothelial L-citrulline production – At the end of the reaction, 
ice cold 100% methanol was added to each well to lyse the cells prior to measurement of 
the extent of conversion of [14C]-L-arginine to [14C]-L-citrulline (Hardy & May 2002). 
The sample was mixed with AG 50W-X8, sodium form, cation exchange resin (Bio-Rad 
Laboratories) equilibrated in stop buffer (50 mM HEPES, pH 5.5, 5 mM EDTA). The 
samples were transferred to spin-cups (Costar Spin-X, 0.45 µm) and centrifugation was 
carried out for 2 minutes at 14000g. The flow-through was concentrated by vacuum 
centrifugation and a portion of the flow-through was retained for analysis by reverse-
phase HPLC (Antoine et al. 1999; Tcherkas et al. 2001). Samples were precolumn 
derivatized with o-phthaldialdehyde reagent solution (Sigma-Aldrich) and then separated 
isocratically on a System Gold HPLC system with 126 solvent module and 166 UV 
detector (Beckman-Coulter) using a C18 small pore, 250 mm x 4.6 mm 201SP54 column 
(Grace Vydac) with column guard. Fractions were collected and mixed with Cytoscint 
(MP Biomedical) and counts were determined by liquid scintillation counting in an 
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LS6500 (Beckman-Coulter). L-NAME-inhibitable L-citrulline production was calculated 
from the L-citrulline peak as determined by reverse-phase C18 column separation. 
To test the validity of the ratios observed for apparent production of NO relative to 
production of L-citrulline by endothelial cells, we determined the ratios of these two 
products formed in an in vitro assay using recombinant eNOS and [14C]-L-arginine. 
Under these in vitro conditions there would be no recycling of L-citrulline to L-arginine 
and no dilution of products by endogenous metabolites. The apparent ratio of NO (as 
nitrite) to L-citrulline produced was approximately 2, indicating that the ratios observed 
for the cellular assays are valid. 
 Intracellular L-arginine concentrations under normal and L-arginine deprived 
culture conditions – Following the 48 h L-arginine deprivation of BAEC, the cells were 
rinsed five times with HBSS/HEPES. Ice cold 100% methanol was added to each well to 
lyse the cells prior to measurement of intracellular L-arginine concentrations. Samples 
were collected and removed to spin-cups to remove particulate matter. Following 
precolumn derivatization with o-phthaldialdehyde reagent solution, each sample was 
injected onto a C18, 250 mm x 4.6 mm 201SP54 column as described previously for L-
arginine separation and fractions were collected. The collected fractions were removed to 
a 96-well black plate (Greiner) and fluorescence was measured using a BMG 
Labtechnologies Fluostar Galaxy platereader (excitation = 320 nm; emission = 360 nm). 
L-arginine standards were also analyzed in the same manner. The area under the curve 
(AUC) for L-arginine was calculated using SigmaPlot 8.0 and was used to calculate 
intracellular L-arginine concentrations. 
L-citrulline percent recovery from cation exchange resin – Samples were analyzed 
to calculate the amount of L-citrulline flow-through from the cation exchange resin. In 
vitro assay tubes were prepared with 50 mM HEPES, pH 7.4, 3 µM tetrahydrobiopterin, 
1 µM flavin adenine dinucleotide, 1 µM flavin mononucleotide, 1.5 µM calmodulin, 1 
mM calcium chloride, 0.1 mM dithiothreitol, 312 µM NADPH, 3 µM L-arginine, 0.2 µM 
L L-[2,3,4,5-3H]-arginine monohydrochloride (GE Healthcare), 75 µM L-[ureido-14C]-
citrulline (PerkinElmer Life and Analytical Sciences) and either 44 µg heat-inactivated 
bovine recombinant eNOS or recombinant protein buffer (50 mM HEPES, pH 7.4, 10% 
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glycerol, 5 mM CHAPS and 100 µM dithiothreitol). The reaction tubes were incubated at 
37°C for 15 min and the reaction was stopped with 1.5 mM EGTA. A portion of the 
reaction mixture was retained for liquid scintillation counting and separation of L-
arginine and L-citrulline by reverse-phase HPLC. The remainder of the sample was 
mixed with cation exchange resin and processed as described in the measurement of 
endothelial L-citrulline production section. A portion of the flow-through was retained 
for liquid scintillation counting and separation of L-arginine and L-citrulline by reverse-
phase HPLC. Samples were analyzed as described in the measurement of endothelial L-
citrulline production section. L-citrulline percent recovery from the reaction mixture and 
flow-through samples was calculated from the L-citrulline peak as determined by 
reverse-phase C18 column separation.  The mean percent recovery ± SEM from two 
independent experiments performed in triplicate was 82.6 ± 2.2. 
 [14C]-L-citrulline radiospecific activity – BAEC were treated for 90 min with 
[14C]-L-arginine in Hanks/HBSS. Samples were treated as detailed in the measurement of 
endothelial L-citrulline production section. Following precolumn derivatization with o-
phthaldialdehyde reagent solution, each sample was injected onto a C18, 250 mm x 4.6 
mm 201SP54 column as and fractions were collected for fluorescence detection and 
liquid scintillation counting. The peak corresponding to L-citrulline from fluorescence 
detection and [14C]-L-citrulline from liquid scintillation counting was used to calculate 
intracellular L-citrulline radiospecific activity in µCi/µmol. The calculated radiospecific 
activity of the [14C]-L-citrulline product after cell lysis was used to calculate the amount 
of [14C]-L-citrulline formed in endothelial cells. Because the calculated radiospecific 
activities also include some endogenous L-citrulline, the calculated amounts of [14C]-L-
citrulline formed may be an over-estimation in relation to NO formation. 
 Statistics – The presented data were calculated from a minimum of three 
independent experiments. Duplicate wells were tested in each experiment. Results from 
representative experiments are expressed as the mean ± SEM. Statistical analysis was 
performed using an unpaired t test (SPSS 14.0 for Windows). A value of p<0.05 was 
considered statistically significant. 
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Results 
 Comparative assays for NO and L-citrulline production in endothelial cells – 
Previous work from our laboratory, and others, suggested that the recycling of L-
citrulline to L-arginine via the citrulline-NO cycle plays an essential role in providing L-
arginine for endothelial NO production (Goodwin et al. 2004). However, there has been 
no direct demonstration that NO production is tightly coupled to the citrulline-NO cycle. 
Thus, based on previous work, we proposed that the L-arginine used by eNOS is 
provided by the combined action of AS and AL, as components of the citrulline-NO 
cycle. In the current study, we provide direct evidence for this hypothesis. The amounts 
of NO and L-citrulline produced were simultaneously quantitated by measuring the 
formation of nitrite, a stable end-product of NO and molecular oxygen in aqueous 
solutions (Dejam et al. 2004; Kleinhenz et al. 2003; Lundberg & Weitzberg 2005; Misko 
et al. 1993), and the conversion of [14C]-L-arginine to [14C]-L-citrulline (Hardy & May 
2002). If L-citrulline recycling plays no role, or only a minor role in NO production, the 
apparent amounts of NO and L-citrulline produced should be approximately the same 
when measured under identical conditions. If, however, L-citrulline recycling provides L-
arginine for NO production, the apparent amount of NO produced should be significantly 
greater than the amount of L-citrulline produced due to the efficient recycling of L-
citrulline to L-arginine as part of the citrulline-NO cycle. 
 Endothelial cells can be stimulated to produce NO by bradykinin or other 
physiological effectors that signal an increase of intracellular calcium thereby leading to 
activation of eNOS. Calcium ionophores, such as A23187, bypass the receptor-mediated 
pathway by increasing available calcium for eNOS activation. We previously showed 
that the tyrosine phosphatase inhibitor, sodium orthovanadate, further enhanced 
stimulation of endothelial NO production (Hellermann et al. 2000). As shown in Figure 
2, the apparent amount of NO formation is much greater than the apparent amount of L-
citrulline formation under either basal or stimulated conditions in cultured endothelial 
cells. Moreover, the apparent ratio of NO to L-citrulline produced under basal and 
stimulated (bradykinin and sodium orthovanadate) conditions was approximately 8:1 
(Table 1). These results indicate that the recycling of L-citrulline to L-arginine and 
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subsequent conversion of this L-arginine to NO is very efficient under all conditions. 
These results also have important implications for the measurement of cellular eNOS 
activity, indicating that measurements based on L-citrulline production alone may lead to 
a substantial underestimation of cellular eNOS activity and the degree of stimulation. It 
should be noted that the calculated ratios of NO to L-citrulline produced represent 
minimum estimates because NO is estimated as nitrite (does not include nitrate) and L-
citrulline estimates are based on radiospecificity measurements that include some 
endogenous cold L-citrulline. Thus, NO is probably under-estimated, while L-citrulline is 
probably over-estimated. 
 Inhibition of NO production by inhibition of AS – In a previous study we showed 
that selective reduction of endothelial AS expression by transfection of endothelial cells 
with AS siRNA also reduced the capacity of these cells to produce NO, supporting an 
essential role for AS in NO production (Goodwin et al. 2004). In the present study, we 
confirm and extend these results through the use of the inhibitor, α-methyl-DL-aspartic 
acid (MDLA), which is specific for AS (Shen et al. 2005). Assessment of cell viability 
using trypan blue exclusion of stimulated BAEC with up to 8 mM MDLA indicated there 
was no significant cell death compared to stimulated cells alone (data not shown). As 
shown in Figure 3, the AS inhibitor, MDLA inhibited NO and L-citrulline production in 
stimulated endothelial cells in a dose dependent manner. However, even when NO 
production was substantially inhibited (~80%), the ratio of NO (as nitrite) to L-citrulline 
produced was still high (~7:1), indicating a direct correlation between NO production and 
AS inhibition and further supporting the tight coupling of the L-citrulline-NO cycle to 
NO production. Thus, inhibition of AS does not cause an uncoupling of endothelial NO 
production and the citrulline-NO cycle as indicated by the relatively constant ratio of NO 
to L-citrulline produced. 
 Effect of L-arginine deprivation – Intracellular L-arginine concentrations were 
calculated based on an endothelial cell volume of 1.02 pL/cell (Baydoun et al. 1990; 
Rubin et al. 1989). The average intracellular L-arginine concentration of normal BAEC 
versus 48 h L-arginine deprived BAEC was 1.76 to 0.36 mM, respectively. This 
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corresponds to an 80% decrease in intracellular L-arginine levels following 48 h L-
arginine deprivation (Mann et al. 2003). 
 If endothelial NO production is dependent on the bulk intracellular source of L-
arginine, the apparent extent of formation of NO should be reduced in L-arginine 
deprived cells. As shown in Figure 4, there was only a modest decrease in NO production 
in L-arginine deprived cells compared to the extent of L-arginine depletion in these cells. 
Although L-arginine deprivation may result in multiple effects that are beyond the scope 
of this study, these results support the hypothesis that there is a separate and distinct 
cellular source of L-arginine substrate directed to endothelial NO production, separate 
from the bulk intracellular source of L-arginine, consistent with earlier observations that 
led to the “arginine paradox” (Hardy & May 2002; Hecker et al. 1990; Wu & Meininger 
1993). 
77 
Discussion 
 The present results provide direct evidence for an efficient and essential coupling 
of the citrulline-NO cycle to endothelial NO production. These results support a growing 
body of evidence for the key role of this cycle in NO production since its original 
discovery by Vane and coworkers in 1990 (Hecker et al. 1990; Sessa et al. 1990). 
However, the functional importance of this cycle, to provide L-arginine for NO 
production, was not fully appreciated. This may be due to assumptions regarding 
alternative sources of L-arginine, including intracellular L-arginine pools and/or the 
CAT1 transport system which transports most of the intracellular L-arginine. As 
discussed in the Introduction, the CAT1 transport system may play an important role in 
endothelial NO production, but not through provision of L-arginine for NO production 
(Li et al. 2005). 
 L-Arginine has multiple metabolic precursor functions other than serving as a 
precursor of NO. This may explain the mixed, and sometimes adverse, effects of L-
arginine supplementation to improve vascular function (Bode-Boger 2006). L-Citrulline, 
in contrast, has only one known precursor metabolic function, conversion to 
argininosuccinate in either the hepatic urea cycle, renal arginine synthesis, or recycling to 
L-arginine via the citrulline-NO cycle. Thus, L-citrulline can serve as a precursor of L-
arginine directed to NO production without perturbing other metabolic functions 
associated with L-arginine metabolism. L-arginine dedicated to NO synthesis and 
provided by the citrulline-NO cycle thus functions to segregate L-arginine directed to NO 
production sparing bulk intracellular L-arginine for other metabolic roles. The present 
results, together with previous results from our laboratory (Flam et al. 2001; Goodwin et 
al. 2004; Solomonson et al. 2003), and others (Braissant et al. 1999; Daniel et al. 2000; 
Lee et al. 2002; Shuttleworth et al. 1995; Su et al. 1999; Van Geldre et al. 2002), provide 
a unique view and understanding of endothelial NO production, showing that a caveolar 
complex involved in substrate (L-arginine) regeneration via a tightly coupled citrulline-
NO cycle must be functional to sustain NO production and to maintain cell viability. 
 Endothelial NO production is very important for vasoregulation and other 
physiological functions. Adverse effects, and disease states, can be due to either over- or 
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under-production of NO by endothelial cells. Consistent with the physiological 
importance of this system, there are several different levels of control, including 
reversible phosphorylation and other post-translational modifications, protein-protein 
interactions, cellular translocation, and substrate or cofactor availability. The results of 
the present study, indicating an efficient and essential coupling of L-citrulline recycling 
to endothelial NO production, suggest an additional level of control that may provide a 
unique therapeutic target for modulating endothelial NO production. 
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Table 1. NO (as nitrite) and L-citrulline produced under basal and stimulated 
conditions. BAEC were treated and samples were collected for NO (as nitrite) and L-
citrulline production as described in methods. The results shown are the mean ± SEM 
from six independent experiments. Statistical analyses comparing basal and stimulated 
(10 µM bradykinin and 20 µM sodium orthovanadate) nitrite and L-citrulline production 
were performed using an unpaired t test. *p<0.01 was considered statistically significant. 
 
 
NO (nitrite) 
(pmol/minute/1x106 cells) 
L-Citrulline 
(pmol/minute/1x106 cells) 
Basal 0.39 ± 0.06 0.05 ± 0.01 
Stimulated 7.55 ± 0.81 * 1.01 ± 0.23 * 
 
Figure 1. The L-citrulline-NO cycle. L-arginine is converted to nitric oxide and L-
citrulline by endothelial nitric oxide synthase. L-citrulline and aspartate are then 
converted to argininosuccinate by argininosuccinate synthase. Argininosuccinate is 
converted to fumarate and L-arginine by argininosuccinate lyase. 
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Figure 2. NO and L-citrulline production in endothelial cells. BAEC were treated and 
samples were collected for NO (as nitrite) and L-citrulline production as described in 
methods. The results shown are the mean ± SEM from six independent experiments. 
Statistical analysis was performed using an unpaired t test. *P<0.01 was considered 
statistically significant. 
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Figure 3. Inhibition of endothelial NO and L-citrulline production by α-methyl-DL-
aspartic acid (MDLA). BAEC were treated and samples were collected for NO (as 
nitrite) and L-citrulline production as described in methods. The results shown are the 
mean ± SEM from three independent experiments. 
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Figure 4. Effect of L-arginine deprivation on endothelial NO production in 
endothelial cells. BAEC were treated and samples were collected for NO (as nitrite) 
production as described in methods. The results shown are the mean ± SEM from six 
independent experiments in the L-arginine sufficient state (+arg) and three independent 
experiments in the L-arginine deprived state (-arg). Statistical analyses were performed 
using an unpaired t test. **P<0.05 was considered statistically significant. 
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Objectives — Nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS) 
as part of the citrulline-NO cycle is essential for cardiovascular health. However, 
impairment of citrulline-NO cycle proteins by dynamic post-translational protein 
modifications, like O-linked ß-N-acetylglucosamine (O-GlcNAc) modifications at 
serine/threonine residues may lead to impaired signaling in the pathway. This study 
examines the effects of glucosamine treatment on NO production and O-GlcNAc 
modifications of endothelial cell proteins. 
Methods and Results — Glucosamine enters the hexosamine biosynthetic pathway after 
the rate limiting step catalyzed by glutamine:fructose-6-phosphate transferase. Increased 
concentrations of glucosamine lead to increased uridine diphospho-N-acetylglucosamine 
(UDP-GlcNAc) production, which is added to proteins by O-GlcNAc transferase. Basal 
or stimulated endothelial cells were treated for 20-26 hours with increasing 
concentrations of glucosamine. Basal NO production was elevated after chronic 
glucosamine treatment while glucosamine treatment blunted calcium agonist-stimulated 
NO production in endothelial cells. In stimulated endothelial cell lysates, 
argininosuccinate synthase and eNOS proteins were elevated in glucosamine treated 
cells. There was a slight increase in total O-GlcNAc protein modifications in 
glucosamine treated, stimulated endothelial cell lysates as assessed by immunoblotting. 
Conclusions — These data suggest that after chronic glucosamine treatment, elevated 
basal NO production results from O-GlcNAc modifications of citrulline-NO cycle 
proteins. After chronic glucosamine treatment in stimulated endothelial cells, decreased 
eNOS activity caused by O-GlcNAc modifications leads to a reduction in endothelial NO 
production. 
 
Key words: nitric oxide; glucosamine; O-linked ß-N-acetylglucosamine; endothelial 
nitric oxide synthase; argininosuccinate synthase 
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Introduction 
 Protein modification is a mechanism to regulate enzyme activity, localization and 
signaling pathways and is typically achieved by phosphorylation and dephosphorylation 
on serine, threonine or tyrosine residues. These events are catalyzed by kinases for 
phosphorylation and phosphatases for dephosphorylation. In 1984, Torres and Hart found 
another mode of dynamic and regulated protein modification (Torres et al. 1984). The O-
linked ß-N-acetylglucosamine (O-GlcNAc, Appendix D) moiety added to or removed 
from serine or threonine residues regulates signaling pathways, enzyme activity and 
localization. This type of protein modification is distinct from protein phosphorylation 
and dephosphorylation, although adjacent sites can regulate the addition of either O-
GlcNAc or phosphate (Kamemura et al. 2002). 
 The uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) moiety is the 
product of the hexosamine biosynthetic pathway (Figure 1) and can act as a nutrient 
sensor (Slawson et al. 2003; Wells et al. 2003). Approximately 2-5% of glucose entering 
the cell is directed to the hexosamine biosynthetic pathway where it is converted to 
glucose-6-phosphate. Glucose-6-phosphate is converted to fructose-6-phosphate which is 
converted to glucosamine-6-phosphate by glutamine:fructose-6-phosphate 
amidotransferase (GFAT) in the rate limiting step. Glucosamine (Appendix D), 
synthesized from fructose-6-phosphate and glutamine, enters the hexosamine 
biosynthetic pathway after the GFAT rate limiting step (Figure 1). GFAT is regulated by 
feedback inhibition by UDP-GlcNAc concentrations within mammalian cells in a 
competitive manner with respect to fructose-6-phosphate. 
 Glucosamine induces insulin resistance at lower concentrations than glucose 
(Vosseller et al. 2002). Incubation of heart and skeletal muscle with high concentrations 
of glucosamine increases glucosamine-6-phosphate concentrations within the cell and 
depletes intracellular ATP levels (Buse 2006). Buse et al. also saw changes in gene 
expression in 3T3-L1 adipocytes incubated with 5 mM glucose, 2.5 mM glucosamine and 
0.6 nM insulin as compared to cells incubated with 25 mM glucose and 0.6 nM insulin. 
These gene expression changes were specific to glucosamine exposure rather than just 
increased glucose flux through the hexosamine biosynthetic pathway (Buse 2006). 
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Endothelial cells experience changes in gene expression (e.g. transforming growth factor-
beta1 and plasminogen activator inhibitor-1) where these changes may only be seen after 
exposure to high glucose or glucosamine (Du et al. 2000; Goldberg et al. 2002). 
Therefore, regulation of the hexosamine biosynthetic pathway by controlling entry of 
either glucose or glucosamine may be a method of controlling some of the multigenic 
effects due to type 2 diabetes, insulin resistance and cardiovascular disease (Akimoto et 
al. 2005). 
Nitric oxide (NO) produced by arginine endothelial nitric oxide synthase (eNOS) 
is important in preventing early atherosclerotic events and later cardiovascular disease 
since it suppresses CD11/CD18 expression on circulating leukocytes, protecting blood 
vessels from leukocyte adhesion to endothelial cells (Forstermann et al. 2006). Citrulline, 
the other reaction product, is converted by argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL), respectively, to arginine, as the substrate for eNOS. Our 
laboratory showed that exogenous citrulline in the presence of saturating levels of 
arginine for eNOS (Km ~ 2.9 µM) significantly increased NO production in stimulated 
endothelial cells as compared to endothelial cells incubated with arginine alone. 
Furthermore, we showed a co-fractionation of citrulline-NO cycle enzymes from 
endothelial cell caveolae membranes (Flam et al. 2001; Solomonson et al. 2003). Using 
an antibody against GM130 (golgi matrix protein of 130 kDa), we showed that the 
caveolae membrane fraction did not contain other membrane proteins. More recently we 
showed a direct interaction and association of citrulline-NO cycle proteins (Paper II) 
along with arginine recycling (Solomonson et al. 2003). Consistent with these 
observations, transcriptional or post-translational protein modifications may affect the 
ability of citrulline-NO cycle enzymes to effectively recycle citrulline to arginine for 
endothelial NO production. 
 O-GlcNAc protein modifications occur on chromatin, transcription factors, (e.g. 
Sp1 and AP-1), kinases (e.g. casein kinase II and phosphoinositol 3-kinase), heat shock 
proteins (e.g. hsp60 and hsp70) and eNOS (Anderson et al. 1991; Brasse-Lagnel et al. 
2003; Du et al. 2001; Jackson et al. 1988; Kim et al. 2006; Majumdar et al. 2006; 
Walgren et al. 2003). The O-GlcNAc modification around serine 1173 in bovine eNOS 
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leads to a decrease in serine 1179 phosphorylation by Akt causing decreased eNOS 
enzyme activity (Du et al. 2001; Federici et al. 2002). AS, which catalyzes the rate-
limiting step of the citrulline-NO cycle has three Sp1 transcription binding sites within 
the promoter region (Anderson & Freytag 1991). Sp1 is modified by phosphorylation 
(Jackson et al. 1993) and O-glycosylation (Jackson & Tjian 1988). These modifications 
change Sp1’s association with transcription binding sites in gene promoter regions 
causing changes in mRNA and protein expression. In Caco-2 cells, a human intestinal 
cell line, glutamine and glucosamine increased O-GlcNAc modifications of Sp1 causing 
greater nuclear translocation and greater Sp1 binding to the AS promoter initiating 
increased transcription (Brasse-Lagnel et al. 2003). In the rat AL promoter, there is one 
Sp1 and one nuclear factor-Y (NF-Y) transcription factor binding site (Matsubasa et al. 
1994; Takiguchi et al. 1995). Examination of the NF-Y sequence with the YinOYang 
prediction server shows many potential O-GlcNAc modification sites. Therefore, O-
GlcNAc modifications of Sp1 and/or NF-Y may cause a change in the binding of this 
transcription factor to the AL promoter leading to increased or decreased gene 
transcription. Thus, O-GlcNAc modifications may function in the control of gene 
transcription or protein translation in the citrulline-NO cycle. This study examined the 
effects of glucosamine treatment on NO production in endothelial cells and its effects on 
citrulline-NO cycle proteins. 
 
95 
Methods 
Cell culture and reagents – Bovine aortic endothelial cells (BAEC) and bovine 
pulmonary artery endothelial cells (BPAEC) were cultured in Dulbecco’s modification of 
Eagle’s medium (DMEM) containing 10% fetal bovine serum (fbs), 100 IU penicillin, 
100 µg/mL streptomycin and 0.25 µg/mL amphotericin B at 37°C in a 5% CO2/95% air 
incubator. Cells were cultured and grown to confluence in 6 or 12-well plates. The cells 
were rinsed with Hanks balanced salt solution (HBSS) without phenol red, containing 20 
mM HEPES. Then DMEM, without serum, containing 0.2 mM L-glutamine and 15 mM 
HEPES plus or minus 10 µM bradykinin was added to each well. Cells were treated with 
increasing concentrations of glucosamine for up to 26 hours. Some cells were treated 
with 2 mM L-NAME, an eNOS inhibitor, 20 µM DON, a glutamine amidotransferase 
inhibitor or 40 µM PUGNAc, an O-GlcNAcase inhibitor. DMEM, HBSS, HEPES, and L-
glutamine were obtained from Mediatech, Inc. Fetal bovine serum was obtained from 
HyClone. DMEM without phenol red was obtained from Invitrogen. Bradykinin, 
glucosamine hydrochloride, L-NAME and DON were obtained from Sigma-Aldrich. 
PUGNAc was obtained from Carbogen (Aarau, Switzerland). See Appendix D for 
chemical structures. 
Assay of endothelial NO production – After addition of DMEM and glucosamine, 
a portion of the medium was removed from each well for NO determination (as nitrite). 
At the end time point, another sample of medium was removed for NO determination (as 
nitrite). Nitrite was measured according to the method of Misko et al. (Misko et al. 1993). 
2,3-Diaminonaphthalene used to quantitate nitrite production was obtained from Sigma-
Aldrich (Dejam et al. 2004; Kleinhenz et al. 2003; Lundberg et al. 2005; Misko et al. 
1993). Samples were read in a Jasco FP-770 spectrofluorometer (excitation = 365 nm; 
emission = 409 nm), and a standard curve was generated from sodium nitrite standards. 
BAEC lysate preparation – After samples of medium were removed for NO 
determination at the last time point, the plates were placed on ice, medium was removed 
and 1% SDS and 2x reducing sample buffer (Bio-Rad Laboratories) were added to each 
well. Cells were scraped from the dish and the cell lysates were heated at 95°C for 10 
minutes. Lysates were stored at -80°C until analyzed. 
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Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting – Endothelial cell lysates were mixed with reducing sample buffer, 
heated for 5 minutes at 95°C and loaded on a 4-20 % Tris-HCl gradient gel (Life Gels). 
The proteins were separated using a Mini-Protean II (Bio-Rad Laboratories) following 
the manufacturer’s instructions. Following SDS-PAGE, the proteins were transferred to 
Immobilon-P polyvinylidene fluoride (PVDF) membranes (Millipore) using a Mini-
Protean transfer system (Bio-Rad Laboratories). For eNOS, AS and GAPDH detection, 
the membrane was removed and blocked in 5% non-fat dry milk (NFDM) in Tris-
buffered saline containing 0.1% Tween-20 (TBST) for 1 hour at room temperature. 
Primary antibody, 1:2500 anti-eNOS, mouse monoclonal (BD Transduction Labs); 
1:2500 anti-AS, mouse monoclonal (BD Transduction Labs) or 1:1000 anti-GAPDH, 
mouse monoclonal (Novus Biologicals) prepared in 5% NFDM/TBST was added to the 
membrane and incubated overnight at 4°C. The membrane was then rinsed with TBST 
several times. A secondary antibody, peroxidase-conjugated affinipure goat anti-mouse 
IgG (Jackson ImmunoResearch Labs), prepared in 5% NFDM/TBST was added to the 
membrane and incubated for 1 hour at room temperature. The membrane was again 
washed with TBST and proteins were detected using ECL (GE Healthcare). For O-linked 
ß-N-acetylglucosamine (O-GlcNAc) modified protein detection, the membrane was 
blocked in Tris-buffered saline containing 0.3% Tween-20 (TBS-HT) for 1 hour at room 
temperature. Primary antibody, 1:1000 anti-O-GlcNAc, CTD110.6, mouse IgM 
(Covance), prepared in TBS-HT was added to the membrane and incubated overnight at 
4°C. The membrane was then rinsed with Tris-buffered saline containing 0.3% Tween-
20, 0.1% sodium deoxycholate, 0.05% SDS and 0.5% Triton X-100 (TBS-D) followed by 
TBS-HT. A secondary antibody, peroxidase-conjugated affinipure goat anti-mouse IgM 
(Jackson ImmunoResearch Labs), prepared in TBS-HT was added to the membrane and 
incubated for 1 hour at room temperature. The membrane was again washed with TBS-D 
followed by TBS-HT and proteins were detected using ECL. 
Statistics – Results from representative experiments are expressed as the mean ± 
SEM. The presented data were calculated from a minimum of two independent 
experiments. Duplicate wells were tested in each experiment. Statistical analysis was 
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performed using a one-way ANOVA with Dunnett’s 2-tail test or unpaired t-test (SPSS 
for Windows version 14.0). A value of P<0.05 was considered statistically significant. 
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Results 
Basal NO (as nitrite) produced by BAEC in the presence of high and low glucose 
and glutamine – The amount of NO (as nitrite) produced by BAEC in the presence of 5 
mM glucose and either low glutamine (0.2 mM) or high glutamine (2 mM) was 
significantly greatly with the low glutamine treatment. NO (as nitrite) produced by 
BAEC in the presence of 20 mM glucose and either low glutamine (0.2 mM) or high 
glutamine (2 mM) was greater with the low glutamine treatment. To prevent conversion 
of glutamine to UDP-GlcNAc, the substrate for O-GlcNAc transferase, BAEC were 
treated with 50 µM 6-diazo-5-oxo-L-norleucine (DON), a glutamine amidotransferase 
inhibitor of the rate limiting-step of the hexosamine biosynthetic pathway. Using the 
DON inhibitor, the amount of NO (as nitrite) produced by BAEC in the presence of 2 
mM glutamine and either 5 mM or 20 mM glucose and was increased as compared to 
cells not treated with the inhibitor (Table 1). This indicates the involvement of glutamine 
in the hexosamine biosynthetic pathway since DON inhibits the conversion of glutamine 
and fructose-6-phosphate into the downstream UDP-GlcNAc, the substrate for O-
GlcNAc transferase. 
O-GlcNAc modifications have been shown to decrease eNOS activity and 
increase AS translation (Brasse-Lagnel et al. 2003; Du et al. 2001). These data compare 
with results from Wu et al. who used bovine venular endothelial cells in the presence of 
10 mM glucose and showed that high glutamine caused a decrease in NO production in 
basal endothelial cells and that the effect was reversed by using a GFAT inhibitor to 
prevent production of UDP-GlcNAc (Wu et al. 2001). 
NO produced by basal BAEC in the presence of glucosamine – In basal BAEC 
treated with 0.2 mM L-glutamine, 10 mM glucose and glucosamine, there was a 
significant dose dependent increase in NO production (as nitrite) at 2.1, 10.5 and 15 mM 
glucosamine (Figure 2). The concentration of 10 mM glucose in the medium was to 
ensure sufficient NADPH as a cofactor for eNOS over the 24 hour treatment (Wu et al. 
2001). Duplicate experiments were performed using bovine pulmonary artery endothelial 
cells (BPAEC) to determine if the increase in NO production (as nitrite) was due to 
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endothelial cell type. The amount of NO (as nitrite) produced by BPAEC under the same 
conditions was similar to that seen with the BAEC (data not shown). 
The dose dependent effects of glucosamine, observed under basal conditions, 
were in contrast to the results seen by Wu et al. (Wu et al. 2001) who observed a 
significant decrease in NO production. Fulton et al. showed that the ratio of eNOS to von 
Willebrand factor, an endothelial marker, was approximately 2.5 times greater in the 
circumflex artery than the aorta (Fulton et al. 2000). NO production has also been shown 
to be lower in venous as compared to arterial endothelial cells (Rotmans et al. 2005). 
Endothelial NOS distribution differs between different endothelial cell types and may 
even vary within the endothelial cell itself which could explain differences in NO 
production (Oess et al. 2006). The amount of basal NO (as nitrite) produced by the 
BAEC in our experiments was approximately 25 times greater than the amount of basal 
NO (as nitrite plus nitrate) produced by the coronary venular endothelial cells. The 
differences seen between the two experiments may be due to the source of the endothelial 
cells and the cells were maintained in different concentrations of glucose. 
NO produced by stimulated BAEC in the presence of increasing concentrations of 
glucosamine – In stimulated BAEC (10 µM bradykinin) treated with 0.2 mM L-
glutamine, 10 mM glucose and glucosamine, there was a dose dependent decrease in NO 
production (as nitrite) at 2 and 8 mM glucosamine (Figure 3). eNOS activity is decreased 
by O-GlcNAc modifications (Du et al. 2001). AS translation is increased due to O-
GlcNAc modifications of Sp1 which binds to response elements in the AS promoter, 
causing increased translation (Brasse-Lagnel et al. 2003). However, increased AS 
translation may be unable to overcome eNOS inhibition by O-GlcNAc modifications, 
especially if the stimulated citrulline-NO cycle is expected to produce more NO than in 
the basal state. 
Glucosamine effects on eNOS protein, AS protein and O-GlcNAc protein 
modifications in treated endothelial cells – We then looked at the levels of eNOS and AS 
using protein specific antibodies and also O-GlcNAc modification of proteins using an 
antibody to detect O-GlcNAc protein modifications in cell lysates from bradykinin-
stimulated endothelial cells in the absence and presence (2 mM and 8 mM) of 
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glucosamine. We found increases in total eNOS and AS proteins upon incubation with 2 
mM and 8 mM glucosamine for 26 hours (Figure 4). Also shown is the ratio of band 
density for eNOS and AS compared to GAPDH, used as a loading control. AS protein 
levels increased with glucosamine addition as expected. In the presence of high 
glutamine concentrations, Brasse-Lagnel et al. showed increased UDP-GlcNAc levels, 
the substrate for O-GlcNAc transferase, leading to increased O-GlcNAc modified Sp1, 
which translocates to the nucleus and increases AS gene transcription in Caco-2 cells 
(Brasse-Lagnel et al. 2003). Du et al. did not see a change in total cellular eNOS protein 
levels upon incubation with high glucose, although they showed an increase in O-
GlcNAc modified eNOS protein along with a decrease in phosphorylated (serine 1177) 
eNOS protein. Our results showed an increase in eNOS protein levels upon incubation 
with 2 and 8 mM glucosamine. The differences between the two experiments may be due 
to the source of the eNOS protein. Du et al. transfected a plasmid encoding myc-tagged 
human eNOS into BAEC and then determined total eNOS protein with antibodies against 
myc (human eNOS) or eNOS (human and bovine) (Du et al. 2001). In our experiments, 
total cellular bovine eNOS protein was detected using an antibody against eNOS. 
Although we saw a decrease in eNOS activity (based on NO production) along with an 
increase in total cellular eNOS protein, it is possible that this additional eNOS protein 
was not enzymatically active and therefore would not contribute to endothelial NO 
production. 
Glucosamine addition caused a slight increase in total cellular O-GlcNAc 
modified proteins in bradykinin-stimulated endothelial cell lysates (Figure 5). Those cells 
treated with 40 µM PUGNAc, an O-GlcNAcase inhibitor, showed increased O-GlcNAc 
modified proteins as compared with untreated cells. Our results are in agreement with Du 
et al. who showed an increase in total cellular O-GlcNAc modified endothelial cell 
proteins upon incubation with high glucose (Du et al. 2001). 
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Discussion 
 Nandi et al. (Nandi et al. 2006) demonstrated a technique to locate O-GlcNAc 
modified proteins on a global scale for proteomic analysis. They used HeLa cervical 
adenocarcinoma cells incubated with a peracetylated azido-GlcNAc which was taken up 
into cells and converted to UDP-azido-GlcNAc. The UDP-azido-GlcNAc was added to 
proteins that typically experience O-GlcNAc modifications by O-GlcNAc transferase. 
Following labeling, HeLa cell lysates were prepared and analyzed by nano-HPLC/tandem 
mass spectrometry. Proteins that showed O-GlcNAc modifications were analyzed further 
by immunoprecipitation to confirm mass spectrometry results. The authors confirmed O-
GlcNAc modifications on many proteins while increasing the known number of O-
GlcNAc modified proteins to over 200. Two members of the heat shock protein 90 
(hsp90) family, hsp90 alpha and beta, were confirmed to have O-GlcNAc modifications. 
Hsp90 was shown to associate with eNOS in endothelial cells by using fusion-tagged 
caveolin-1 to isolate the proteins from endothelial cell lysates (Gratton et al. 2000). 
Gratton et al. also showed direct protein-protein associations between recombinant eNOS 
and purified hsp90. Nandi et al. determined that AS can be O-GlcNAc modified (Nandi 
et al. 2006). 
Under conditions of high glucose, glutamine or glucosamine, alone or in 
combination, endothelial cell Sp1 becomes more O-GlcNAc modified leading to 
increased AS promoter binding and increased AS transcription (Anderson & Freytag 
1991; Brasse-Lagnel et al. 2003). Nandi et al. showed that AS protein undergoes O-
GlcNAc modifications which may change its enzyme activity or ability to associate with 
proteins involved in endothelial NO generation (Nandi et al. 2006). The increased 
activity or quantity of AS may be able to overcome the inhibition of eNOS by O-GlcNAc 
modification under basal conditions pushing the citrulline-NO cycle to produce more 
NO. However, under calcium agonist stimulated conditions, if eNOS is O-GlcNAc 
modified and has decreased activity, even endothelial cells having increased AS activity 
or quantity may be unable to generate NO at the same rate as cells not treated with 
glucosamine. Additionally, S. Solomon’s laboratory showed that calmodulin gene 
transcription is turned on by insulin treatment in H-411E liver hepatoma cells (Majumdar 
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et al. 2006). The calmodulin gene promoter contains three Sp1 binding sites. O-GlcNAc 
modification of Sp1 causes the modified transcription factor to translocate to the nucleus 
where it is then deglycosylated and subsequently phosphorylated. The newly 
phosphorylated Sp1 binds to sites in the calmodulin promoter, increasing gene 
transcription (Majumdar et al. 2003; Majumdar et al. 2006). It is possible that under high 
glucosamine concentrations, more calmodulin is expressed. Calmodulin binds to eNOS, 
displacing caveolin-1, causing dimerization and activation of eNOS. More activated 
eNOS leads to increased NO production depending on whether or not eNOS has already 
been O-GlcNAc modified which would decrease its enzyme activity. 
In summary, our data demonstrate an increase in NO production by glucosamine 
in basal endothelial cells and a reduction in NO production by glucosamine in 
bradykinin-stimulated endothelial cells. The O-GlcNAc modifications of eNOS, AS and 
possibly AL may play a role in these seemingly contradictory results. Further study into 
modifications of these citrulline-NO cycle proteins in endothelial cells along with chronic 
versus acute glucosamine and glutamine exposure under various physiologic states is 
needed to determine the exact mechanisms causing these observed results. 
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Table 1. NO (as nitrite) in nmol/hour/1x106 cells produced by BAEC under basal 
conditions with high and low glucose. BAEC were treated and samples were collected 
for NO (as nitrite) as described in methods. The results shown are the mean ± SEM from 
at least two independent experiments. Statistical analyses comparing low glucose (5 mM) 
and high glucose (20 mM) nitrite production were performed using an unpaired t test. 
P<0.05 (*) was considered statistically significant. 
 
Glutamine (mM) Glucose (mM) Basal NO(N) 
Basal NO in presence of 
DON (50 µM) (N) 
0.2 5.0 14.92 ± 2.39 (7) 4.17 ± 0.98 (2) 
2.0 5.0 2.31 ± 1.74 (2) * 7.84 ± 1.54 (2) 
0.2 20.0 13.27 ± 3.52 (3) 8.14 ± 4.87 (3) 
2.0 20.0 7.91 ± 5.06 (3) 10.79 ± 3.47 (3) 
 
 
Figure 1. UDP N-acetylglucosamine pathway. Glucose-6-phosphate is converted to 
fructose-6-phosphate which is converted to glucosamine-6-phosphate by 
glutamine:fructose-6-phosphate amidotransferase (GFAT) in the rate limiting step. 
Glucosamine-6-phosphate is then converted to UDP-GlcNAc used as the donor sugar for 
O-GlcNAc modifications on proteins. Glucosamine, synthesized from fructose-6-
phosphate and glutamine, enters the hexosamine biosynthetic pathway after the rate 
limiting step catalyzed by GFAT. GFAT activity is inhibited by 6-diazo-5-oxo-L-
norleucine (DON). 
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Figure 2. NO production by basal endothelial cells in the presence of glucosamine. 
BAEC were treated for 20-26 hours with glucosamine and samples were collected for NO 
(as nitrite) production as described in methods. The results shown are the mean ± SEM 
from at least two independent experiments. Statistical analysis was performed using a 
one-way ANOVA with 2-tail Dunnett t-test. P<0.05 (*) was considered statistically 
significant. 
 
BAEC
0
5
10
15
20
25
30
35
0.0 2.1 10.5 15.0
Glucosamine (mM)
nm
ol
 n
itr
ite
/h
r/
10
^6
 c
el
ls
*
*
 
 
106 
Figure 3. NO production by stimulated endothelial cells in the presence of 
glucosamine. BAEC were treated for 20-26 hours with glucosamine and stimulated with 
10 µM bradykinin and samples were collected for NO (as nitrite) production as described 
in methods. The results shown are the mean ± SEM from a minimum of two independent 
experiments. Statistical analysis was performed using a one-way ANOVA with 2-tail 
Dunnett t-test. P<0.05 (*) was considered statistically significant. 
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Figure 4. Glucosamine effects on eNOS and AS proteins in stimulated endothelial 
cells. BAEC were treated with glucosamine and stimulated with 10 µM bradykinin (Bk) 
and samples were collected for protein analysis. Proteins were separated by SDS-PAGE 
followed by transfer to PVDF membrane for immunoblotting with antibodies against 
eNOS, AS and GAPDH. The leftmost lane contains prestained protein molecular weight 
markers. The results shown are representative from two experiments. Density analysis 
was performed using ImageQuant 5.2 (GE Healthcare) and eNOS and AS protein levels 
were normalized to GAPDH. 
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Figure 5. Glucosamine effects on O-GlcNAc protein modifications in crude lysates 
isolated from stimulated endothelial cells. BAEC were treated with glucosamine and 
stimulated with 10 µM bradykinin (Bk) and samples were collected for protein analysis. 
Some cells were also treated with PUGNAc, an inhibitor of O-GlcNAcase. Proteins were 
separated by SDS-PAGE followed by transfer to PVDF membrane for immunoblotting 
with an antibody against O-GlcNAc modified proteins. The leftmost lane contains 
prestained protein molecular weight markers. The results shown are representative from 
two experiments. 
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Conclusions 
 Endothelial cells contain enzymes responsible for the production of endothelial 
nitric oxide (NO) and for the downstream effects of vasodilation, vascular health and 
maintenance of cell viability (Cooke 2004; Goodwin et al. 2004). In the healthly 
endothelium, NO is produced, as part of the citrulline-NO cycle, from arginine 
(regenerated from citrulline) by the sequential action of three enzymes, endothelial nitric 
oxide synthase (eNOS), argininosuccinate synthase (AS) and argininosuccinate lyase 
(AL) as part of the citrulline-NO cycle (Fig. 1). However, underlying diseases or risk 
factors (e.g. obesity, type 2 diabetes, atherosclerosis, insulin resistance, high-fat diet) 
cause endothelial dysfunction and decreased NO production due to changes in citrulline-
NO cycle proteins and may lead to cardiovascular disease. Unfortunately over the past 
three decades the prevalence of cardiovascular disease has increased dramatically and it 
has been reported that one in three Americans suffers from some type of cardiovascular 
disease (Poirier et al. 2006). Obtaining a greater understanding of the enzymes, reactions 
and the extracellular stimuli affecting the citrulline-NO cycle may ultimately allow 
researchers and clinicians to better design therapeutic interventions to restore endothelial 
function in individuals with compromised NO production. 
 In this work we show that the enzymes involved in the citrulline-NO cycle 
supporting endothelial NO generation, eNOS, AS and AL, are functionally associated, 
reactions are efficiently coupled and that nutrient levels affect the citrulline-NO cycle 
proteins. First, we show that even in the presence of saturating levels of arginine for 
eNOS, addition of exogenous arginine or exogenous citrulline causes an increase in 
endothelial NO production. We also show that eNOS, AS and AL co-fractionate with 
endothelial caveolae membranes. To further support our hypothesis, we show a direct 
interaction as well as associations between the enzymes of the citrulline-NO cycle using 
recombinant proteins, in vitro translated proteins and endothelial cell lysates. Next we 
show, by simultaneously measuring endothelial NO and citrulline production, a coupling 
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of the reactions involved in the citrulline-NO cycle. Finally, we show that glucosamine 
which enters the hexosamine biosynthetic pathway past the rate limiting step, causes 
changes in basal and stimulated endothelial NO production along with changes in some 
of the citrulline-NO cycle proteins when added to endothelial cell culture in high 
concentrations.  
 Shortly after NO was determined to be the endothelial-derived relaxing factor by 
Furchgott, Ignarro and Murad, who received the Nobel Prize in Physiology and Medicine 
for their work, Vane and colleagues reported on an interesting phenomenom observed in 
cultured endothelial cells (Hecker et al. 1990b). The researchers hypothesized that urea 
cycle enzymes, AS and AL, might be involved in endothelial NO generation. After 
depleting endothelial cells of arginine, they supplemented the cultures with the urea cycle 
intermediates, citrulline and argininosuccinate. Arginine-depleted endothelial cells 
incubated with argininosuccinate did not increase intracellular arginine levels as 
compared with arginine-depleted cells without argininosuccinate. They determined that 
argininosuccinate did not increase intracellular arginine levels since it was unable to 
either diffuse or be transported across the cell membrane. The interesting observation was 
that the arginine-depleted cells converted 8.4% of 14C-citrulline into 14C-arginine over a 
60 minute period. Nondepleted cells converted 3% of 14C-citrulline into 14C-arginine over 
a 60 minute period (Hecker et al. 1990b). Vane’s group also found that incubating 
endothelial cells with glutamine and stimulating in the presence of a calcium ionophore, 
caused an approximately three-fold increase in citrulline levels. This observation 
indicated that glutamine caused a buildup of citrulline and inhibited the recycling of 
citrulline to arginine in endothelial cells (Hecker et al. 1990a; Sessa et al. 1990). 
Subsequently, Wu and Meininger looked at arginine regeneration from citrulline in 
venular and aortic endothelial cells. They determined that in venular endothelial cells, 
arginine regeneration was not saturated at normal plasma citrulline levels of 50-100 µM 
up to 500 µM. Wu and Meininger determined that in intact endothelial cells, independent 
of extracellular arginine concentrations, citrulline is recycled to arginine (Wu & 
Meininger 1993).  
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During this time, our laboratory was working on pathways involved in 
methylarginine generation to regulate of eNOS activity. The enzyme, dimethylarginine 
dimethylaminohydrolase (DDAH), converts NG-methylarginine or NG,NG-
dimethylarginine, to citrulline and monomethylamine or dimethylamine, respectively. We 
added citrulline to endothelial cells expecting to inhibit the enzyme DDAH, preventing 
methylarginine breakdown, which was expected to inhibit eNOS activity and lower 
endothelial NO production. However, we found that the addition of the citrulline caused 
an increase in endothelial NO production (Appendix C). We then measured NO 
production in stimulated endothelial cells in the presence of increasing concentrations of 
arginine and citrulline. Thirty minutes prior to stimulation with bradykinin, endothelial 
cells were switched to Dulbecco’s modified Eagle’s medium (DMEM) containing 
concentrations of arginine or citrulline from 5-500 µM (DMEM normally formulated 
with 440 µM arginine). After 30 minutes, the cells were stimulated with 10 µM 
bradykinin and endothelial NO production was measured after 60 minutes. We found a 
significant increase in NO production in the presence of increasing concentrations of 
citrulline or arginine from 125-500 µM (Paper I, Figure 1). Next we measured the effect 
of exogenous arginine or exogenous citrulline on intracellular citrulline or arginine 
concentrations in bradykinin-stimulated endothelial cells. The endothelial cell medium 
was switched to DMEM containing arginine or citrulline from 0-1000 µM for 30 minutes 
prior to bradykinin stimulation. Sixty minutes after bradykinin stimulation, endothelial 
NO production was determined and the cells were harvested. Intracellular arginine and 
citrulline concentrations were determined by reversed-phase HPLC. The relative 
intracellular arginine or citrulline levels (threonine was used as an internal standard) 
increased proportionally with increasing extracellular arginine or citrulline, respectively. 
Relative intracellular arginine levels did not change with increasing extracellular 
citrulline concentrations. Relative intracellular citrulline levels did not change with 
increasing extracellular arginine concentrations even though there were associated 
increases in NO production (Paper I, Figure 2). This suggested that citrulline was 
recycled to arginine (preventing a buildup of citrulline), that extracellular arginine or 
citrulline could support NO production even though intracellular levels of arginine were 
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well above the Km of eNOS for arginine and that exogenous citrulline was able to mimic 
the effects of exogenous arginine on NO production. Next we determined the effects of 
exogenous citrulline or exogenous arginine in arginine-depleted DMEM or arginine-
supplemented DMEM on bradykinin-stimulated endothelial cells. Endothelial cells were 
switched to arginine-depleted DMEM containing: (A) 0 µM arginine, (B) 500 µM 
arginine, (C) 500 µM citrulline, or arginine-supplemented DMEM containing: (D) 440 
µM arginine, (E) 940 µM arginine or (F) 440 µM arginine plus 500 µM citrulline. After 
30 minutes, the endothelial cells were stimulated with bradykinin for 60 minutes and 
endothelial NO production was calculated for the different culture conditions. In 
conditions A-C, exogenous arginine or exogenous citrulline enhanced bradykinin-
stimulated endothelial NO production (B and C) over that of stimulated endothelial NO 
production in arginine-depleted DMEM (A) (Paper I, Figure 3A). In conditions, D-E in 
arginine-supplemented DMEM, there was no significant difference between the amount 
of endothelial NO produced by bradykinin-stimulated cells indicating that arginine 
uptake into the cells was saturating under these conditions (Paper I, Figure 3B). 
Interestingly, arginine-supplemented DMEM with exogenous citrulline (F) caused a 
significant increase in bradykinin-stimulated endothelial NO production over that of 
stimulated endothelial NO production in arginine-sufficient DMEM (D-E) (Paper I, 
Figure 3B). Taken together, these data show that even in the presence of saturating levels 
of arginine, citrulline is a limiting factor and that regeneration of arginine from citrulline 
provides the substrate for eNOS necessary for endothelial NO production (Paper I and 
Appendix C). 
These results indicated an efficient recycling of arginine from citrulline in 
endothelial cells. Therefore we decided to study protein-protein associations of the 
enzymes of the citrulline-NO cycle. Earlier it was shown that urea cycle intermediates 
channel substrates from one enzyme to the next for efficient reactions (Cheung et al. 
1989). Therefore, we proposed that the citrulline-NO cycle enzymes might be co-
localized to the same cellular compartment for efficient enzyme reactions. Endothelial 
cells contain specialized plasma membrane compartments, called caveolae, that are rich 
in cholesterol and sphingolipids and are known to contain many signaling molecules (e.g. 
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eNOS) (Garcia-Cardena et al. 1997; Sase & Michel 1997). We performed two methods of 
endothelial caveolae membrane isolation (Smart et al. 1995; Song et al. 1996). Caveolae 
membranes were isolated by a detergent-free alkaline method and a detergent-free non-
alkaline method of density separation. We collected fractions from each method and 
spotted these onto nitrocellulose membranes and probed with antibodies against eNOS, 
AS and AL along with the structural protein of caveolae, caveolin-1. Using the detergent-
free non-alkaline method (Paper I, Figure 4) and the detergent-free alkaline method 
(Paper I, Figure 5), citrulline-NO cycle proteins co-fractionated in pooled fractions 4-5 or 
pooled fractions 3-4, respectively. Then we took the same fractions from the detergent-
free alkaline method, separated the proteins by SDS-PAGE and used western blotting 
with antibodies against eNOS, AS and caveolin-1 to detect these citrulline-NO cycle 
proteins in the caveolae membrane fraction, pooled fractions 3-4 (Paper I, Figure 6). We 
also used an antibody against GM130, a golgi matrix protein and found that this protein 
co-fractionated with the pooled cytosolic fractions 5-10 indicating our fractionation 
protocol was successful. A protein assay confirmed that most protein was contained in 
the cytosolic fractions (Paper I, Figure 6). We concluded that the enzymes involved in the 
citrulline-NO cycle, eNOS, AS and AL, were contained in the same cell compartment 
and could represent an efficient arginine regeneration mechanism for endothelial NO 
production (Paper I and Appendix C). 
 It was previously shown by in vitro binding assays that both eNOS and caveolin-1 
and eNOS and heat shock protein 90 (hsp90) directly associated with one another 
(Fontana et al. 2002; Garcia-Cardena et al. 1997; Ghosh et al. 1998; Gratton et al. 2000; 
Ju et al. 1997). Venema et al. also showed an interaction through hsp90 between eNOS 
and soluble guanylate cyclase when NO binds to the heme within the soluble guanylate 
cyclase (Venema et al. 2003). eNOS interacting protein (NOSIP) was shown to associate 
with eNOS promoting its translocation from the caveolae to other subcellular fractions 
(Dedio et al. 2001) and overexpression of NOSTRIN caused a decrease in eNOS activity 
due to eNOS translocation away from the plasma membrane (Oess et al. 2006; 
Zimmermann et al. 2002). 
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AS and AL are also regulated by the intracellular environment and differences in 
regulation vary among cell types. In the liver, AS and AL play important roles in the urea 
cycle to remove excess nitrogen. However, these enzymes are expressed in many cell 
types, including endothelial cells which do not produce urea. It is important to note that 
in hepatocytes, AS and AL are localized to the outer mitochondria membrane (Cohen 
1996) while in the endothelium, AS and AL co-fractionate with the caveolae membrane 
fraction (Paper I). As mentioned previously, the significance of AS and AL expression in 
endothelial cells was not realized until the endothelial-derived relaxing factor was 
identified as NO and that the other product of the reaction catalyzed by eNOS, citrulline, 
could be recycled to arginine. Pendleton et al. demonstrated that the mRNA coding 
regions for AS isolated from liver and the endothelium are the same (Appendix B). 
However, there are two variant forms of AS mRNA containing extended 5´ untranslated 
regions (UTR) found only in the endothelium that may account for tissue-specific 
differences. These AS mRNA variants may cause endothelial AS to be localized to 
different subcellular fractions and may influence protein-protein interactions between AS 
and other citrulline-NO cycle components. AS, AL and eNOS contain transcriptional 
regulatory domains within their promoters that may cause differential expression 
depending on the stimuli received by the endothelium. For example, if arginine is 
replaced with citrulline in tissue culture using a human nasal septum squamous cell 
carcinoma line, there is increased transcription of the AS gene (Jackson et al. 1988a). 
Based on observations of citrulline-NO cycle protein co-fractionation and variant 
endothelial-specific AS mRNA 5´ UTRs in endothelial cells (Paper I and Appendix B 
and Appendix C), we decided to use in vitro interaction assays to further explore precise 
protein-protein interactions. 
 AS and AL proteins were bacterially-expressed as glutathione-S-transferase 
(GST) or hexahistidine-T7 tag (6xHis) fusion proteins in the Rosetta 2 E. coli strain. This 
particular E. coli strain improves eukaryotic protein yield by incorporating a plasmid in 
the Rosetta 2 to express seven rare prokaryotic tRNA. pGEX-5X vectors were used for 
GST protein expression and pET-28 vectors were used for 6xHis protein expression. The 
Studier method of autoinduction was used for recombinant protein expression (Studier 
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2005). GST fusion proteins were purified using glutathione agarose for GST-AS and 
GST-AL (Paper II, Figures 1A, 1C). 6xHis fusion proteins were purified using Ni-NTA 
agarose (Paper II, Figures 1A, 1B). The in vitro interaction assay uses a fusion-tagged 
recombinant protein as bait and either in vitro translated protein, recombinant protein or 
an endothelial cell lysate as prey. The bait protein is bound to a solid support, typically 
agarose beads, and the prey protein is added and the mixture is incubated for several 
hours. Following extensive washing to remove non-specifically bound proteins, reducing 
sample buffer is added to the agarose beads. Bait and prey proteins are separated by SDS-
PAGE and western blotting with an antibody against the prey protein is used to detect the 
protein binding partner. There is a direct protein-protein interaction if a protein band is 
visible in the samples containing bait and either in vitro translated protein or recombinant 
protein as prey. There is a protein-protein association if a protein band is visible in the 
samples containing bait and endothelial cell lysate as prey. Since the endothelial cell 
lysate contains many proteins, it cannot be assumed that the interaction is direct. 
 In vitro translated (ivt) AS was incubated with GST-AL, GST-AS or GST. Both 
GST-AL and GST-AS were able to pull down the ivt AS. This demonstrated a direct 
interaction between these proteins (Paper II, Figure 2). This is not surprising due to their 
involvement in the citrulline-NO cycle for arginine regeneration and since AS and AL 
both exist as homotetrameric proteins (O'Brien 1979; O'Brien et al. 1981). These data 
confirm and extend our co-fractionation studies where endothelial AS and AL co-
fractionated with one another. 
 Next we looked for protein-protein associations in unstimulated or stimulated 
endothelial cells using bacterially expressed AS or AL. As shown previously by 
Hellermann et al. (Appendix A) and others (Venema et al. 2003), activation of proteins 
upstream of and involved in the citrulline-NO cycle can alter their associations. 
Unstimulated or bradykinin plus sodium orthovanadate-stimulated endothelial cell lysates 
were prepared. 6xHis-AL or 6xHis-AS fusion proteins were incubated with these 
unstimulated or stimulated endothelial cell lysates. An association between eNOS and 
6xHis-AL or 6xHis-AS was detected with an antibody against eNOS (Paper II, Figure 3) 
and an association between caveolin-1 and 6xHis-AL or 6xHis-AS was detected with an 
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antibody against caveolin-1 (Paper II, Figure 4). There did not appear to be a significant 
difference in the amount of eNOS or caveolin-1 that was pulled down by either 6xHis-AL 
or 6xHis-AS from unstimulated or stimulated endothelial cell lysates. These data confirm 
and extend our earlier observations of a co-fractionation of AS and AL with eNOS and 
caveolin-1 from endothelial cell caveolae membranes. 
 While these data presented in Papers I and II are exciting and support our 
hypothesis of a close functional association among components of the citrulline-NO 
cycle, namely, AS, AL, eNOS and caveolin-1, further research on direct associations with 
known or unknown protein partners is needed. For example, ivt or recombinant eNOS 
could be mixed with AS or AL fusion proteins to determine whether these proteins have a 
direct interaction. Additionally, mutations at sites of reversible phosphorylation and O-
glycosylation could be made to ivt AS, AL and eNOS. These mutated ivt proteins could 
be mixed with GST or 6xHis fusion protein partners to determine the effects of these 
modified residues on protein-protein interactions in the citrulline-NO cycle. Different 
domains of the ivt proteins could be prepared to resolve the exact amino acids involved in 
direct protein-protein interactions. Also, citrulline-NO cycle proteins with GST, 6xHis or 
other fusion tags could be transfected into endothelial cells. The cells could then be left 
unstimulated or stimulated to produce more NO. Following the treatments, lysates could 
be prepared and using affinity chromatography to isolate the fusion tagged proteins and 
interacting protein partners, potentially novel protein binding partners could be detected 
using immunoblotting or mass spectrometry techniques. This is a more complex system, 
but may give a better picture of protein-protein interactions involved in endothelial NO 
generation. 
Post-translational modifications of a protein can change protein-protein 
interactions or protein subcellular localization leading to alternative cellular pathways. 
For example, phosphorylation of bovine eNOS on serine 1179, serine 635, serine 617 and 
tyrosine 83 enhances its activity (Fulton et al. 2005; Gallis et al. 1999; McCabe et al. 
2000; Michell et al. 2002). Serine 116 phosphorylation decreases eNOS activity, while 
phosphorylation on threonine 497 inhibits eNOS activity (Corson et al. 1996; Fleming et 
al. 2001; Kou et al. 2002; Schulz et al. 2005). Threonine 497 dephosphorylation causes 
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eNOS to produce superoxide and NO and that the balance of production of NO over 
superoxide can be modulated by eNOS accessory proteins or phosphorylation (Lin et al. 
2003). Church and Fulton reported on differences seen in bovine eNOS activity between 
wild-type eNOS and mutated eNOS that remains cytosolic (Church et al. 2006). The 
mutated eNOS was unable to undergo acylation and remained in the cytosol, and thus 
never translocated to the plasma membrane or Golgi. They reported that the differences 
seen in activity were due to differences in the phosphorylation state of serines 617, 635, 
1179. This caused a decrease in the amount of calcium-calmodulin binding to eNOS 
causing less dimerization of the enzyme and reduced enzyme activity. These changes in 
the acylation state of eNOS could have implications on protein-protein interactions 
between eNOS and known binding partners especially if the enzyme is unable to target a 
particular subcellular fraction. 
 Bradykinin, a biologically active polypeptide from blood globulin (Bae et al. 
2003) and sodium orthovanadate, a tyrosine phosphatase inhibitor (Appendix A), are 
effectors which increase endothelial NO production. Hellermann et al. determined that 
BAEC stimulated with sodium orthovanadate plus either bradykinin or calcium 
ionophore produced more endothelial NO than the sum of endothelial NO produced by 
either sodium orthovanadate plus bradykinin or sodium orthovandate plus calcium 
ionophore. Sodium orthovanadate did not have a direct effect on cellular lysate eNOS 
activity in vitro. Hellermann et al. also performed endothelial cell lysate fractionation and 
showed that sodium orthovanadate did not change the subcellular localization (caveolae 
versus cytosolic) of eNOS. However, sodium orthovanadate plus bradykinin endothelial 
cell treatment resulted in an increase in tyrosine phosphorylation of three proteins of 
apparent 75, 105 and 125 kDa. They concluded that the increase in NO production seen 
with sodium orthovanadate plus bradykinin treatment was due to a change in the 
association of proteins with eNOS, perhaps enhancing its activity (Appendix A). 
The concept of arginine regeneration from citrulline for endothelial NO 
production has been explored in great detail. For example, researchers have sought to 
determine the cause of the “arginine paradox” (Hardy & May 2002). Earlier it was 
demonstrated that endothelial cells had the capacity to recycle citrulline to arginine in 
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order to have arginine available for NO synthesis (Hecker et al. 1990b; Wu & Morris 
1998; Wu & Meininger 1993) (Paper I). They concluded that citrulline was recycled to 
arginine by AS and AL. This recycling pathway would allow for arginine availability to 
eNOS during periods of sustained NO production. Van Geldre et al. showed that in 
muscle layer nerve fibers and in neurons in the myenteric plexus in the rat gastric fundus, 
AS and AL co-localized with nNOS. Using smooth muscle strips, they also showed that 
administration of arginine completely, and citrulline partially, prevented L-NAME NOS-
inhibition of muscle relaxation (Van Geldre et al. 2002). Mohacsi et al. demonstrated that 
arginine availability was not limiting for recombinant eNOS activity so adenovirus 
mediated eNOS transfer into rabbit aorta was performed which improved vascular 
relaxation with or without arginine administration (Mohacsi et al. 1999). Simon et al. 
demonstrated that there are different intracellular compartments of arginine depending on 
cell type and eventual fate (Simon et al. 2003). Tsikas et al. noted that only 0.1% of 
administered arginine enters the L-citrulline-NO cycle (Tsikas et al. 2006) suggesting that 
endothelial cells must have a functioning arginine regeneration system in place for 
endothelial NO production. McDonald et al. demonstrated using confocal microscopy in 
porcine aortic endothelial cells (PAEC) that caveolin-1, the structural protein of caveolae 
co-localized with the cationic amino acid transporter 1, system y+ (CAT1) and that eNOS 
and CAT1 co-localized in the PAEC caveolae (McDonald et al. 1997). They concluded 
that the intracellular arginine was inaccessible to eNOS and that eNOS was co-localized 
with the arginine transporter, CAT1, at the plasma membrane surface to allow for NO 
production from arginine transported into the cell. More recently, Li et al. established that 
eNOS and CAT1 directly interact, but that this interaction increases NO production in an 
arginine transport-independent manner (Li et al. 2005). 
 Therefore we proposed to directly measure the production of both NO and 
citrulline in unstimulated (basal) and sodium orthovanadate plus bradykinin stimulated 
(stimulated) endothelial cells to determine the degree of recycling of citrulline to 
arginine. 14C-Arginine was added to the endothelial cells and after 90 minutes, the 
reaction was stopped and both NO from the tissue culture medium and citrulline from the 
cells were measured in the samples. To prevent arginine depletion by arginase, all cells 
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were treated with (S)-(2-Boronoethyl)-L-cysteine hydrochloride (BEC-HCl), an inhibitor 
of arginases I and II (Berkowitz et al. 2003). Some cells were also treated with L-NAME, 
an eNOS inhibitor, to determine eNOS-specific NO and citrulline generation. We 
determined that under both basal and stimulated conditions, the ratios of NO (measured 
as nitrite, an end-product) formed to citrulline were 8:1 (Paper III, Table I and Figure 2). 
The apparent amount of NO compared to citrulline produced in the basal or stimulated 
state was significantly greater, indicating that recycling of citrulline to arginine and 
conversion of arginine to NO is very efficient under all conditions. We also showed that 
due to arginine recycling, eNOS activity and the degree of stimulation can be 
substantially underestimated if measurements are made based on citrulline production 
alone. 
Inhibiting AS activity in endothelial cells should prevent the recycling of 
citrulline to arginine. To determine the direct effects of stimulation on the citrulline-NO 
cycle, we used α-methyl-DL aspartic acid (MDLA), an AS inhibitor (Shen et al. 2005). 
Sodium orthovanade plus bradykinin-stimulated endothelial cells were incubated in 
increasing concentrations of MDLA and again, simultaneous measurement of NO and 
citrulline was performed. Although NO production was inhibited by 80% at the highest 
concentration of MDLA, the ratio of NO to citrulline was 7:1, indicating a substantial 
degree of coupling where most of the citrulline produced was recycled to arginine for NO 
production (Paper III, Figure 3). 
Lastly, to show that recycling of arginine occurs within a specific intracellular 
location, we deprived endothelial cells of arginine for 48 hours. Arginine-sufficient 
(cultured in the presence of 340 µM arginine) or arginine-deprived cells (cultured in the 
presence of ~10 µM arginine) were either left in the basal state or stimulated, and NO 
production was determined (Paper III, Figure 4). If endothelial NO production was 
dependent on bulk intracellular arginine, which ranges between 0.1-0.8 mM, then we 
would have expected to see a dramatic decrease in the amount of NO produced in the 
arginine deprived versus arginine sufficient cells. There was only a modest decrease in 
NO production by arginine-deprived cells, relative to the extent of arginine depletion, 
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consistent with our hypothesis that the primary source of arginine directed to NO 
production is provided by the citrulline-NO cycle. 
Endothelial cell function and citrulline-NO cycle proteins are also affected by the 
extracellular environment. Increases in NO production are rapid and are caused by 
reversible phosphorylation, O-glycosylation, protein-protein associations, cellular 
translocation and substrate/cofactor availability of citrulline-NO cycle proteins. A 
specific protein modification, O-glycosylation, leads to rapid changes in protein function. 
Researchers determined that O-glycosylation of the transcription factor, Sp1, causes its 
translocation into the nucleus where it binds to response elements in the AS promoter 
region leading to increased gene transcription (Anderson & Freytag 1991; Brasse-Lagnel 
et al. 2003). Glucose, glutamine and glucosamine enter the hexosamine biosynthetic 
pathway increasing UDP-GlcNAc concentrations, so it is possible that cell culture 
conditions of high glucose, glutamine or glucosamine or a combination can change 
endothelial cell nitric oxide production or O-linked ß-N-acetylglucosamine (O-GlcNAc, 
Appendix D) protein modifications. 
 Incubation of endothelial cells with glucosamine causes increased O-GlcNAc 
modifications on plasminogen activator inhibitor 1 (PAI-1) (Goldberg et al. 2002). As 
previously mentioned, Sp1 is O-GlcNAc modified and it binds to transcription sites in the 
PAI-1 promoter causing increased translation of PAI-1 (Du et al. 2000). Glucosamine 
increased O-GlcNAc modifications on eNOS protein near the PKB phosphorylation site 
(Du et al. 2001). This increased activity of PAI-1 along with decreased eNOS activity due 
to O-GlcNAc modifications may cause PAI-1 overexpression leading to pathological 
atherosclerosis (Federici et al. 2002; Swiatkowska et al. 2000). Werstuck et al. recently 
demonstrated that high glucosamine and glucose concentrations caused protein 
misfolding in the endoplasmic reticulum, leading to ER stress, and that this ER stress was 
correlated with atherogenic lesion development in apoE-deficient mice (Werstuck et al. 
2006). Glucosamine induces insulin resistance at lower concentrations than glucose 
(Vosseller et al. 2002). Incubation of heart and skeletal muscle with high concentrations 
of glucosamine increases glucosamine-6-phosphate concentrations resulting in depleted 
intracellular ATP levels within the cell (Buse 2006). Buse et al. also saw changes in gene 
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expression in 3T3-L1 adipocytes incubated with 2.5 mM glucosamine and 0.6 nM insulin 
and either low glucose (5 mM) or high glucose (25 mM). Endothelial cells experience 
similar changes in gene expression where these changes may only be seen after exposure 
to glucosamine (Du et al. 2000; Goldberg et al. 2002).  
 We designed experiments to determine changes in endothelial NO production and 
citrulline-NO cycle proteins in BAEC, resulting from either high glucose, glutamine or 
glucosamine treatment. The amount of NO produced by BAEC after 20-24 hours in the 
presence of 5 mM glucose and either low glutamine (0.2 mM) or high glutamine (2 mM) 
was significantly greater with the low glutamine treatment. The amount of NO produced 
by BAEC after 20-24 hours in the presence of 20 mM glucose and either low glutamine 
(0.2 mM) or high glutamine (2 mM) was greater with the low glutamine treatment. To 
prevent conversion of glutamine to UDP-GlcNAc, the substrate for O-GlcNAc 
transferase, BAEC were treated with 50 µM 6-diazo-5-oxo-L-norleucine (DON, 
Appendix D), a glutamine amidotransferase inhibitor of the rate limiting-step of the 
hexosamine biosynthetic pathway. Using the DON inhibitor, the amount of NO produced 
by BAEC after 20-24 hours in the presence of 2 mM glutamine and either 5 mM or 20 
mM glucose was increased as compared to cells not treated with the inhibitor (Paper IV, 
Table 1). These data were in agreement with Wu et al. who showed that using a GFAT 
inhibitor (DON) to prevent production of UDP-GlcNAc demonstrated the involvement of 
glutamine in the hexosamine biosynthetic pathway (Wu et al. 2001a). These data were 
also in agreement with Du et al. who showed that O-GlcNAc modifications decrease 
eNOS activity leading to lowered endothelial NO production (Du et al. 2001). 
 Next we measured NO production in basal (unstimulated) or bradykinin-
stimulated endothelial cells treated with glucosamine for 20-26 hours. Under basal 
conditions there was a significant dose dependent increase in NO production at 2.1, 10.5 
and 15 mM glucosamine (Paper IV, Figure 2). However, under bradykinin-stimulated 
conditions, there was a dose dependent decrease in NO production at 2 and 8 mM 
glucosamine (Paper IV, Figure 3). The dose dependent effects of glucosamine observed 
under basal conditions were completely opposite to the results seen by Wu et al. (Wu et 
al. 2001a). The differences seen between the two experiments may be due to the source 
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of the endothelial cells and the cells were maintained in different concentrations of 
glucose. Our endothelial cells are typically maintained in 5 mM glucose (physiological), 
while Wu et al. maintained their endothelial cells in 20 mM glucose. 
Under conditions of high extracellular glucose, glutamine or glucosamine, alone 
or in combination, O-GlcNAc substitution of Sp1 increases leading to increased AS 
promoter binding and increased AS transcription (Anderson & Freytag 1991; Brasse-
Lagnel et al. 2003). Nandi et al. showed that AS can be O-GlcNAc modified, which we 
speculate may improve/enhance its enzyme activity or its ability to associate with 
proteins involved in endothelial NO generation (Nandi et al. 2006). Either the increased 
activity or quantity of O-GlcNAc modified AS, induced by high extracellular 
concentrations of glucose, glutamine or glucosamine, may be able to overcome the 
inhibition caused by O-GlcNAc modification of eNOS under basal conditions pushing 
the citrulline-NO cycle to produce more NO. However, under stimulated conditions, if 
eNOS is O-GlcNAc modified and has decreased activity, even endothelial cells having 
increased AS activity due to O-GlcNAc modification or quantity induced by high 
extracellular concentrations of glucose, glutamine or glucosamine, may be unable to 
generate NO at the same rate as cells not treated with glucosamine. 
 We then looked at the levels of eNOS and AS using protein specific antibodies 
and also O-GlcNAc modification of proteins using an antibody to detect O-GlcNAc 
protein modifications in cell lysates from bradykinin-stimulated endothelial cells in the 
absence and presence (2 mM and 8 mM) of glucosamine. We found increases in total 
eNOS and AS proteins upon incubation with 2 mM and 8 mM glucosamine for 26 hours 
(Paper IV, Figure 4). Glucosamine addition caused a slight increase in total cellular O-
GlcNAc modified proteins in bradykinin-stimulated endothelial cell lysates (Paper IV, 
Figure 5). AS protein levels increased with glucosamine addition as expected. In the 
presence of high glutamine concentrations, Brasse-Lagnel et al. showed increased UDP-
GlcNAc levels, the substrate for O-GlcNAc transferase, leading to increased O-GlcNAc 
modified Sp1, which translocates to the nucleus and increases AS gene transcription in 
Caco-2 cells (Brasse-Lagnel et al. 2003). Our results which showed an increase in total 
endothelial cellular O-GlcNAc protein modifications upon incubation with glucosamine 
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are in agreement with Du et al. who showed an increase in total cellular O-GlcNAc 
modified endothelial cell proteins upon incubation with high glucose (Du et al. 2001). Du 
et al. did not see a change in total cellular eNOS protein levels upon incubation with high 
glucose, although they showed an increase in O-GlcNAc modified eNOS protein along 
with a decrease in phosphorylated (serine 1177) eNOS protein. Our results showed an 
increase in eNOS protein levels upon incubation with 2 and 8 mM glucosamine. The 
differences between the two experiments may be due to the source of the eNOS protein. 
Du et al. transfected a plasmid encoding myc-tagged human eNOS into BAEC and then 
detected total eNOS protein with antibodies against myc (human eNOS) or eNOS (human 
and bovine). In our experiments, total cellular bovine eNOS protein was detected using 
an antibody against eNOS. Although we saw a decrease in eNOS activity (based on NO 
production) along with an increase in total cellular eNOS protein, it is possible that this 
additional eNOS protein was not enzymatically active and therefore would not contribute 
to endothelial NO production. 
 While these data presented in Paper IV are intriguing, additional research to 
determine the effects of glucose, glutamine or glucosamine alone or in combination on 
expression and activity of citrulline-NO cycle enzymes is needed. For example, using 
immunoprecipitation with antibodies or lectins (which bind to the O-GlcNAc moiety) it 
would be important to measure cellular levels of O-GlcNAc modified eNOS and AS, in 
the presence of varying concentrations of glucose, glutamine or glucosamine alone or in 
combination and compare the amount of modified proteins found in the presence or 
absence of the inhibitors DON or O-(2-acetamido-2-deoxy-D-glucopyranosylidene)-
amino-N-phenylcarbamate (PUGNAc, Appendix D). DON inhibits the rate limiting step 
of the hexosamine biosynthetic pathway, preventing the production of UDP-GlcNAc 
(moiety for O-GlcNAc modifications) from glucose and glutamine. PUGNAc is an O-
GlcNAcase inhibitor and specifically prevents the removal of the O-GlcNAc protein 
modification. By comparing results from western blot data plus and minus inhibitors, the 
pathways involved in AS and eNOS protein modifications may be further elucidated. 
Also, nuclear extracts from cell experiments similar to those outlined above should be 
performed. Electrophoretic mobility shift assays could be performed to look for 
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differences in binding to specific promoter regions known to contain binding sites for 
Sp1 (eNOS, AS and AL) or NF-Y (AL) in cells treated with glucose, glutamine or 
glucosamine alone or in combination, plus and minus the inhibitors DON and PUGNAc. 
 In summary we showed that citrulline and arginine increased endothelial NO 
production (Paper I and Appendix C). We also showed a co-fractionation of the 
citrulline-NO cycle proteins, eNOS, AS and AL with the endothelial caveolae membrane 
fraction (Paper I and Appendix C). Using in vitro interaction assays, we showed a direct 
association between AS-AL and an interaction between AS-eNOS, AL-eNOS and AL-
caveolin-1 providing further proof for protein-protein interactions between citrulline-NO 
cycle proteins (Paper II). Pendleton et al. (Appendix B) provided evidence for a 
difference in endothelial and liver AS targeting, while Hellermann et al. (Appendix A) 
provided evidence for a change in eNOS protein-protein interactions upon endothelial 
cell stimulation with sodium orthovandate plus bradykinin. We then showed evidence for 
a tight coupling of the reactions of the citrulline-NO cycle, to ensure citrulline recycling 
to arginine for endothelial NO production by eNOS (Paper III). Finally we provided 
evidence that the endothelial extracellular environment plays a crucial role in the function 
of citrulline-NO cycle proteins (Paper IV). We and others have shown that NO 
production is necessary to maintain cell viability (Goodwin et al. 2004), that a close 
association of proteins of the citrulline-NO cycle provides a more efficient method to 
produce endothelial NO by regenerating its precursor arginine from a specific 
intracellular source and location (Papers I-III) and that the endothelial extracellular 
environment can change protein function (Paper IV). It is hoped that the contribution of 
the studies from our laboratory will lead to increased understanding of the expression, 
localization and regulation of citrulline-NO cycle enzymes and their role in endothelial 
function and NO production. 
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Abstract 
Nitric oxide (NO) production by endothelial cells in response to bradykinin (Bk) 
treatment was markedly and synergistically enhanced by cotreatment with sodium 
orthovanadate (vanadate), a phosphotyrosine phosphatase inhibitor. This enhancement 
was blocked by tyrosine kinase inhibitors. Calcium ionophore – (A23187) activated 
production of NO was also enhanced by cotreatment with vanadate. No significant 
changes were found in total endothelial NO synthase (eNOS) protein or in eNOS 
distribution between membrane (caveolae) and cytosolic fractions in response to the 
various treatments. Vanadate had no direct effect on eNOS activity, and lysates prepared 
from cells treated with vanadate showed little change in specific activity of eNOS. 
Western blots of immunoprecipitated eNOS showed the presence of a major tyrosine-
phosphorylated protein band at a mass corresponding to ≈125 kDa and 2 minor bands 
corresponding to ≈105 and 75 kDa after treatment with vanadate/Bk. No tyrosine 
phosphorylation of eNOS after treatment with vanadate/Bk was observed. Geldanamycin, 
an inhibitor of heat shock protein 90, also inhibited the enhancement of NO production 
by vanadate/Bk or vanadate/A23187, and there was an increase in the amount of heat 
shock protein 90 that coimmunoprecipitated with eNOS after treatment with 
vanadate/Bk. These results show that there is a clear link between tyrosine 
phosphorylation and stimulation of eNO production, which does not appear to involve 
direct modification of eNOS, changes in eNOS levels, or compartmentation, but rather 
appears to be due to changes in proteins associating with eNOS, thereby enhancing the 
state of activation of eNOS. 
 
Key Words: nitric oxide, endothelial, vanadate, bradykinin, tyrosine phosphorylation 
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Endothelial nitric oxide synthase (eNOS) plays a key role in vasoregulation 
through the highly regulated production of eNO, which diffuses to the smooth muscle 
layer, causing relaxation. Several studies have suggested a linkage between 
phosphorylation/dephosphorylation events and eNO production. An early study by 
Michel et al (Michel et al. 1993) demonstrated that short-term incubation of endothelial 
cells with bradykinin (Bk) or calcium ionophore A23187 led to serine phosphorylation of 
eNOS, which appeared to be associated with intracellular translocation of eNOS 
(Prabhakar et al. 1998). More recent studies have demonstrated that Akt (protein kinase 
B) activates eNOS by phosphorylation of a specific serine residue (Dimmeler et al. 1999; 
Fulton et al. 1999; Michell et al. 1999). The involvement of tyrosine phosphorylation in 
eNOS regulation has also been studied. Exposure of endothelial cells to vanadate resulted 
in a low level of tyrosine phosphorylation, compared with a much greater level of serine 
phosphorylation (Garcia-Cardena et al. 1996). The in vitro activity measured on 
immunoprecipitates of eNOS suggested that tyrosine phosphorylation reduced the 
activity of eNOS by about one half (Garcia-Cardena et al. 1996). Fleming et al (Fleming 
et al. 1998) found a low level of basal tyrosine phosphorylation of eNOS, which was lost 
after treatment of endothelial cells with a phospho-tyrosine phosphatase inhibitor 
(phenylarsine oxide). Venema et al (Venema et al. 1996) observed neither basal nor Bk-
mediated stimulation of tyrosine phosphorylation of eNOS but did find that Bk activation 
of eNOS was accompanied by tyrosine phosphorylation of an eNOS-associated protein 
(ENAP-1). Activation of eNOS by flow-mediated shear stress appears to involve tyrosine 
phosphorylation, the activation being reduced by tyrosine kinase inhibitors and 
stimulated by inhibitors of phosphotyrosine phosphatases (Corson et al. 1996; Fleming et 
al. 1997; Fleming et al. 1998; Fleming et al. 1996). Corson et al (Corson et al. 1996) 
proposed that shear stress–mediated eNOS activity might be regulated by 
phosphorylation of the enzyme. They found an increase in serine/threonine 
phosphorylation, but not tyrosine phosphorylation, of eNOS after application of shear 
stress. Thus, the precise role of tyrosine phosphorylation in the regulation of eNOS 
activity is still uncertain. 
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In the present study, we examined the effect of phosphotyrosine phosphatase 
inhibition by sodium orthovanadate (vanadate) on eNO production and found an 
unexpectedly large and sustained increase in the amount of eNO produced after Bk-or 
calcium ionophore–mediated activation of eNOS. Although eNOS does not appear to be 
directly tyrosine-phosphorylated under these conditions, changes in the level of certain 
eNOS-associated phosphotyrosine-containing and other proteins suggest a role for 
tyrosine phosphorylation/ dephosphorylation in the physiological regulation of eNOS 
activity. 
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Methods 
Cell Culture – Endothelial cells used in this study were isolated from bovine 
aortas (BAECs) according to a standard method (Gimbrone 1976) and verified as 
endothelial by positive immunostaining for von Willebrand factor, negative staining for 
muscle actin, and morphological examination by electron microscopy (Jaffe 1984). Cells 
were routinely seeded in 12-well culture plates (Corning/Costar) at dilutions of 1:3 to 1:5 
and grown to confluence in Dulbecco’s modified Eagle’s medium containing 10% fetal 
bovine serum, 100 U penicillin, 100 µg streptomycin, 0.25 µg amphotericin B, and 50 µg 
gentamycin per milliliter at 37°C in an atmosphere of 95% air/5% CO2. 
Treatment Conditions – Cells were used 2 to 3 days after reaching confluence at 
a density of 1.5 to 1.7x105 cells/cm2 and >98% viability by the trypan blue dye-exclusion 
test. Cell monolayers in 12-well cluster dishes were rinsed 3 times with standard PBS at 
37°C, followed by the addition of 0.7 mL of Dulbecco’s modified Eagle’s medium 
containing antibiotics but no serum to each well. The NOS inhibitor NG-nitro-L-arginine 
methyl ester (L-NAME) was added, where indicated, to a final concentration of 1 
mmol/L and incubated for 30 minutes at 37°C before addition of the test compounds. 
Phosphatase or kinase inhibitors were added 5 minutes before eNOS activation with Bk, 
A23187, vanadate, vanadate/Bk, or vanadate/A23187. Incubations were carried out at 
37°C and test compounds were present throughout the incubation period. Solutions of 
sodium orthovanadate at a concentration of 5 mmol/L were prepared by heating at 95°C 
for 10 minutes, and actual concentrations of orthovanadate were determined by 
spectrophotometric measurement at 260 nm by using a millimolar extinction coefficient 
of 3.55 (Gordon 1991). 
Assay for NO as Nitrite in Culture Medium – The method for measuring nitrite, 
a stable reaction product of NO, involves the conversion of 2,3-diaminonaphthalene to 
the highly fluorescent 1(H)-naphthotriazole through specific reaction with nitrite under 
acidic conditions (Misko et al. 1993). Cell counts were performed on a sampling of wells 
by using a microscope with an eyepiece micrometer, and the average was used in 
converting the readings to a per-106-cell basis. Fluorescence intensity was determined at 
room temperature with a Jasco FP-770 spectrofluorometer. 
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Preparation of Caveolin-Enriched Membrane Fractions – The method of Song 
et al (Song et al. 1996) was used to prepare caveolae from BAECs. All steps were carried 
out at 4°C. In brief, confluent cell monolayers were treated with various agents, washed 
with PBS, and suspended in 500 mmol/L Na2CO3, pH 11. The alkaline cell suspension 
was lysed with a Dounce homogenizer followed by further homogenization with a 
Polytron tissue homogenizer and brief sonication, as described by Song et al (Song et al. 
1996). One milliliter of each lysate was mixed with an equal volume of 90% sucrose, 
transferred to the bottom of a centrifuge tube, and overlaid with a step gradient consisting 
of 1.0 mL of 35% sucrose, 0.5 mL of 25% sucrose, 0.5 mL of 15% sucrose, and 0.5 mL 
of 5% sucrose, all with the same buffer composition as the 45% sucrose sample solution. 
Tubes were centrifuged in an SW60 Ti rotor at 40 000 rpm for 17 hours. Fractions of 0.4 
mL were collected from the top of the gradient. The caveolar peak corresponded to 
fraction 3. 
Preparation and Processing of Cell Lysates – After the indicated incubation 
period, cells were rinsed 3 times with cold PBS and stored at -80°C until processed. 
Lysates were prepared by scraping cells from each well into 250 µL of cell-disruption 
buffer containing 20 mmol/L HEPES (pH 7.5); 0.1 mol/L NaCl; 5 µg/mL each of 
pepstatin A, leupeptin, and trypsin inhibitor; 0.5 mmol/L PMSF; 0.1 mmol/L DTT; 1 
mmol/L sodium orthovanadate; and 10 mmol/L KF. Three rounds of freeze/thaw or three 
6-second bursts of sonication with a microprobe at a 25-W output were sufficient to lyse 
>90% of the cells, as judged microscopically. Cell lysates were used directly, separated 
into caveolar fractions (see above), or separated into membrane and cytosolic fractions by 
15 minutes of centrifugation at 100 000g in a TL-100 ultracentrifuge with a fixed-angle 
rotor. Protein determinations were done using the bicinchoninic acid protein assay kit 
(Pierce) with bovine serum albumin as the standard. 
Immunodetection of Proteins and Immunoprecipitation – For determination of 
eNOS protein levels, aliquots of cell lysates or fractions were either directly adsorbed to 
nitrocellulose membranes with a dot-blot apparatus (Bio-Rad) or separated by SDS–
polyacryl-amide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose 
membranes. For immunoprecipitations, cell lysates (≈100 µg protein) were incubated 
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with a specific antibody (≈1 µg) for 1 hour at 4°C, followed by 1 hour at 4°C with protein 
A/G Sepharose (Sigma). Precipitated proteins were solubilized with SDS-PAGE sample 
buffer and electrophoretically separated. Blots were blocked in 1% gelatin or 5% nonfat 
dry milk in 10 mmol/L Tris·HCl (pH 7.5), 0.1 mol/L NaCl, and 0.2% Tween 20 and then 
incubated, where indicated, with 1:1000 dilutions of monoclonal antibodies specific for 
eNOS (Transduction Labs), caveolin-1 (Transduction Labs), protein tyrosine phosphate 
(clone PY20, Zymed Labs), or heat shock protein 90 (hsp90; StressGen Labs). 
Horseradish peroxidase– conjugated IgG (Transduction Labs) was used to detect the 
respective primary monoclonal antibody by means of a horseradish peroxidase–activated 
chemiluminescent substrate (enhanced chemiluminescence, Amersham). Densitometric 
measurements on scanned images were completed by using ImageQuaNT software 
(Molecular Dynamics). 
In Vitro Assay for eNOS Activity – The possible direct effect of sodium 
orthovanadate on eNOS activity in lysates of endothelial cells was tested by using an 
eNOS assay based on the conversion of [3H]L-arginine to [3H]citrulline (Bredt et al. 
1990). Assay mixtures contained 25 mmol/L HEPES (pH 7.4), 3 µmol/L 
tetrahydrobiopterin, 1 µmol/L FAD, 1 µmol/L flavin mononucleotide, 1 mmol/L 
NADPH, 0.6 mmol/L CaCl2, 0.1 µmol/L calmodulin, and 20 µCi/mL [3H]L-arginine (60 
Ci/mmol). Assays were run for 30 and 60 minutes in the presence or absence of 1 
mmol/L sodium orthovanadate at 37°C, and activity was compared with background 
levels in the absence of calcium or in the presence of the NOS inhibitor L-NAME. 
Lysates from cells treated with Bk and/or vanadate were also assayed for eNOS activity 
to determine whether the treatments resulted in any change in specific activity of eNOS. 
Statistical Analysis – Data are expressed as mean ± SEM. At least triplicate 
determinations were performed for quantitative analyses. Student’s t test was used for 
evaluating significance. 
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Results 
Vanadate-Stimulated eNO Production – Endothelial cells were incubated with 
the protein phosphotyrosine phosphatase inhibitor (Gordon 1991) sodium orthovanadate, 
and the rate of eNO production was measured during continuous exposure to either Bk or 
calcium ionophore A23187. A small, continuous basal level of eNO was produced in the 
absence of vanadate, Bk, or A23187. Bk stimulated eNO production to a level about 
double that of the untreated controls (Figure 1A), whereas A23187, which acts in a 
receptor-independent manner to directly raise the intracellular calcium concentration, 
caused a 4-to 5-fold increase in NO production (Figure 1B). Vanadate alone stimulated 
the formation of eNO in a time-dependent manner even in the absence of added Bk or 
A23187. When Bk or A23187 was added to endothelial cells in the presence of vanadate, 
however, there was a dramatic and sustained enhancement of eNO formation to levels 10 
to 20 times that of controls (Figure 1). The amount of eNO generated by treatment with a 
combination of vanadate and either Bk or A23187 was >2-fold greater than the sum of 
eNO generated by treatment with the individual components, indicating a synergistic 
effect of vanadate and Bk or A23187 (Figure 1, summation curves). 
We also examined the effect of phosphotyrosine phosphatase inhibition by 
vanadate over a range of Bk or A23187 concentrations. When cells were incubated with 
Bk (Figure 2A), the enhancing effects of 50 µmol/L vanadate were most apparent at the 
lower concentrations and reached a plateau as Bk activation peaked at ≈10 µmol/L. 
Incubation of endothelial cells with A23187 led to a rapid and sustained rise in eNOS 
activity due to calcium influx, and vanadate further stimulated eNO production. This 
enhancement was most striking at A23187 concentrations <5 µmol/L, but enhancement 
of eNO production by vanadate occurred even under conditions of apparent calcium 
saturation (Figure 2B). Incubation of cells in medium lacking calcium or containing 
EGTA completely abolished the sustained generation of eNO, indicating the necessity of 
a continuous influx of calcium from outside the cells for extended eNOS activity. 
Likewise, removal of L-arginine from the medium prevented the sustained generation of 
eNO (data not shown). 
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Effects of Protein Kinase and Other Inhibitors on Vanadate-Stimulated NO 
Production – The specific involvement of tyrosine phosphorylation in the enhancement 
of eNO production is shown in Figure 3. Cells were pretreated with the protein tyrosine 
kinase inhibitors genistein (Akiyama et al. 1987) or tyrphostin ST638 (Gazit et al. 1991) 
before activation with either Bk (Figure 3A) or A23187 (Figure 3B), and the effects of 
vanadate were abrogated. Phenylarsine oxide, which inhibits a class of phosphotyrosine 
phosphatases that contain vicinal sulfhydryls at the active site (Kussmann et al. 1995), in 
contrast to vanadate, which mimics the transition state of phosphotyrosine phosphatase–
catalyzed reactions (Zhang et al. 1997), did not cause enhancement of eNO generation 
(Figure 3A), indicating that the class of phosphotyrosine phosphatases inhibited by 
phenylarsine oxide was not involved in the regulation of eNO production under these 
conditions. Pretreatment of endothelial cells with the NOS inhibitor L-NAME (Moncada 
et al. 1989) blocked eNO production, whereas co-treatment with dexamethasone, which 
blocks induction of the inducible isoform of NOS (Radomski et al. 1990), had little effect 
(Figure 3B). Treatment with the protein synthesis inhibitor cycloheximide did not alter 
the vanadate response over the first 2 hours, suggesting that the enhancement most likely 
involved a constitutive protein (data not shown). Okadaic acid, a potent inhibitor of the 
phosphoserine/phosphothreonine phosphatases pp1 and pp2a (Cohen et al. 1989), 
reduced the vanadate enhancement of eNO production in Bk-treated cells (Figure 3A). 
When endothelial cells were activated by A23187 in the presence of okadaic acid, 
however, there was no effect on the vanadate response, indicating that involvement of a 
putative serine kinase was specific for the Bk-mediated signaling pathway (Figure 3B). 
The same basic experiments were repeated with primary cultures of BAECs and human 
umbilical vein endothelial cells, with essentially the same results (data not shown). 
Effect of Vanadate on eNOS Compartmentation and Expression – To determine 
whether vanadate affects the intracellular location of eNOS, the relative levels of eNOS 
protein were measured in cell lysates and subcellular fractions by immunoblotting and 
densitometry. After centrifugation of endothelial cell lysates at 100 000g, ≈95% of total 
eNOS protein was associated with the particulate fraction, and vanadate treatment, in the 
presence or absence of Bk, caused little or no change in this distribution. Also, there was 
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no significant difference in total eNOS protein under the various treatment conditions 
compared with controls. Treatment of endothelial cells with Bk, vanadate, or vanadate/Bk 
had no significant effect on the subcellular distribution of eNOS, as indicated by 
isopycnic centrifugation of cell lysates through a sucrose gradient under conditions 
designed to separate caveolae from denser membrane fractions (Song et al. 1996). Most 
of the eNOS protein was associated with the caveolar peak fraction (fraction 3) under all 
treatment conditions (Figure 4). This fraction corresponded to the interface between 15% 
and 25% sucrose. Noncaveolar membrane fractions were distributed in denser regions of 
the gradient (fractions 4 to 8) (Song et al. 1996). The presence of eNOS and caveolin-1 in 
the peak fractions shown in Figure 4 was confirmed by Western blotting (data not 
shown). Because the samples were loaded from the bottom of the gradients, cytosolic and 
cytoskeletal proteins would remain in the 45% sucrose sample zone (fractions 8 to 10). 
Effect of Vanadate on eNOS Activity Measured In Vitro – To determine whether 
vanadate affected eNOS directly, lysates of untreated endothelial cells were assayed for 
eNOS activity in the presence or absence of vanadate. No effect of vanadate, at a 
concentration of 1 mmol/L, was observed (data not shown), indicating that vanadate had 
no direct effect on eNOS. Lysates prepared from cells that had been incubated with 
vanadate or vanadate/Bk for 4 hours showed a slight increase in eNOS activity compared 
with controls (31.2±2.4 versus 25.3±2.0 pmol citrulline produced per minute per 
milligram protein), but this possible increase in eNOS activity measured in vitro does not 
account for the striking increase in NO production by endothelial cells after treatment 
with vanadate/Bk. 
Vanadate-Induced Changes in Tyrosine-Phosphorylated Proteins – The state of 
tyrosine phosphorylation of eNOS and other protein components after the various 
treatment conditions was analyzed by Western blotting, after immunoprecipitation with 
anti-eNOS, by using an antibody probe to protein tyrosine phosphate. A tyrosine-
phosphorylated protein with an apparent molecular mass of ≈125 kDa, along with lesser 
amounts of tyrosine-phosphorylated proteins with apparent molecular masses of ≈105 
and 75 kDa, appeared to be specifically associated with eNOS after vanadate/Bk 
treatment, as indicated by coimmunoprecipitation with anti-eNOS (Figure 5). The 
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apparent molecular mass of eNOS run under identical conditions was ≈140 kDa. Little or 
no tyrosine phosphorylation of eNOS was observed under these conditions. 
Possible Role of hsp90 on Vanadate Stimulation of eNO Production – hsp90 is a 
molecular “chaperone” with a molecular mass of ≈90 kDa that functions, in part, to 
facilitate the folding of certain signal-transducing proteins (Buchner 1999; Caplan 1999). 
hsp90 has been shown to associate with and stimulate eNOS activity (Garcia-Cardena et 
al. 1998). Geldanamycin, an inhibitor of hsp90 (Buchner 1999; Caplan 1999), inhibited 
the vanadate/Bk and vanadate/A23187 stimulation of eNO production with an apparent 
IC50 of ≈6 µmol/L (data not shown). Direct involvement of hsp90 in the enhancement of 
eNOS activity under these conditions was further supported by the finding that an 
increased amount of hsp90 coimmunoprecipitated with eNOS after vanadate/Bk 
treatment (Figure 6). 
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Discussion 
Early studies with purified NOS showed that the enzyme could be a substrate for 
a number of protein kinases (Nakane et al. 1991). Although the bulk of in vivo eNOS 
phosphorylation occurs on serine/threonine, there have been reports of tyrosine 
phosphorylation of eNOS itself (Fleming et al. 1998; Garcia-Cardena et al. 1996). 
Garcia-Cardeña et al (Garcia-Cardena et al. 1996) found that treating endothelial cells 
with high levels (1 mmol/L) of vanadate caused an increase in basal tyrosine 
phosphorylation of eNOS and reduced eNOS activity by ≈50% in an in vitro 
immunoprecipitation-complex assay. Our results, in contrast, indicate that lower levels 
(50 µmol/L) of vanadate enhanced the Bk-and calcium ionophore–mediated production 
of eNO. This enhancement was apparently indirect, because there was no change in 
eNOS activity measured in vitro and no tyrosine phosphorylation of eNOS was observed. 
These apparently contradictory results may be due to different experimental conditions. 
We used a significantly lower concentration of vanadate (50 µmol/L versus 1 mmol/L) 
and focused on receptor-mediated production of eNO. It is unlikely that vanadate at the 
low concentration used in this study (50 µmol/L) could cause such an enhancement of 
eNOS activity through a nonspecific cellular effect. Venema et al (Venema et al. 1996) 
also reported that binding of Bk to endothelial cells did not elicit tyrosine 
phosphorylation of eNOS, but rather of a 90-kDa ENAP-1, which appeared to lead to the 
translocation of eNOS to a detergent-insoluble fraction. The change in eNOS 
localization, however, did not result in a change in enzyme activity. Inhibition of tyrosine 
kinases blocked phosphorylation of ENAP-1 and also prevented the translocation of 
eNOS. We did not observe an alteration in the overall pattern of eNOS intracellular 
distribution under our experimental conditions. It should be noted, however, that our 
results represent a “steady-state” condition, because eNO production was monitored over 
several hours under the various conditions. Therefore, transient changes would not be 
detected in phosphorylation states or in intracellular location that have been reported by 
other investigators (Prabhakar et al. 1998). 
We found that continuous treatment of endothelial cells with Bk for up to 6 hours 
stimulated eNO production to about twice the basal level, whereas cotreatment with 
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vanadate caused a much greater (≈20-fold) and synergistic agonist response. The 
response to vanadate was abolished by the tyrosine kinase inhibitors genistein (Akiyama 
et al. 1987) and tyrphostin (Gazit et al. 1991), thus demonstrating the specific 
involvement of tyrosine phosphorylation in this enhancement. We also observed a 
synergistic enhancement by vanadate of A23187-mediated activation of eNO production, 
suggesting that the observed vanadate effect was not mediated by Bk. 
The tyrosine phosphorylation–associated enhancement of eNO production cannot 
be explained through an increase in the relative amounts of eNOS because Western blots 
showed no significant change in the distribution or in total eNOS levels in either 
particulate or cytosolic fractions after vanadate treatment, consistent with the lack of 
effect of cycloheximide on enhancement of eNO production by vanadate. The observed 
vanadate enhancement appears to be indirect, because vanadate had no effect on the 
specific activity of eNOS when included in an NOS assay of lysates from untreated cells. 
There was also little difference in the specific activity of eNOS from lysates of cells 
treated with Bk, vanadate, or Bk/vanadate. 
Activation of eNOS may occur within the plasma membrane subcompartments 
known as caveolae, which are cho-lesterol-rich structures consisting of a scaffolding 
protein, caveolin-1, and an array of receptors and signal transduction factors. Caveolin-1 
overexpression was found to inhibit eNOS activity in lysates from COS-7 cells 
coexpressing eNOS, and the effect was reversed by addition of calmodulin (Michel et al. 
1997). It has also been reported that eNOS undergoes a flow-mediated dissociation from 
caveolin and a reassociation with calcium-calmodulin (Rizzo et al. 1998), which could 
serve to potentiate eNOS activity through maintaining the active dimeric form of the 
enzyme (Hellermann et al. 1997). Other proteins have been shown to bind to and modify 
eNOS activity, including ENAP-1 (Venema et al. 1996), the Bk B2 receptor (Ju et al. 
1998; Marrero et al. 1999) and hsp90 (Garcia-Cardena et al. 1998; Russell et al. 2000). 
We found that a 125-kDa tyrosine-phosphorylated protein, and possibly 105-and 75-kDa 
tyrosine-phosphorylated proteins, were associated with eNOS after treatment with 
Bk/vanadate. It was previously reported that eNOS coimmunoprecipitated with hsp90 
(Garcia-Cardena et al. 1998). Binding of hsp90 is associated with stimulation of eNOS 
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activity (Garcia-Cardena et al. 1998), and enhanced binding of hsp90 to eNOS also 
appears to be involved in the estrogen receptor–mediated activation of eNOS (Russell et 
al. 2000). We found that hsp90 was apparently involved in the vanadate/Bk stimulation 
of eNO production, on the basis of the inhibition of this stimulation by geldanamycin, a 
specific inhibitor of hsp90, and on the apparent increase in hsp90 that 
coimmunoprecipitated with eNOS after exposure to vanadate. It should be noted that 
hsp90 and ENAP-1 are of the same apparent size and may even be the same protein (R.C. 
Venema, personal communication, 2000). Thus, the increase in tyrosine phosphorylation 
of certain proteins appears to trigger a marked enhancement of the activation state of 
eNOS through association with specific proteins that are presumably involved in 
regulating eNOS activity in vivo. 
Clearly, there are different pathways that may affect eNOS activity, depending on 
the relative types and levels of phosphorylation/dephosphorylation in a system. Through 
this regulated interaction of enzymes and accessory proteins, a fluid complex is formed 
that promotes efficient coupling of the components of the signaling pathway. Our results 
support the view that protein tyrosine phosphorylation plays a prominent role in the 
complex signaling network regulating eNOS activity in vivo. This tyrosine 
phosphorylation–mediated modulation of eNOS activity appears to be due, in large part, 
to association/dissociation of “modulator” proteins, rather than to a direct modification of 
tyrosine residues of eNOS. 
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Figure 1. Treatment of endothelial cells with sodium orthovanadate causes 
enhancement of both Bk-and A23187-stimulated NO production. BAECs were 
incubated with either 2 µmol/L Bk (A) or 1 µmol/L A23187 (B) with or without 50 
µmol/L vanadate. Samples were taken at the indicated times and nitrite content was 
determined. Control, ●; Bk and A23187, ▲; vanadate, ■; Bk/vanadate and 
A23187/vanadate, ∆; summation of Bk and vanadate or A23187 and vanadate, +. 
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Figure 2. Dose response for Bk or A23187 on NOS activity with or without sodium 
orthovanadate. Bk (A) or A23187 (B) at the indicated concentrations was incubated 
with BAECs for 4 hours in the presence (▲) or absence (●) of 50 µmol/L vanadate. 
Nitrite content in the culture medium was then determined. 
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Figure 3. Effects of NOS inhibitors and protein phosphatase or kinase inhibitors on 
the sodium orthovanadate enhancement of Bk-or A23187-stimulated NO 
production. BAECs were incubated for 4 hours in the presence of 2 µmol/L Bk (A) or 1 
µmol/L A23187 (B). Where indicated, the following compounds were also present: 
vanadate (V, 50 µmol/L), genistein (Gen, 40 µmol/L), tyrphostin ST638 (Tyr, 20 
µmol/L), okadaic acid (OA, 0.5 µg/mL), phenylarsine oxide (PAO, 10 µmol/L), L-
NAME (NAME, 1 mmol/L), or dexamethasone (Dex, 50 µmol/L). Samples of culture 
medium were taken after 4 hours of incubation and nitrite content was determined. Minus 
sign under left bar indicates control. 
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Figure 4. Effects of vanadate treatment on caveolar localization of eNOS in 
endothelial cells stimulated with Bk. BAECs were incubated for 4 hours as indicated 
with 10 µmol/L Bk, 50 µmol/L sodium orthovanadate (V), or both (Bk/V). Lysates of 
cells were then subjected to isopycnic density gradient centrifugation and fractionation as 
described in Methods. Aliquots of the fractions were dot-blotted, and the blot was probed 
with an eNOS-specific polyclonal antibody. Fraction 1 represents the top and fraction 10, 
the bottom of the gradient. The caveolar peak corresponds to fraction 3, as determined by 
immunoblot analysis with anti– caveolin-1 (not shown). 
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Figure 5. Effect of vanadate on phosphotyrosine-containing proteins in Bk-
stimulated endothelial cells. BAECs were incubated for 4 hours with 2 µmol/L Bk in 
the presence or absence of 50 µmol/L vanadate (V). Cell lysates were prepared, 
immunoprecipitated with anti-eNOS monoclonal antibody, and run on SDS PAGE. Blots 
were probed with an anti-phosphotyrosine monoclonal antibody (left) and anti-eNOS 
monoclonal antibody (right). C indicates control. 
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Figure 6. Immunoprecipitation of Bk-treated endothelial cell lysates with anti-eNOS 
monoclonal antibody. BAECs were incubated for 4 hours with 2 µmol/L Bk in the 
presence or absence of 50 µmol/L vanadate (V), followed by preparation of cell lysates 
and immunoprecipitation with an anti-eNOS monoclonal antibody. Immunoprecipitated 
proteins were separated by SDS PAGE and immunoblotted with the indicated 
monoclonal antibodies. C indicates control. 
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Abstract 
 Based on the integral role that argininosuccinate synthase (AS) plays in the 
production of nitric oxide in vascular endothelial cells and urea in liver, an analysis was 
carried out to determine whether signals reside in the AS mRNA to account for tissue 
differences in AS function and location. Reverse transcriptase-PCR and sequence 
analysis showed that the AS mRNA coding region was the same for both endothelial cells 
and liver; however, 5´-RACE analysis (rapid amplification of cDNA ends) identified AS 
mRNA species in endothelial cells in addition to a major 43-nucleotide (nt) 5´-
untranslated region (UTR) AS mRNA with overlapping extended 5´-UTRs of 66 and 92 
nt. Comparison to the genomic sequence immediately upstream of the reported 
transcription start site for the human and mouse AS gene suggested that expression of all 
three species of bovine endothelial AS mRNA are driven by a common promoter and that 
5´-UTR diversity in endothelial cells results from three transcriptional initiation sites 
within exon 1. RNase protection analysis and real-time reverse transcriptase-PCR 
verified and quantitated the differential expression of the extended 5´-UTR species 
relative to the major 43-nt 5´-UTR AS mRNA. In vitro translation studies showed a less 
pronounced but similar discordant expression. Sequential deletions starting from the 5´ 
terminus of the 92-nt 5´-UTR construct resulted in a corresponding increase in 
translational efficiency, but the most pronounced effect resulted from mutation of an 
upstream open reading frame, which restored translational efficiency of the 92-nt 5´-UTR 
AS mRNA. When the different AS mRNA 5´-UTRs, cloned in front of a luciferase 
reporter gene, were transfected into endothelial cells, the pattern of luciferase expression 
was nearly identical to that observed for the different 5´-UTR AS mRNAs in endothelial 
cells. Given the different roles ascribed for argininosuccinate synthase, urea versus NO 
production, these results suggest that sequence in the AS gene represented by position -92 
to 43 nt from the translation start site in the extended AS mRNA 5´-UTRs plays an 
important role in differential and tissue-specific expression. 
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The abbreviations used are: AS, argininosuccinate synthase; UTR, untranslated region; 
nt, nucleotide; ORF, open reading frame; uORF, upstream ORF; AL, argininosuccinate 
lyase; BAEC, bovine aortic endothelial cells; RACE, rapid amplification of cDNA ends; 
RPA, ribonuclease protection assay; RT, reverse transcriptase; TBST, Tris-buffered 
saline Tween 20; NO, nitric oxide. 
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 Argininosuccinate synthase (AS) catalyzes the reversible ATP-dependent ligation 
of citrulline and aspartate to produce argininosuccinate, AMP, and inorganic 
pyrophosphate. The primary role of AS is the detoxification of ammonia via the urea 
cycle in the liver (Morris 1992). Although this essential physiological function occurs in 
the liver and to a lesser extent in the small intestine, virtually all other mammalian tissues 
possess detectable levels of AS and a second urea cycle enzyme argininosuccinate lyase 
(AL). Together these two enzymes have the net effect of generating arginine from 
citrulline and aspartate. In the kidney, AS and AL are responsible for the de novo 
synthesis of arginine to be released into the bloodstream (Wu et al. 1998). In other 
tissues, however, the function of this metabolic pathway remained obscure until the 
discovery of arginine-derived nitric oxide (NO) (Hecker et al. 1990). 
 In endothelial cells, AS catalyzes the rate-limiting step (Xie et al. 1997) in the 
synthesis of L-arginine from L-citrulline. Endothelial nitric-oxide synthase then utilizes 
the arginine, converting it back to citrulline to produce NO. Thus, available arginine is a 
prerequisite for NO production. Interestingly, intracellular levels of arginine in 
endothelial cells have been estimated to range from 0.1 to 0.8 mM (Baydoun et al. 1990; 
Block et al. 1995; Gold et al. 1989; Harrison 1997; Hecker et al. 1990; Mitchell et al. 
1990; Xie & Gross 1997), well above the reported Kmof 5 µM for endothelial NO 
synthase (Harrison 1997). Yet an increase in extracellular L-arginine levels and/or an 
increase in the synthesis of arginine from extracellular citrulline will increase NO 
production from stimulated endothelial cells (Flam et al. 2001; Greene et al. 1993; 
Hecker et al. 1990; McDonald et al. 1997a; McDonald et al. 1997b; Shuttleworth et al. 
1995; Xie et al. 2000). Moreover, during shear stress-induced NO synthesis (Dimmeler et 
al. 1999) AS levels are up-regulated along with several other genes suggested to play a 
role in the regulation of NO production (McCormick et al. 2001). These results have been 
taken to suggest that a separate pool of arginine is maintained for NO production in 
endothelial cells by either transport and/or the regeneration of arginine from citrulline 
(Flam et al. 2001; Greene et al. 1993; Hecker et al. 1990; McDonald et al. 1997a; 
McDonald et al. 1997b; Shuttleworth et al. 1995; Xie et al. 2000). The physiological 
importance of the arginine regeneration system also was suggested by a case report of 
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two infants with a deficiency in argininosuccinate lyase (also essential for arginine 
regeneration from citrulline) who were shown to be hypertensive. Infusion of arginine 
resulted in the lowering of blood pressure in these infants, suggesting a critical role for 
arginine regeneration in the regulation of systemic blood pressure (Fakler et al. 1995). 
 More recently we have shown that AS and AL co-fractionate (along with 
endothelial NO synthase) with the endothelial caveolar fraction (Flam et al. 2001); 
therefore, regeneration of arginine from citrulline is not only integral in endothelial NO 
production but also may involve different regulation and cellular localization relative to 
the hepatic AS and urea production. For this reason we have proposed that an endothelial 
isoform expressed from the same gene as the liver form (Freytag et al. 1984b) manifests 
some variations allowing AS to function in a different cellular location (Flam et al. 2001) 
and to be coordinately regulated with NO production (McCormick et al. 2001). In support 
of this hypothesis, variations in the physical properties of the liver and endothelial cell 
AS protein were detected using different physical separation techniques and visualization 
by immunoblotting. 
 Based on these findings, we examined AS cDNA from liver and vascular 
endothelial tissue to determine whether differences in expression and in functional and 
physical properties could be accounted for at the level of the messenger RNA. In this 
report we show that the translatable sequence of AS mRNA is identical for both tissues 
but that the sequence represented by the diversity of endothelial AS mRNA 5´-UTRs may 
account in part for the specialized regulation of expression in nitric oxide production. 
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Experimental Procedures 
 Cell Culture and RNA Isolation — Bovine aortic endothelial cells (BAEC) were 
cultured in Dulbecco’s modified Eagle’s medium (Mediatech) supplemented with 10% 
fetal bovine serum (HyClone Laboratories), penicillin, streptomycin, and amphotericin B 
(Mediatech). Total RNA was isolated from BAEC by the method of Chomczynski and 
Sacchi (Chomczynski et al. 1987) using Tri Reagent (Molecular Research Center) 
according to the manufacturer’s protocol. Total RNA from bovine liver was purchased 
from CLONTECH Laboratories. 
 Reverse Transcriptase-Polymerase Chain Reaction — Total RNA from bovine 
liver and BAEC was reverse-transcribed using Superscript II recombinant Moloney 
murine leukemia virus reverse transcriptase (Invitrogen). The annealing reaction, 10 µg 
of total RNA and 100 ng of random hexamers, was incubated at 65 °C for 10 min and 
then cooled to 4 °C. 1x first strand buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM 
MgCl2), 10 mM dithiothreitol, 40 units of RNasin, 500 µM dNTP each, and 500 units of 
the Superscript RT were added, and the reaction was incubated at 37 °C for 1 h. The 
reaction was stopped by incubation at 80 °C for 10 min. The resulting cDNA was 
amplified by PCR using primers (Integrated DNA Technologies) designed against the 
published bovine liver AS sequence (M26198). Primer sequences are listed in Table I. 
ASL10 was combined with ASR1338, ASR773, and ASR348 to yield fragments of 1328, 
763, and 338 bp, respectively. ASL572 was combined with ASR1209 to yield a 637-bp 
fragment, and ASL882 was combined with ASR1338 to yield a 456-bp fragment. Primers 
were named based on the designation of position 1 as the first base of the AUG start 
codon. 
 All PCR reactions contained 1x assay Buffer B (10 mM Tris-HCl, pH 8.3, and 50 
mM KCl), 200 µM each dNTP, 1.5 mM MgCl2,10 µl of cDNA, 5% Me2SO, 50 pmol of 
each primer, and 2.5 units of Taq polymerase (Fisher Scientific) and consisted of 35 
cycles at 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 3 min. Reactions were started 
by a 5-min denaturation step and ended with a 10-min synthesis step. PCR fragments 
were separated by electrophoresis on a 1.5% agarose gel and visualized by ethidium 
bromide staining. 
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 Rapid Amplification of cDNA Ends (RACE) RT-PCR — 5´-and 3´-RACE analysis 
was carried out using the SMART RACE cDNA amplification kit (CLONTECH 
Laboratories). This technique involved the incorporation of a “Smart Oligo” onto the 5´-
end of the reverse-transcribed cDNA for the 5´-RACE analysis. For the 3´-RACE 
analysis, the Smart Oligo was attached to an oligo (dT) primer to yield cDNA that had a 
complete 3´-UTR, a poly-A tail, and a Smart Oligo sequence extension. The 5´-and 3´-
ends of AS were amplified using a standard PCR protocol. Primers were designed so that 
a short section of the coding region was amplified along with the 5´-or 3´-UTR. ASR348 
was combined with the Smart Oligo primer to amplify the 5´-end, and ASL1188 was 
combined with the Smart Oligo primer to amplify the 3´-end. Primer sequences are listed 
in Table I. Amplified 5´-and 3´-RACE fragments were cloned and sequenced. To 
increase the efficiency of recovery of the specific RACE clones colony lifts were 
performed, and positive clones were selected by hybridization to the 1328-bp AS cDNA 
fragment generated by RT-PCR. 
 Ribonuclease Protection Assays (RPAs) — RPAs were performed using the 
RiboQuant multiprobe RNase protection assay system (BD Pharmingen). A portion of the 
AS 5´-UTR and 5´-coding region was amplified by RT-PCR using primers ASL-82 and 
ASR94 (listed in Table I) and used as a template to produce the RPA probe. The 176-bp 
fragment was cloned using the TOPO TA cloning dual promoter kit (Invitrogen) and 
sequenced. To generate the antisense RNA probe, the plasmid construct containing the 
176-bp fragment was linearized with XhoI, purified by phenol/chloroform extraction and 
ethanol precipitation, and quantitated. The 32P-labeled RNA probe was synthesized using 
T7 RNA polymerase and hybridized to 100 µg of BAEC total RNA or 15 µg of liver total 
RNA following the manufacturer’s protocol. RNase digests were performed as per the 
standard protocol except that the RNase A was optimized to a final concentration of 38 
ng/µl. Protected fragments were analyzed on a 6% acrylamide, 7 M urea sequencing gel. 
The gel was dried and exposed to film. Band densities were quantitated using 
ImageQuant software (Molecular Dynamics). 
 Real-time RT-PCR — Total RNA from bovine liver and BAEC was DNase-
treated using DNA-free DNase treatment and removal reagent (Ambion) following the 
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manufacturer’s protocol. 1 µg of RNA was reverse-transcribed with the Superscript first-
strand synthesis system for RT-PCR (Invitrogen) following the protocol for high G-C 
content mRNAs. An AS-specific primer, ASR348, was used to reverse transcribe, and the 
resulting cDNA was amplified using the SYBR Green PCR master mix (Applied 
Biosystems). PCR conditions were 10 min at 95 °C followed by 40 cycles of 15 s at 95 
°C and 1 min at 60 °C. The PCR products were detected in real time using the iCycler iQ 
detection system (Bio-Rad). Primer sets were designed to amplify regions of AS mRNA 
common to all species, ASL228 and ASR278, as well as to detect the extended 5´-UTRs 
of 66-nt ASL-62 and ASR-12 and 92-nt ASL-84 and ASR-34 (Table I). AS mRNA was 
quantitated relative to a standard curve of AS plasmid DNA generated for each primer 
set. Replicates of five were performed for each primer set with each RT reaction. Results 
were reported as a percentage of the total AS mRNA. 
 Coupled in Vitro Transcription/Translation — Full-length AS cDNA was 
constructed to contain the 92-nucleotide 5´-UTR and subcloned into the vector pPDM-2 
(Epicentre Technologies). AS cDNA was amplified by PCR using Pfu Turbo DNA 
polymerase (Stratagene) to contain each of the three 5´-UTRs. 5´-primers contained a 
BamHI site, T7 promoter sequence, spacer region, and 20 bases of AS cDNA sequence 
corresponding to the first twenty bases of each 5´-UTR species (Table II). A control 5´-
primer contained a BamHI site, T7 promoter sequence, spacer region, and a Kozak 
sequence of six bases (21) followed by the ATG and 20 bases of AS cDNA sequence 
downstream of the start codon. The 3´-primer used for amplification of the full-length AS 
cDNA was ASR1338 (Table I). The PCR products were gel-purified, quantitated, and 
then transcribed and translated using the TNT T7 Quick for PCR DNA 
transcription/translation kit (Promega). For detection, Transcend biotin-lysyl-tRNA 
(Promega) was added to the reaction, resulting in the incorporation of biotinylated lysine 
into the translated protein. 
 In Vitro Translation of Capped AS mRNA — PCR fragments containing four 
different 5´-UTRs (three different AS UTRs plus the control, all with the T7 promoter 
sequence incorporated) were subcloned into the pPDM-2 vector using the BamHI site 
engineered into the fragments at the 5´-end and an EcoRI site at the 3´-end. Constructs 
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were digested with EcoRV at a site past the 3´-end to prevent run-on transcription. 
Template DNAs were transcribed using T7 RNA polymerase with the addition of Ribo 
m7G cap analog (Promega) following the manufacturer’s protocol recommended for 
m7G cap incorporation. Transcribed RNA was DNase-treated and purified using 
minispin G50 Sephadex (CPG) columns. The Flexi Rabbit reticulocyte lysate system 
(Promega) was used for the translation reaction following the manufacturer’s protocol 
with the addition of 0.75 µl of transcend tRNA and 1 µg of capped RNA. KCl conditions 
were optimized to 40 µM. 
 Western Blotting Analysis — Translated proteins were separated by SDS-PAGE 
on 12% Tris-HCl Ready Gels (Bio-Rad). Following electrophoresis, proteins were 
transferred to Immobilon-P membranes (Millipore) using a wet transfer method (Bio-
Rad). Following a blocking step of 1 h in TBST (20 mM Tris, pH 7.4, 150 mM NaCl, 
0.5% Tween 20), the membranes were incubated for 1 h at room temperature with 
Streptavidin-horseradish peroxidase antibody (Promega or Jackson Immuno-Research 
Laboratories) at a final concentration of 0.025 µg/ml. The membranes were then washed 
three times in TBST and three times in nanopure water for 5 min per wash. The in vitro-
translated proteins were visualized using an enhanced chemiluminescent reagent 
according to the manufacturer’s protocol (Amersham Biosciences) or Transcend reagent 
(Promega). Band densities were quantitated using ImageQuant software (Molecular 
Dynamics). Membranes were then placed in blocking buffer composed of 5% nonfat dry 
milk in TBST for 1 h at room temperature. Membranes were incubated with the primary 
antibody, anti-ß-actin, mouse monoclonal, clone AC-15 (Sigma) in blocking buffer for1 h 
at room temperature. Membranes were washed and incubated with the secondary 
antibody, peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories) in blocking buffer for1 h at room temperature. After washing with TBST, 
membranes were visualized using chemiluminescent reagent and exposed to film. Band 
densities were quantitated as before. 
 Mutational Analysis — Deletion mutants were constructed to include 86, 81, 76, 
and 71 nt of the AS 5´-UTR along with the T7 promoter sequence by amplification and 
subcloning as described previously. Primer sequences are listed in Table II. Mutations of 
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the uORF AUG were carried out using a PCR strategy. A sense primer, ASL-70 Mut1, 
was designed to generate a single base mutation, converting the uAUG to AAG. A 
second primer, ASL-73 Mut2, was designed to alter the context of the uAUG by 
changing the surrounding nucleotides. The sequence GGG AUG CGC was mutated to 
AGG AUG GGC, changing critical nucleotides at position -3 and +4 relative to the AUG 
to improve the function of the uAUG (Kozak 1987). These primers were combined with 
ASR429 to amplify fragments of 499 and 502 bp, following the protocol listed in the 
PCR section. PfuTurbo DNA polymerase (Stratagene) was used to reduce the frequency 
of error in the amplification. The amplified fragments were gel-purified, sequenced, and 
used as right primers in a second amplification with ASL-92T7. Fragments were digested 
with BamHI and NarI and subcloned into the existing 92-nt 5´-UTR full-length AS 
cDNA construct. The deletion constructs and mutant AUG constructs were transcribed, 
translated, and analyzed by Western blotting. 
 Transfection Analysis — Luciferase reporter constructs were designed to include 
each of the AS 5´-UTRs cloned directly after the simian virus 40 promoter and before the 
start codon of the luciferase gene. Left primers ASL-92HindIII, ASL-66HindIII, and 
ASL-43HindIII were combined with ASRluc (Table I) to amplify the different sized AS 
5´-UTRs with a HindIII site on the 5´-end and 45 bases of the luciferase gene attached to 
the 3´-end. This strategy took advantage of a NarI site within the luciferase gene close to 
the start codon. The amplified fragments were digested with HindIII and NarI and cloned 
into pGL3Control in place of the existing 5´-UTR. Constructs were verified by 
sequencing. BAEC to be used for transfections were plated at 2 x 104 cells per well in a 
24-well plate. Control plasmids (Promega) included pGL3Control as a positive control, 
pGL3Basic as a promoterless negative control, and pRL-TK, a renilla expression vector, 
as an internal transfection control. Control, Basic, and experimental plasmids (200 ng 
each) and pRL-TK (50 ng) were transiently transfected into BAEC using Transit-LT1 
(Panvera) in serum-free medium. After 4.5 h, the medium was replaced with complete 
medium, and cells were cultured for 48 h. Lysates generated with Passive lysis buffer 
(Promega) were assayed for luciferase and renilla activity using Promega’s Dual-
Luciferase Reporter Assay System according to the manufacturer’s recommendations. 
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Luciferase and renilla activity were measured as relative light units using a luminometer 
(Turner Designs). Experiments were carried out three times in triplicate. Luciferase 
expression was normalized to renilla activity. 
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Results 
 Comparison of RT-PCR Fragments from Bovine Liver and Endothelial Cell AS 
mRNA — To investigate possible differences in the coding region of AS mRNA, total 
RNA from bovine liver and cultured bovine aortic endothelial cells was reverse-
transcribed and amplified by PCR using a series of oligonucleotide primer sets designed 
to cover the entire coding region of the mRNAs. The resulting amplified fragments were 
separated by agarose gel electrophoresis, shown in Fig. 1. As can be seen, the relative 
mobility of each set of amplified fragments was identical, indicating that there were no 
substantial differences in the two AS messages that would indicate splicing variations of 
the ~13 exons that define the AS gene (Freytag et al. 1984a). To confirm this finding 
sequence analysis was carried out, which showed that there were no differences (data not 
shown) within the translatable sequence of endothelial and liver AS mRNA. 
 RACE Analysis of the 5´-and 3´-Ends of Liver and Endothelial Cell AS mRNA — 
Because the UTRs of mRNAs can influence stability, localization, and translation, rapid 
amplifications of the reverse-transcribed 5´-and 3´-ends of AS mRNA were carried out 
on bovine liver and cultured endothelial cell total RNA. The products of the RACE 
analyses were subcloned and sequenced. 
 For the 3´-RACE analysis, minimal differences attributed to minor 
polymorphisms at the level of the gene were observed. Direct sequence analysis further 
confirmed this finding (data not shown). In contrast, the 5´-RACE analysis of endothelial 
AS mRNA yielded clones containing different length extensions of the 5´-UTR. The 
majority of clones represented AS mRNA with 43 nucleotides of sequence upstream of 
the AUG start codon common to liver and endothelial cells (Fig. 2). A single isolated 
clone contained the identical 43 nt in the 5´-UTR but with an additional 23 nt of upstream 
sequence. A second clone verified the sequence of the 66 nt 5´-UTR but contained an 
additional 26 nt of upstream sequence for a total of 92 nt of 5´-UTR. Importantly, the 66-
and 92- nt 5´-UTR clones were only identified by 5´-RACE analysis with endothelial cell 
total RNA. 5´-RACE analysis of liver total RNA yielded only the 43 nt AS 5´-UTR. 
 Extended 5´-UTR Sequence Comparison — To determine the possible genomic 
origin of the endothelial-specific AS 5´-UTR species, these sequences were compared 
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with the 5´-UTR and genomic 5´-flanking regions from human (Jinno et al. 1985) and 
mouse (Surh et al. 1991) (Fig. 3). Comparison of the 43-nt bovine AS mRNA 5´-UTR 
with exon 1 from human and mouse AS gene sequences demonstrated 72 and 64% 
homology, respectively. When a comparison was made of the 92-nt 5´-UTR from 
endothelial AS mRNA with the 5´-flanking genomic sequence from human and mouse, 
the percentage of homology increased to 78 and 71%, respectively. A sequence of 10 nt 
surrounding the TATTA box was identical in all three species. Importantly, the upstream 
AUG found in the extended 5´-UTR AS mRNAs from bovine endothelial cells was 
distinctly identified in the 5´-flanking genomic regions of both human and mouse AS 
genes. 
 Ribonuclease Protection Assays of the 5´-UTR of Liver and Endothelial Cell AS 
mRNA — To verify and quantitate these results, RPAs were carried out on total RNA 
isolated from BAEC and liver using an antisense RNA probe complementary to the AS 
sequence extending from 82 nt upstream of the AUG start codon to 94 nt downstream of 
the start codon. Consistent with the 5´-RACE analysis, RNase protection analysis of the 
endothelial RNA yielded three different sized fragments (Fig. 4) corresponding to the 
predicted sizes of the different 5´-RACE AS mRNA sequences (43, 66, and 92 nt) 
identified previously. Quantitation by densitometry showed that 78% of the total AS 
mRNA contained the shortest 43-nt 5´-UTR sequence followed by 12% for the 92-nt 5´-
UTR sequence and 10% for the 66-nt 5´-UTR. Notably, the RPA for liver AS mRNA 
only demonstrated the existence of the 43-nt 5´-UTR sequence. 
 Real-time RT-PCR Analysis of the 5´-UTR of Liver and Endothelial Cell AS 
mRNA — A second approach to quantitate relative levels of 5´-UTR AS mRNA species 
took advantage of the increased sensitivity of real-time RT-PCR analysis. As shown in 
Fig. 5, real-time RT-PCR analysis corroborated the RPA results, demonstrating again the 
disproportionate expression of three AS mRNA 5´-UTR species found in endothelial 
cells. Because of the linear response of the technique over a large dynamic range, more 
accurate quantitation was generated for the percentages of each mRNA species. Plasmid 
DNA standards were detected in duplicate over a range of 9 orders of magnitude, easily 
allowing for the precise quantitation of mRNA levels differing by a factor of 100 or 
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more. The percentage of the 43-, 66-, and 92-nt 5´-UTR AS mRNA species were 
determined to be 93.79 ± 1.24, 3.75 ± 1.70, and 2.46 ± 0.93%, respectively, of the total 
AS mRNA. The percentages are lower than those detected by ribonuclease protection 
analysis, probably because of the limitations of quantitation from x-ray film over a wide 
range of signal. Although the 66-and 92-nt 5´-UTR species were detected in liver above 
negative controls, levels were significantly lower than in endothelial cells, representing 
less than 0.1 ± 0.06% of total liver AS mRNA. Real-time RT-PCR analysis also 
confirmed differences in AS mRNA expression relative to total RNA, showing that in 
liver there is an ~40-fold higher level of expression compared with endothelial cells. 
 In Vitro Translational Efficiency of the 5´-UTR AS mRNAs — Sequence analysis 
of the diverse 5´-UTR AS mRNAs showed that each contained >70% G+C content and 
that the two longer forms contained a uORF frame. These features have been noted by 
other investigators to affect the translational efficiency of mRNAs (Kozak 1991). For this 
reason, experiments were designed to examine the influence that the diversity of 
endothelial AS 5´-UTRs might have on the translation of AS mRNA. 
 Full-length AS mRNA containing the 92-nt 5´-UTR sequence was cloned and 
then amplified to yield each of the other AS mRNA 5´-UTR species. An additional clone 
of AS mRNA referred to as the control was constructed to contain a 5´-UTR with optimal 
features relative to AUG start codon recognition and initiation (Kozak 1987). These 
constructs were transcribed and translated initially in a coupled transcription/translation 
system that visualized the protein products by immunodetection of biotinylated lysine 
incorporated during translation. Protein expression, analyzed by SDS-PAGE and Western 
blotting, showed that the AS mRNA with the shortest 43-nt upstream sequence translated 
as well or better than the control. The most dramatic effect on translational efficiency was 
observed with the longest endothelial 5´-UTR of 92 nt. A protein product was essentially 
undetectable even after longer exposures, whereas the intermediate length 5´-UTR of 66 
nt translated nearly as well as the 43-nt 5´-UTR (data not shown). 
 Because the coupled system did not produce capped (7-methylguanosine, m7G) 
AS mRNA, the experiments were repeated using AS mRNA that contained a 5´-terminal 
m7G cap. The translation products containing biotinylated lysine generated from the 
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different AS 5´-UTR mRNA species were separated by SDS-PAGE and visualized by 
immunodetection (Fig. 6). This time using capped AS mRNA, a product for the 92-nt 5´-
UTR AS mRNA was detectable, probably reflecting the increased efficiency of 
translation observed for each of the capped species examined. The intermediate length 5´-
UTR of 66 nt translated nearly as well as the control containing the Kozak sequence 
(Kozak 1991); however, the 43-nt 5´-UTR construct translated more efficiently than 
either the 66-nt 5´-UTR construct or the control. Examining the comparative level of AS 
protein produced, where the ratio to control remained essentially identical to that 
observed using uncapped AS mRNA, supported this conclusion. These differences 
demonstrated that the 5´-UTR species of endothelial AS mRNA influenced in vitro 
translational efficiency. 
 Deletion and Mutational Effects on Endothelial 5´-UTR AS mRNAs Translational 
Efficiency — To determine the basis for the decreased translational efficiency of the 
longer 5´-UTR, deletion and mutational analysis was carried out. As shown in Fig. 7, 
sequential deletion of the 92-nt 5´-UTR yielded results demonstrating a direct correlation 
of 5´-UTR length with translational efficiency. However, mutation of the upstream AUG 
to eliminate the uORF restored the translational efficiency of the 92-nt 5´-UTR AS 
mRNA to essentially that observed for the 66-nt 5´-UTR species. When the context of the 
upstream AUG was mutated to conform to an optimal consensus Kozak sequence, there 
was no significant decrease in translational efficiency observed with the 92-nt 5´-UTR 
containing AS mRNA. These results suggest that the uORF is an important feature 
affecting translational efficiency and that at least 22 nt of sequence 5´ to the uORF are 
required for maximum suppression. 
 Effects of AS mRNA 5´-UTRs on Luciferase Expression in Transfection Studies — 
To isolate the effects of the different AS mRNA 5´-UTRs on expression, each 5´-UTR 
sequence was cloned in front of a luciferase reporter gene. Constructs were transfected 
into BAEC, and luciferase expression measured. Relative to the 43-nt 5´-UTR construct, 
expression of the 66 and 92-nt 5´-UTRs were 8-and 6-fold lower, respectively (Fig. 8). 
These results were essentially consistent with the discordant expression of the various 5´-
UTR AS mRNAs in endothelial cells, demonstrating that the sequence from position -92 
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to -43 in the AS gene relative to the translational start codon is sufficient to affect 
differential expression of the three 5´-UTR AS mRNA species in endothelial cells. 
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Discussion 
 Although the physiological role for AS was originally identified with the urea 
cycle in the liver, virtually all other mammalian tissues possess detectable levels of AS 
and a second urea cycle enzyme, AL. In nitric oxide-producing tissue, these two enzymes 
together have the net effect of regenerating arginine from citrulline and aspartate, 
providing arginine for NO production (Wu & Morris 1998). We had previously shown 
that endothelial AS differs from liver AS, not only in its relationship to NO production 
but also by its caveolar co-localization with nitric oxide synthase (Flam et al. 2001). 
 Based on these findings, we examined whether an endothelial isoform of AS may 
exist that is encoded by the same respective hepatic urea cycle AS gene (Freytag et al. 
1984b) but that plays a specialized role in regenerating arginine from citrulline for NO 
production. Although physical differences (mobility and isoelectric point) were observed 
(B. R. Flam, L. C. Pendleton, B. L. Goodwin, L. P. Solomonson, and D. C. Eichler, 
unpublished observations), a comparison of the coding regions of liver and endothelial 
AS mRNA by RT-PCR analysis suggested that alternative splicing could not account for 
these physical differences or for the functional and localization differences. This result 
was further confirmed by direct sequence analysis. 
 Expression of genes that play a key role in metabolic processes are often 
regulated at multiple levels, and differences in regulation and localization have been 
attributed in some cases to differences in UTRs of an mRNA (de Moor et al. 2001; Gray 
et al. 1994; Gray et al. 1998; Kozak 2000; Sonenberg 1993; van der Velden et al. 1999). 
We therefore compared sequences of both the 5´-and 3´-UTR of AS mRNA from liver 
and endothelial cells to assess the possible importance of these regions in the regulation 
of AS expression in endothelial cells. In this report we have shown that AS mRNA from 
bovine liver and bovine aortic endothelial cells differs in the relative level of expression 
and in the diversity observed for the 5´-UTR region. 5´-RACE analysis demonstrated 
unique expression of three different 5´-UTR AS mRNAs in endothelial cells. In contrast, 
only the shortest 5´-UTR of 43 nt was detected in liver. 
 Sequence inspection of the various 5´-UTRs of AS mRNA defined by 5´-RACE, 
RT-PCR, RNase protection analysis, and real-time RT-PCR highlighted the following 
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features. First, the expression of the various AS mRNA 5´-UTR species is 
disproportionate. The AS mRNA with the shortest 43-nt 5´-UTR represents the major 
form (~94%) of the total AS mRNA, whereas the longer 5´-UTRs of 66 and 92 nt 
represent ~4 and 2%, respectively. Second, all 5´-UTRs for endothelial AS mRNA fall 
within the average length of eukaryotic 5´-UTRs (50–100 nt) (Kozak 1987). Third, an 
upstream AUG codon was detected in the 66- and 92-nt extended 5´-UTRs that is out-of-
frame with the downstream AUG start codon but in-frame with multiple ORFs in the 
coding sequence of AS mRNA. Finally, composition analysis revealed that all three 5´-
UTR sequences are highly enriched in G+C content (~76%), suggesting that all are 
capable of forming stable complex secondary structures known to affect translational 
efficiency (Kozak 2000). 
 Sequence analysis also suggested the possible origin of the 5´-UTR AS mRNA 
species. Comparison to the 5´-UTRs from both human (Jinno et al. 1985) and mouse 
(Surh et al. 1991) AS mRNA demonstrated a high degree of homology. This similarity 
increased when the extended 5´-UTR sequences from bovine endothelial AS mRNA were 
compared with the genomic sequence immediately upstream of the reported transcription 
start site for the human and mouse AS gene. Our findings suggest that expression of all 
three species of bovine endothelial AS mRNA are driven by a common promoter, and 
that 5´-UTR diversity in endothelial cells results from three transcriptional initiation sites 
within exon 1. 
 Considerable research related to the 5´-UTR region of mRNAs has suggested a 
regulatory role in translational efficiency in part through cis effects at the primary (e.g. 
upstream short ORFs affecting ribosome scanning), secondary (e.g. hairpins and stem-
loop structures), or tertiary (e.g. pseudoknots) levels (Gray & Hentze 1994; Gray & 
Wickens 1998; Kozak 1987; Kozak 1991; Kozak 2000; Morris et al. 2000; Sonenberg 
1993; van der Velden & Thomas 1999). Such effects may also involve the contribution of 
RNA-binding proteins (Morris & Geballe 2000). Some general principles by which 
uORFs have been proposed to participate in translational control include the process of 
recognition of uORFs, regulation of reinitiation at downstream cistrons after translation 
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of uORFs, and regulatory effects of peptides encoded by uORFs (Morris & Geballe 
2000). 
 In endothelial cells there are only two species of AS mRNA that contain an 
identical uORF, and they represent at most no more than 6% of the total AS mRNA. But 
because these features are regarded as important determinants of translational efficiency, 
this suggested that the diversity at the 5´-end of AS mRNA transcripts may have 
important biological implications on the regulation of translation and may possibly 
explain observed differences between steady-state mRNA levels and protein expression. 
 For this reason, after defining the diversity of 5´-UTR AS mRNAs in endothelial 
cells, an examination was carried out to determine to what extent the various 5´-UTRs of 
AS mRNA influence the efficiency of translation. Results from these experiments clearly 
showed that the nature of the AS mRNA 5´-UTR influenced translation. Based on the in 
vitro translation results for the 92-nt 5´-UTR, we expected that the intermediate length 
66-nt 5´-UTR that still contained the uORF would yield similar results. However, the 66-
nt 5´-UTR AS mRNA expression was nearly 70% of that observed for the 43-nt 5´-UTR 
AS mRNA. Improvement in the translational efficiency of all AS mRNA 5´-UTRs was 
observed in vitro when the message was capped, although disproportionate expression 
was still evident for the 92-and 66-nt 5´-UTR AS mRNAs. We had not anticipated that 
the control in these experiments, which possessed no AS mRNA 5´-UTR and was 
constructed to contain what may be considered an optimal consensus sequence around the 
start codon, would not express protein as well as the 43-nt 5´-UTR AS mRNA. This 
result indicated that features of the 43-nt 5´-UTR as well as features in the translated 
sequence of AS mRNA compensate for the lack of optimal consensus sequence within 
the context of the AUG start codon (Kozak 1991). The fact that loss of the uORF restored 
the translational efficiency of the 92-nt 5´-UTR to that observed for the 66-nt 5´-UTR and 
that the 66-nt 5´-UTR containing this uORF expressed protein at ~70% of the 43-nt 5´-
UTR also suggested that attenuation of translation required ~22 nt of sequence 5´- to the 
uORF for maximum effect. 
 Transfection studies, which focused on the effect of AS 5´-UTR sequence 
diversity on luciferase expression in endothelial cells, produced results essentially 
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consistent with the levels of expression observed in endothelial cells for the different 5´-
UTR AS mRNAs. These findings suggested that sequence in the AS gene encoding 
positions -92 to -43 in the extended 5´-UTRs of AS mRNAs was sufficient to affect 
differential expression. 
 In summary, there is a remarkable diversity and disproportionate expression of 
each of the 5´-UTR AS mRNA transcripts that clearly differentiate AS expression in 
vascular endothelial cells from that in liver. We have demonstrated that expression of a 
43-nt 5´-UTR AS mRNA is robustly enhanced in liver versus endothelial cells and that 
the unique diversity of 5´-UTR AS mRNAs in endothelial cells reflects sequence in the 
AS gene that permits selective modulation and tissue-specific expression. 
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Table II. Primer Design for In Vitro Transcription and Translation 
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Figure 1. Amplification of reverse-transcribed AS mRNA from bovine liver and 
cultured endothelial cells by polymerase chain reaction. A, RT-PCR products from 
endothelial cells (E) and liver (L) fractionated on a 1.5% agarose gel. Numbers on the left 
designate size (bp) of molecular standards. B, expected fragment sizes (bp) and location 
with respect to AS mRNA (bottom). 
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Figure 2. Novel 5´-UTRs of endothelial AS mRNA. The sequence for each AS mRNA 
5´-RACE product as well as the normal start codon (boldface) are indicated by a label 
and an arrow above the sequence. The upstream out-of-frame start codon (boldface) and 
the uORF are underlined. 
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Figure 3. Extended 5´-UTR sequence comparisons. Sequences from the bovine AS 
mRNA 5´-UTRs compared with genomic AS 5´-flanking regions and 5´-UTRs from 
human and mouse. Bovine transcription start sites as well as the translational start codon 
are indicated by an arrow and a label above the sequence. The AUG and uAUG are 
shown in boldface type. The underlined sequence denotes human and mouse exon 1. 
Boxed areas indicate sequence with 100% homology between the three species. 
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Figure 4. Ribonuclease protection assay. A, expected fragment size (bp) for each of AS 
mRNA 5´-UTRs relative to the RNA probe (138 bp for the 43-nt 5´-UTR; 161 bp for the 
66-nt 5´-UTR; and 176 bp for the 92-nt 5´-UTR) and correspondence to the 5´-end of AS 
mRNA. B, autoradiograph of RPA fragments from 100 µg of endothelial cell total RNA 
(E) and 15 µg of liver total RNA (L) separated by a polyacrylamide sequencing gel. 
Molecular weight marker (bp markers) sizes are designated by base pair numbers (right). 
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Figure 5. Quantitation of the different forms of AS mRNA by real-time PCR. The 
percent of total AS mRNA for each of the 5´-UTR AS mRNA species (designated by 43 
nt, 66 nt, and 92 nt, respectively) from endothelial cells (A) and bovine liver (B) as 
determined by real-time RT-PCR. 
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Figure 6. Efficiency of in vitro translation of the 5´-UTR AS mRNAs. A, Western blot 
analysis of the translated protein. Full-length AS cDNA was subcloned to contain each of 
the AS mRNA 5´-UTRs as well as a control 5´-UTR (C) containing only a Kozak 
sequence (Kozak 1991) preceding the AUG start codon. These constructs, designated 92 
nt, 66 nt, 43 nt, and control (C) were transcribed, capped (Ribo m7G Cap Analog), and 
translated. Biotinylated lysine was incorporated into the reaction for immunodetection 
with streptavidin horseradish peroxidase. Protein expression was quantitated by 
subtracting the negative control (no RNA added to the translation reaction) and 
normalizing to ß-actin. B, expression level relative to the 43-nt 5´-UTR AS mRNA. 
 
 
199 
Appendix B (Continued) 
Figure 7. Deletion and mutational analysis of the 5´-UTR AS mRNAs. Full-length AS 
cDNA deletion mutants were constructed to include 86, 81, 76, and 71 nt in the 5´-UTR. 
Constructs were also created in which the upstream uAUG was mutated to AAG 
(Mut1)or altered to a more favorable context (Kozak 1991) by changing nucleotides at -3 
and +4 relative to the uAUG (GGG AUG CGC to AGG AUG GGC, Mut2). Constructs 
were transcribed, capped (Ribo m7G Cap Analog), and then translated. Biotinylated 
lysine was incorporated into the reaction for immunodetection with streptavidin 
horseradish peroxidase. Protein expression was quantitated by subtracting the negative 
control (no RNA added to the translation reaction) and normalizing to ß-actin. Expression 
levels of the mutants are shown relative to the 43-nt 5´-UTR AS mRNA. 
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Figure 8. AS mRNA 5´-UTR effects on luciferase expression in endothelial cells. 
BAEC were transiently transfected with the indicated AS mRNA 5´-UTR luciferase 
construct (Basic, pGL3Basic negative control; Control, pGL3Control positive control; 
and 43 nt, 66 nt, and 92 nt AS 5´-constructs, respectively). Luciferase activity was 
assayed 48 h after transfection, and results were normalized to renilla activity expressed 
from a co-transfected control vector. Error bars indicate the standard error of the mean 
from nine experiments. 
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Summary 
The enzyme endothelial nitric oxide synthase (eNOS) catalyzes the conversion of 
arginine, oxygen and NADPH to NO and citrulline. Previous results suggest an efficient, 
compartmentalized system for recycling of citrulline to arginine utilized for NO 
production. In support of this hypothesis, the recycling enzymes, argininosuccinate 
synthase (AS) and argininosuccinate lyase (AL), have been shown to colocalize with 
eNOS in caveolae, a subcompartment of the plasma membrane. Under unstimulated 
conditions, the degree of recycling is minimal. Upon stimulation of NO production by 
bradykinin, however, recycling is co-stimulated to the extent that more than 80% of the 
citrulline produced is recycled to arginine. These results suggest an efficient caveolar-
localized arginine regeneration system, plays a key role in receptor-mediated stimulation 
of endothelial NO production. To investigate the molecular basis for the unique location 
and function of endothelial AS and AL, endothelial AS mRNA was compared with liver 
AS mRNA. No differences were found in the coding region of the mRNA species, but 
significant differences were found in the 5′-untranslated region (5′-UTR). The results of 
these studies suggest that sequence in the endothelial AS-encoding gene, represented by 
position –92 nt to –43 nt from the translation start site in the extended AS mRNA 5′-
UTRs, plays an important role in differential and tissue-specific expression. Overall, a 
strong evidential case has been developed supporting the proposal that arginine 
availability, governed by a caveolar-localized arginine regeneration system, plays a key 
role in receptor-mediated endothelial NO production. 
 
Key words: nitric oxide, eNOS, endothelial nitric oxide synthase, arginine, citrulline, 
arginine regeneration system, argininosuccinate synthase, argininosuccinate lyase, 
caveolae, nitric oxide production. 
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Introduction 
Endothelial nitric oxide synthase (eNOS), the enzyme that catalyzes the 
production of NO from the amino acid arginine in endothelial cells, plays a key role in 
vasoregulation as well as in other important physiological processes such as 
angiogenesis. Impaired production of endothelial NO has been associated with 
hypertension, heart failure, hypercholesterolemia, atherosclerosis and diabetes (Govers et 
al. 2001; Maxwell 2002; Vallance et al. 2001). Circulating effectors, such as bradykinin, 
bind to receptors on the luminal surface of endothelial cells, signaling the transient 
release of NO to the adjacent smooth muscle layer and resulting in relaxation of the 
vessel wall. 
The signal for eNOS activation is a transient increase in intracellular calcium, 
which activates the enzyme through binding of a calcium–calmodulin complex (Ca–
Cam). Endothelial NOS activation also occurs in response to shear stress (Govers & 
Rabelink 2001; Maxwell 2002). Consistent with the important physiological roles of 
eNOS, the enzyme appears to be subject to multiple modes of regulation, in addition to 
primary regulation through reversible Ca–Cam binding and activation. These include 
reversible phosphorylation and palmitoylation, substrate and cofactor availability, 
dimerization of enzyme subunits, intracellular translocation and protein–protein 
interactions (Govers & Rabelink 2001). Several of these potential modes of regulation 
appear to be interrelated. As a component of caveolae, a subcompartment of the plasma 
membrane that serves to sequester proteins involved in cell signaling, eNOS may 
transiently interact with several different caveolar components. Previous work from 
several different laboratories has suggested that a diverse group of proteins, including 
calmodulin, caveolin-1, bradykinin B2 receptor, heat shock protein 90, argininosuccinate 
synthase (AS), argininosuccinate lyase (AL), Raf-1, Akt, extracellular signal-related 
kinase, eNOS interacting protein, eNOS traffic inducer and unidentified tyrosine-
phosphorylated proteins (Govers & Rabelink 2001; Hellermann et al. 2000; Maxwell 
2002; Nedvetsky et al. 2002), may be transiently and functionally associated with eNOS. 
A potential limiting factor for endothelial NO production is the availability of the 
substrate, arginine. Intracellular levels of arginine have been estimated to range from 100 
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µmol l
–1 
to 800 µmol l
–1
, which is well above the Km value of 5 µmol l
–1 
for eNOS 
(Harrison 1997). Endothelial NO production can, nonetheless, be stimulated by 
exogenous arginine (Vallance & Chan 2001). This phenomenon, termed the ‘arginine 
paradox’, suggests the existence of a separate pool of arginine directed to endothelial NO 
synthesis. As illustrated in Fig. 1, arginine has a number of metabolic roles in addition to 
NO production, including production of major metabolites such as urea, polyamines, 
creatine, ornithine and methylarginine derivatives. The observed stimulation of 
endothelial NO production by exogenous arginine suggests that the arginine directed to 
NO production may be segregated from bulk cellular arginine utilized for these other 
metabolic roles. 
One possible site of control is at the level of arginine uptake. McDonald et al. 
(McDonald et al. 1997) showed that the CAT1 transporter, responsible for 60–80% of 
total carrier-mediated arginine transport into endothelial cells, colocalizes with eNOS in 
caveolae. They proposed that the arginine utilized by eNOS might, at least in part, be 
maintained by the CAT1 transporter. Another important mechanism for controlling the 
availability of arginine directed to NO production may be the regeneration of arginine 
from the other product of the eNOS-catalyzed reaction, citrulline. Hecker et al. (Hecker et 
al. 1990) initially demonstrated that citrulline, produced in the conversion of arginine to 
NO, can be recycled to arginine. A possible link between NO production and arginine 
regeneration from citrulline was subsequently established for other cell types (Nussler et 
al. 1994; Shuttleworth et al. 1995). This regeneration is catalyzed by the enzymes AS and 
AL, both of which also play an essential role in the urea cycle in liver. The potential 
importance of this regeneration system for endothelial NO production was supported by a 
report of two infants with a deficiency of AL who were shown to be hypertensive (Fakler 
et al. 1995). Upon infusion of arginine, the blood pressure of these infants decreased to 
near normal levels, suggesting a critical role for arginine regeneration in the regulation of 
systemic blood pressure. More recent evidence from DNA microarray analysis suggests 
an important role for the arginine regeneration system by clearly demonstrating 
significant and coordinate upregulation of AS-encoding gene expression in response to 
shear stress stimulation of endothelial NO production (McCormick et al. 2001). It was 
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concluded that available arginine is a prerequisite for NO production and that in the 
absence of synthesis of additional eNOS, shear stress-induced increases in NO synthesis 
depend on an increase in synthesis of arginine from citrulline through increased AS 
expression. Although supplemental arginine can be beneficial in some cases (Wu et al. 
2002), in other cases it may lead to adverse effects owing to the multiple metabolic roles 
of arginine (Chen et al. 2003; Loscalzo 2003). 
Recent work further supports the hypothesis that the arginine regeneration system, 
comprised of a caveolar complex that includes eNOS, AS and AL, plays an important, 
and most likely essential, role in the receptor-mediated production of NO by vascular 
endothelial cells. 
 
Effects of exogenous arginine and citrulline on endothelial NO production 
Endothelial NOS is localized in plasmalemmal caveolae. The localization of 
eNOS in this signaling subcompartment of the plasma membrane may have important 
implications with regard to the regulation and catalytic efficiency of eNOS (Everson et al. 
2001; Shaul 2002). We have recently found evidence for an efficient cycling of citrulline 
to arginine, raising the possibility of a channeling complex of eNOS and the enzymes of 
the citrulline–arginine cycle (AS and AL) localized in caveolae. Our initial research 
effort that led to this finding was designed to test the hypothesis that an intracellular 
pathway exists for the generation of methylarginines to regulate NO production in nitric 
oxide-producing tissues. The goal of this initial work was to determine the physiological 
significance of intracellular methylarginines as regulators of NOS activity. To examine 
the levels of endogenous methylarginines, we developed methods that allowed for the 
rapid and quantitative analysis (by HPLC) of arginine, citrulline and the methylarginines 
from endothelial cell extracts. There was no apparent change in levels of methylarginines 
following stimulation of endothelial cells with either bradykinin or the calcium ionophore 
A23187. In an attempt to raise intracellular methylarginine levels, and further test our 
hypothesis, we added citrulline, which we expected to inhibit dimethylarginine 
dimethylaminohydrolase, the enzyme that converts N
G
-methylarginine or N
G
,N
G
-
dimethylarginine to citrulline and monomethylamine or dimethylamine, respectively. The 
objective was to determine whether inhibition of the degradation of methylarginines 
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would increase their intracellular concentrations and thereby inhibit NO production. To 
our surprise, stimulation of NO production by bradykinin was increased by the addition 
of citrulline, rather than decreased, and there was no apparent change in methylarginine 
levels. To further examine the molecular basis for the stimulation of NO production by 
citrulline, we compared the effect of exogenous citrulline with the effect of exogenous 
arginine on NO production and levels of intracellular arginine following bradykinin 
activation. Surprisingly, added arginine did not cause as great an increase in endothelial 
NO production as did added citrulline. In addition, there was a much larger increase in 
intracellular arginine in response to exogenous arginine compared with exogenous 
citrulline. Added citrulline caused only a modest increase in intracellular arginine, while 
added arginine caused a substantial increase. Thus, there appeared to be no correlation 
between total intracellular arginine levels and endothelial NO production. To the best of 
our knowledge, this represents the first attempt to correlate NO production with the levels 
of intracellular arginine. Furthermore, the effects of arginine and citrulline on NO 
production appeared to be synergistic, since a combination of arginine and citrulline 
stimulated endothelial NO production more than did either arginine or citrulline alone 
(Flam et al. 2001). Since arginine has a number of potential metabolic fates, while 
citrulline has only one known metabolic fate (Fig. 1), the efficiency of NO production 
could be enhanced if a separate pool of arginine is maintained by endothelial cells. 
Recycling the product of the NOS-catalyzed reaction, citrulline, back to arginine via the 
enzymes of the arginine regeneration system, AS and AL, would maintain this separate 
pool. The pool of arginine used for NO synthesis would be essentially isolated from the 
bulk of intracellular arginine through the efficient operation of an arginine regeneration 
system. The apparent efficiency of the process suggests a channeling of intermediates and 
a compartmentalized complex of eNOS and enzymes of the arginine regeneration system. 
These results further support a model in which eNOS is localized together with this 
arginine regenerating system, and regulatory components, to ensure optimal efficiency of 
NO production and regulation without affecting other arginine-dependent cellular 
processes. 
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Caveolar localization of arginine regeneration enzymes with eNOS 
Endothelial NOS is targeted by acylation to caveolae, where it interacts with 
caveolin-1 (Everson & Smart 2001; Shaul 2002). In liver cells, the arginine-generating 
enzymes AS and AL are associated with the outer mitochondrial membrane, reflecting 
the functional role of these enzymes in the production of urea (Cohen et al. 1996). To test 
the model for a colocalization of AS and AL with eNOS, we used two different 
fractionation protocols for the purification of caveolae (Smart et al. 1995; Song et al. 
1996). Both protocols generated a caveolar membrane fraction that was highly enriched 
in caveolin-1, eNOS, AS and AL (Flam et al. 2001). These results support the proposal 
that a separate pool of arginine, directed to NO synthesis, is effectively separated from 
the bulk of intracellular arginine through the functional localization of arginine 
regeneration enzymes and eNOS with plasmalemmal caveolae. A possible consequence 
of this functional association would be the channeling of intermediates through AS, AL 
and eNOS such that intermediates of the complex would not equilibrate with bulk 
intracellular arginine. 
 
Degree of recycling 
Cellular activity of eNOS has been estimated by measuring the rate of conversion 
of [
3
H]arginine to [
3
H]citrulline (Hardy et al. 2002). If recycling of citrulline to arginine 
is tightly coupled to NO production, this measurement would underestimate the cellular 
activity of eNOS. Estimating cellular activity of eNOS by measuring rate of production 
of NO (as the degradation product nitrite), on the other hand, should give a better 
estimate of cellular activity of eNOS. To test this hypothesis, and to estimate the degree 
of recycling of citrulline to arginine, we simultaneously measured the apparent rate of 
arginine-to-citrulline conversion and the rate of production of NO under both 
unstimulated and stimulated (addition of bradykinin) conditions. The ratio of these 
activities was close to one under unstimulated conditions. An increase in the ratio of NO 
produced to citrulline produced was approximately eight upon exposure of endothelial 
cells to agonist (B. R. Flam, D. C. Eichler and L. P. Solomonson, unpublished), 
indicating that recycling and NO production were costimulated. These preliminary results 
suggest an efficient caveolar complex for the regeneration of arginine directed to 
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receptor-mediated production of NO in endothelial cells and an efficiency of greater than 
80% for the recycling of citrulline to arginine under conditions of maximum stimulation 
of NO production. Although recycling of citrulline to arginine has been assumed to be 
important for conservation and efficient utilization of arginine, the degree of recycling 
relative to NO production has not, to the best of our knowledge, been quantified. Our 
results suggest that this recycling, especially under stimulated conditions, may play a 
more important role in endothelial NO production than previously recognized. 
 
Molecular basis for functional role and location of endothelial AS 
In liver tissue, AS plays an essential role in urea synthesis and appears to be 
associated with the outer mitochondrial membrane (Cohen & Kuda 1996). By contrast, 
endothelial AS appears to be the rate-limiting enzyme in the recycling of citrulline to 
arginine used for NO synthesis and is localized in caveolae (Flam et al. 2001). 
Immunoblotting experiments suggested small differences in subunit molecular masses 
and isoelectric points of endothelial AS compared with liver AS (B. R. Flam, D. C. 
Eichler and L. P. Solomonson, unpublished). We speculated that these differences could 
be due to a splice variant, but analysis of the coding sequence of AS mRNA indicated no 
differences between the mRNA from endothelial cells and liver (Pendleton et al. 2002). 
Because upstream and downstream untranslated regions (UTRs) of mRNA can influence 
regulation of gene expression, we carried out both 5′-RACE (rapid amplification of 
cDNA ends) and 3′-RACE analysis to investigate possible differences in the UTRs. We 
found AS mRNA species with three different length 5′-UTRs in endothelial cells (Fig. 2). 
Only one of these products, the shortest 5′-UTR of 43 nt, was quantitatively expressed in 
liver. No significant variation was found in the 3′-UTR. The 5′-RACE analysis identified 
endothelial AS mRNA species with extended 5′-UTRs of 66 nt and 92 nt, in addition to a 
major 43 nt 5′-UTR AS mRNA (Fig. 2). Compositional analysis revealed that all three 
AS mRNA 5′-UTRs were enriched in G+C content (approximately 76%) and were likely 
to form complex and stable secondary structures. An upstream open reading frame 
(uORF) that was out-of-frame with the AS mRNA AUG start codon was detected in the 
66 nt and 92 nt 5′-UTRs. RNase protection analysis (RPA) and real-time reverse 
transcriptase-PCR (RT-PCR) verified and quantified the differential expression of the 
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extended 5′-UTR species relative to the major 43 nt 5′-UTR AS mRNA. Estimates from 
RPA of the amount of the 92 nt and 66 nt species, relative to the 43 nt species, were 
approximately 15% and 13%, respectively.  
Features of mRNA UTRs, specifically uORFs, are regarded as important 
determinants of translational efficiency and may have important biological implications 
for the regulation of translation. We therefore designed experiments to determine to what 
extent the various 5′-UTRs of AS mRNA influenced translation. Translational 
efficiencies for the 66 nt and 92 nt AS 5′-UTR constructs were 70% and 25%, 
respectively, of the translational efficiency for the 43 nt 5′-UTR AS mRNA. Sequential 
deletions, starting with the 5′-terminus of the 92 nt 5′-UTR construct, resulted in a 
corresponding increase in translational efficiency, but the most pronounced effect 
resulted from mutation of the uORF, which restored translational efficiency to that 
observed with the 43 nt species. When the different AS mRNA 5′-UTRs, cloned in front 
of a luciferase reporter gene, were transfected into endothelial cells, the pattern of 
luciferase expression was nearly identical to that observed for the different 5′-UTR AS 
mRNAs in endothelial cells. These results suggest that a complex transcriptional/ 
translational infrastructure exists to coordinate AS expression and NO production 
(Pendleton et al. 2002). 
 
Model for coupling of arginine regeneration to endothelial NO production 
A model depicting our view of the coupling of arginine regeneration to 
endothelial NO production through the compartmentalized complex of AS, AL and eNOS 
is shown in Fig. 3. This coupling may be largely ‘disengaged’ under unstimulated 
conditions but is ‘engaged’ and tightly coupled in response to agonists such as 
bradykinin. The molecular determinants and mechanisms involved in this coupling are 
not fully understood at this time. Based on our studies, and evidence from other labs, we 
believe the coupling of arginine regeneration to endothelial NO production is important 
for the overall regulation of endothelial NO production and may be essential for agonist-
stimulated endothelium-dependent vasorelaxation. 
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Figure 1. Metabolic roles and fates of arginine. In addition to incorporation into 
protein, arginine serves as a metabolic precursor for several important metabolites, as 
indicated by the arrows. Also indicated is the two-step conversion of citrulline to 
arginine. 
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Figure 2. Novel 5′ untranslated regions (UTRs) of endothelial argininosuccinate 
synthase mRNA. 
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Figure 3. Model for the coupling of endothelial NO production to the regeneration 
of the substrate, arginine, from the product, citrulline. Shown is the CAT1 transporter 
involved in arginine transport and the complex of argininosuccinate synthase and 
argininosuccinate lyase with endothelial nitric oxide synthase. 
 
 
217 
Appendix C (Continued) 
218 
References 
Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic 
treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO 
synthase double-knockout mice. Arterioscler Thromb Vasc Biol 2003; 23 (1):97-103. 
Cohen NS, Kuda A. Argininosuccinate synthetase and argininosuccinate lyase are 
localized around mitochondria: an immunocytochemical study. J Cell Biochem 1996; 60 
(3):334-40. 
Everson WV, Smart EJ. Influence of caveolin, cholesterol, and lipoproteins on nitric 
oxide synthase: implications for vascular disease. Trends Cardiovasc Med 2001; 11 
(6):246-50. 
Fakler CR, Kaftan HA, Nelin LD. Two cases suggesting a role for the L-arginine nitric 
oxide pathway in neonatal blood pressure regulation. Acta Paediatr 1995; 84 (4):460-2. 
Flam BR, Hartmann PJ, Harrell-Booth M, Solomonson LP, Eichler DC. Caveolar 
localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, 
with endothelial nitric oxide synthase. Nitric Oxide 2001; 5 (2):187-97. 
Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J 
Physiol Renal Physiol 2001; 280 (2):F193-206. 
Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric oxide synthase 
activity in cultured endothelial cells. Free Radic Biol Med 2002; 32 (2):122-31. 
Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin 
Invest 1997; 100 (9):2153-7. 
Hecker M, Sessa WC, Harris HJ, Anggard EE, Vane JR. The metabolism of L-arginine 
and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured 
endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 1990; 87 
(21):8612-6. 
Hellermann GR, Flam BR, Eichler DC, Solomonson LP. Stimulation of receptor-
mediated nitric oxide production by vanadate. Arterioscler Thromb Vasc Biol 2000; 20 
(9):2045-50. 
Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: consequences 
of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003; 23 
(1):3-5. 
Appendix C (Continued) 
219 
Maxwell AJ. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. 
Nitric Oxide 2002; 6 (2):101-24. 
McCormick SM, Eskin SG, McIntire LV, Teng CL, Lu CM, Russell CG, Chittur KK. 
DNA microarray reveals changes in gene expression of shear stressed human umbilical 
vein endothelial cells. Proc Natl Acad Sci USA 2001; 98 (16):8955-60. 
McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the 
cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the 
"arginine paradox". J Biol Chem 1997; 272 (50):31213-6. 
Nedvetsky PI, Sessa WC, Schmidt HH. There's NO binding like NOS binding: protein-
protein interactions in NO/cGMP signaling. Proc Natl Acad Sci USA 2002; 99 
(26):16510-2. 
Nussler AK, Billiar TR, Liu ZZ, Morris SM. Coinduction of nitric-oxide synthase and 
argininosuccinate synthetase in a murine macrophage cell-line - Implications for 
regulation of nitric-oxide production. J Biol Chem 1994; 269 (2):1257-61. 
Pendleton LC, Goodwin BL, Flam BR, Solomonson LP, Eichler DC. Endothelial 
argininosuccinate synthase mRNA 5´-untranslated region diversity. Infrastructure for 
tissue-specific expression. J Biol Chem 2002; 277 (28):25363-9. 
Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. 
Annu Rev Physiol 2002; 64:749-74. 
Shuttleworth CW, Burns AJ, Ward SM, O'Brien WE, Sanders KM. Recycling of L-
citrulline to sustain nitric oxide-dependent enteric neurotransmission. Neuroscience 1995; 
68 (4):1295-304. 
Smart EJ, Ying YS, Mineo C, Anderson RG. A detergent-free method for purifying 
caveolae membrane from tissue culture cells. Proc Natl Acad Sci USA 1995; 92 
(22):10104-8. 
Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. Co-purification 
and direct interaction of Ras with caveolin, an integral membrane protein of caveolae 
microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 1996; 
271 (16):9690-7. 
Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001; 
85 (3):342-50. 
Appendix C (Continued) 
220 
Wu G, Meininger CJ. Regulation of nitric oxide synthesis by dietary factors. Annual 
Review of Nutrition 2002; 22:61-86. 
 
 
Appendix D 
 
 
 
 
 
Structures of Commonly Used Compounds 
Chemical Structures 
 
Sugar 
D-(+)-Glucosamine hydrochloride 
  
Post-translational modification 
Proteins are glycosylated on serine 
or threonine residue with a 
monosaccharide ß-N-
acetylglucosamine, in an O-
glycosidic linkage (O-GlcNAc) 
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Inhibitors 
Nitric oxide synthase (NOS) 
inhibitor 
Nω-Nitro-L-arginine methyl ester 
hydrochloride (L-NAME) 
  
 
L-glutamine:D-fructose-6-
phosphate amidotransferase 
(GFAT) inhibitor 
6-Diazo-5-oxo-L-norleucine 
(DON) 
  
 
ß-D-N-acetylglucosaminidase (O-
GlcNAcase) inhibitor 
O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc) 
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